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The Health Protection 
Surveillance Centre celebrates 
ten years in existence this 
year.  It was established as the 
National Disease Surveillance 
Centre in November 1998.  
This, our 9th annual report, 
clearly demonstrates the huge 
improvements in communicable 
disease surveillance over the past ten years and sets out 
the challenges for the future.
In 2007 we saw a welcome decline in the number of 
Haemophilus Influenzae B (Hib) cases following the 
successful Hib catch-up campaign during 2005-2006 and 
the addition of a routine booster for all children over 12 
months of age in September 2006. Non-capsular strains 
of H. influenzae are now responsible for the majority of 
invasive H. influenzae cases.  
Measles notifications continued to fall in 2007 with 53 
cases notified, 20 of which were confirmed. While the 
number of mumps cases fell in 2007, we have already 
seen an increase in 2008. The reported complications 
in 2007 include nine cases of orchitis, six cases of 
deafness and one case each of meningitis, encephalitis 
and mastitis. The planned MMR catch-up programme 
in schools in 2009 should prevent these mumps 
outbreaks and help Ireland to meet the European goal 
of eliminating measles in Europe by 2010. 
The most welcome change in the past ten years has 
been the big reduction in cases of meningococcal 
meningitis from over 500 cases in 1999 to less than 
200 in 2007. This decrease is largely due to the MenC 
vaccination programme.  88% of our current cases are 
now caused by serogroup B disease and sadly six deaths 
were caused by this strain in 2007. However, trials of a 
new serogroup B vaccine are currently taking place and 
we look forward to the results with interest.
 On September 1st 2008 a new vaccine against 
pneumococcal disease was introduced into the Irish 
infant immunisation schedule. In 2007 five children 
under two year of age died from invasive pneumococcal 
disease so this new vaccine will provide important 
protection for children. It is essential that a permanently 
resourced reference laboratory is provided to monitor 
the impact of this new vaccine and inform future public 
health policy in this area.
The 2007/2008 influenza season saw the emergence of 
resistance to oseltamivir (Tamiflu) in 11% of influenza A 
H1N1 specimens tested by the National Virus Reference 
Laboratory (NVRL). While the current Irish national 
guidance on the use of antivirals remains in place it will 
be kept under review as specimens are tested in the 
upcoming influenza season.
Sixteen cases of legionnaires’ disease were reported to 
HPSC in 2007. While the numbers were small this was 
the highest annual number recorded to date. We can 
expect an increase in the number of notified cases in 
future years due to the greater use of newer diagnostic 
methods such as urinary antigen testing. 
There were 465 cases of tuberculosis notified in 2006 
and provisionally 478 cases in 2007. In 2006, 35% of 
cases were born outside of Ireland. New updated 
guidelines on the prevention and management of 
tuberculosis are being finalised following a consultation 
process.
There were increases in many infectious intestinal 
diseases in 2007, including a large waterborne outbreak 
of cryptosporidiosis in HSE West. This was the largest 
Cryptosporidium outbreak notified in Ireland since 
surveillance of outbreaks began. In April 2008 the 
Environmental Protection Agency (EPA) published a 
Remedial Action List of public water supplies and the 
work arising from this prioritisation exercise should 
lead to a reduction in waterborne illness in Ireland 
in the coming years. However, as in previous years, 
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drinking water from untreated private water supplies 
remains a very important risk factor for verotoxigenic 
E. coli (VTEC) infection in Ireland. Private well owners 
are reminded of the need to maintain their wells 
adequately. In line with other EU countries there has 
been an increase in listeriosis cases in Ireland in 2007. 
The increase was seen particularly in pregnant women 
and neonatal cases. An information leaflet on ways to 
minimise the risk of listeriosis is available from Safefood.
Bloodborne and sexually transmitted infections (STIs) 
remain high. The number of hepatitis C cases notified 
continued to rise with 1,558 cases notified in 2007, 
up 28% from 2006. However, hepatitis C notification 
rates may not accurately reflect incidence trends as it is 
likely that a significant proportion of notified cases do 
not represent newly acquired infections. As infection is 
often asymptomatic at first, a large proportion of cases 
are diagnosed through screening of at-risk groups such 
as injecting drug users. Three hundred and sixty two 
cases of HIV infection were reported to HPSC during 
2007. Trends within risk groups should be interpreted 
with caution as information on risk was not available 
for 21% of cases. Unfortunately, delays in the reporting 
of STIs mean that annual data are often not available 
as quickly as they should be. Adequate resourcing of 
STI surveillance is vital if we are to improve control of 
STIs and HIV infections.  Additionally, the introduction 
on 1st September 2008 of universal infant hepatitis B 
vaccination into the childhood immunisation schedule is 
to be welcomed.
It was good to see a continued rise in immunisation 
uptake figures.  In 2007, the 24 month uptake of the 5 
in 1 vaccine was 92% and the uptake of the first dose of 
MMR was 87%. However, we need to enhance national 
and regional monitoring of the school-based vaccination 
programmes to add to these improvements.
Antimicrobial consumption in both hospital and 
community settings increased in 2007, with community 
consumption rising steadily at 3% per year since 
2000. However, on a positive note, the proportion of 
Staphylococcus aureus bacteraemia reports that were 
meticillin resistant (MRSA) submitted to HPSC as part 
of the European Antimicrobial Resistance Surveillance 
System (EARSS) has fallen from 42.0% in 2006 to 38.5% 
in 2007.  Despite this encouraging trend, antimicrobial 
resistance continues to be a growing problem in other 
pathogens such as enterococci and E. coli. Measures 
to promote prudent antibiotic use in both hospital and 
community settings are required to reduce the burden 
of antimicrobial resistance in Ireland.
Once again, I’d like to thank the Scientific Advisory 
Committee and the HPSC sub-committees for all 
their hard work throughout the year.  Special thanks 
also to the staff at HPSC whose commitment and 
professionalism is reflected throughout this report.
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In 2007, 31 cases of invasive Haemophilus influenzae 
disease were notified in Ireland (0.7/100,000 total 
population).  This was similar to previous years when 
38 and 34 cases were notified in 2006 and 2005, 
respectively (figure 1). 
The main changes in 2007, when compared to 2006, 
is the decline by half of the number of H. influenzae 
type b (Hib) cases and a decrease by a quarter of  the 
number of invasive H. influenzae cases due to non-
capsular strains (figure 1). No other noteworthy change 
in the number of cases due to other serotypes has been 
observed in recent years.
Non-capsular strains accounted for the majority of 
the invasive H. influenzae cases notified in 2007 (48%, 
n=15/31).  The remaining cases were due to Hib (n=7, 
23%), type e (n=1), type f (n=3) and five isolates were 
not typed. The cases ranged in age from one week to 
95 years. The incidence rates were highest in infants 
<1 year (8.2/100,000) and adults ≥65 years of age 
(2.8/100,000), followed by the 1-4 year old age group 
(1.7/100,000) (table 1.1).
Cases occurring in children <10 years of age (n=9) and 
elderly adults ≥65 years (n=13) accounted for 71% of 
the invasive H. influenzae notifications in 2007 (table 1).
The clinical manifestations of invasive H. influenzae 
disease in the nine children <10 years of age in 2007 
were meningitis, cellulitis, epiglottitis and pneumonia 
with one case each and clinical diagnosis not reported 
(n=5).
Four invasive H. influenzae related deaths were reported 
in 2007, one was associated with a type b strain, one 
with a non-capsular strain, and two were not typed. One 
death occurred in a child <1 year of age, one in a 10-14 
year old and the remaining two occurred in adults aged 
>65 years.
H. influenzae type b (Hib) accounted for 23% of the 
invasive H. influenzae notifications in 2007, with seven 
cases being notified (0.2/100,000 total population).  
1.1 Haemophilus influenzae (invasive) 
Number of cases, 2007: 31
Number of cases, 2006: 38
Number of cases, 2005: 34
Crude incidence rate, 2007:0.7/100,000
Summary
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Figure 1. Annual number of invasive Haemophilus influenzae cases 
notified in Ireland, 2004-2007
type b
non-capsular
not typed
other types
Year
2007
Three of the seven Hib cases (43%) occurred in children 
≤4 years of age, with two cases occurring in infants <1 
year and one in the 1-2 years age group.
In contrast, in 2006, 14 Hib cases were notified, with 
five (36%) occurring in children ≤4 years of age. In 2005 
when 18 cases in total were notified, the number of 
Hib cases in the same age group was 13 (72%). The 
introduction of a Hib booster catch-up campaign for 
children under four years of age in November 2005 and 
a routine Hib booster dose at 12 months in September 
2006 has lead to a reduction in the incidence of Hib 
disease in young children in 2007.
In 2007, two true Hib vaccine failures occurred in 
children aged 14 years or less, one of whom died from 
septicaemia. Both children received three doses of Hib 
vaccine when they were less than one year of age.  In 
contrast, the number of true vaccine failures in 2006 
was four, but in 2005 the number was markedly higher 
at 14; highlighting once more the positive impact the 
Hib booster catch up campaign has had in Ireland.  
Of note in 2007, was the fact that one of the two true 
vaccine failures occurred in a slightly older child, aged 
10-14 years who would not have been targeted by the 
catch-up programme.  
In 2007, there were no apparent Hib vaccine failures, 
compared to three in 2006 and one in 2005. Apparent 
failures are defined as cases in children who are 
incompletely vaccinated. 
From September 2008, the, Hib booster dose will be 
administered at 13 months of age as part of the routine 
childhood immunisation schedule in addition to the 
three doses at 2, 4 and 6 months of age.
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) system on 19th August 2008.  
These figures may differ slightly from those published 
previously due to ongoing updating of notification data 
on CIDR.
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Table 1. Number and incidence rates of invasive Haemophilus influenzae cases by serotype and age group and number of Hib vaccine failures 
by age group, 2007
 Type b Type e Type f
Non-
capsular Not Typed Total
ASIR of 
Hib
ASIR of 
all H. 
influenzae TVFs
<1 2 0 0 2 1 5 3.3 8.2 1
1-4 1 1 0 2 0 4 0.4 1.7 0
5-9 0 0 0 0 0 0 0.0 0.0 0
10-19 1 0 0 0 0 1 0.2 0.2 1
20-54 1 0 0 2 2 5 0.0 0.2 0
55-64 0 0 1 2 0 3 0.0 0.7 0
65+ 2 0 2 7 2 13 0.4 2.8 0
All ages 7 1 3 15 5 31 0.2 0.7 2
CIR 0.2 0.02 0.07 0.4 0.12 0.7 – – –
CIR, crude incidence rate per 100,000 total population
ASIR, age specific incidence rate per 100,000
TVFs, true Hib vaccine failures
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Measles notifications continued to decline in 2007 
(figure 1).  There were a total of 53 notified cases 
(1.3/100,000) during 2007 compared to 83 (2.0/100,000) 
in 2006.
Thirty-three cases in 2007 were classified as possible 
while 20 were classified as confirmed, giving a crude 
confirmed incidence rate of 0.5 per 100,000 total 
population.  Fourteen of the confirmed cases were 
laboratory confirmed while six were epidemiologically 
linked to a laboratory confirmed case.  
Measles cases ranged in age from 8 months to 63 years 
(age was unknown for one case).  Of the 53 total cases 
the largest number (n=15) was in the age group one to 
two years while of the 20 confirmed cases the largest 
number (n=5) was in the age group 5-9 years (figure 
2).  Of the 53 total cases the highest incidence rate was 
in those aged less than one year (14.7/100,000) while 
among the 20 confirmed cases the highest incidence 
rates were in those aged one to two years (2.5/100,000) 
and those aged three to four years (2.5/100,000) (figure 
3).  Of the 53 measles cases 29 were male and 24 were 
female.
Laboratory results were provided for 25 (47%) cases.  
Fourteen cases were laboratory positive for measles.  
Eleven cases were laboratory negative for measles, 
however, for five of these the oral fluid specimens were 
not taken at the optimal time following disease onset 
or the date of specimen collection in relation to disease 
onset was unknown (the optimal time for collecting oral 
fluid specimens for measles IgM testing following onset 
of measles is greater than seven days to two months).  
All cases reported as laboratory negative for measles 
were classified as possible measles cases.  
Measles vaccine in Ireland is available as part of the 
combined measles-mumps-rubella (MMR) vaccine.  In 
Ireland, vaccination with the first dose of MMR (MMR1) 
is routinely recommended at twelve months of age and 
1.2 Measles 
Summary
Number of cases, 2007: 53
Number of confirmed cases, 2007: 20
Crude incidence rate, 2007: 1.3/100,000
Crude confirmed incidence rate, 2007: 0.5/100,000
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Figure 1.  Annual number (logarithmic scale) of measles notifications in Ireland 1948-2007 and year of introduction of measles vaccine and the 
measles-mumps-rubella (MMR) vaccine (A measles and rubella (MR) campaign for primary school-age children was conducted in 1995)
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the second dose (MMR2) at four to five years of age.
Vaccination status was reported for 39 (74%) cases 
in 2007.  Eighteen cases (n=18/39, 46%) were 
unvaccinated; eight of these were less than 12 months 
of age.
Fourteen cases (n=14/39, 36%) had one dose of 
MMR vaccine.  Only three of these were classified as 
confirmed cases.  Ten of these cases were known to 
be less than six years of age.  The date of vaccination 
in relation to disease onset was reported for 10 cases, 
all 10 were vaccinated ≥ 2 months prior to onset.  An 
additional case, aged 20 months, received at least one 
dose of MMR.  This case was classified as a possible 
case.
Six cases were reported as having received two doses 
of MMR.  The dates of vaccination were reported for 
four of these cases, all four were vaccinated  ≥ 3 months 
prior to onset.  Two of the cases vaccinated with two 
doses of MMR were laboratory confirmed (the dates of 
vaccination were not provided for one of these).
Two cases were hospitalised representing six percent 
(n=2/35) of all cases with known hospitalisation status.  
Both cases were laboratory confirmed for measles.  
One case was unvaccinated while the second case was 
reported to have two doses of MMR, however, the 
vaccination dates were not reported.
None of the 23 cases, where information on measles 
associated complications was reported, had pneumonia, 
encephalitis or seizures.  No measles deaths were 
reported.  
Three localised outbreaks of measles were notified 
during 2007, with a total of 13 cases of illness.
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) system on 21st August 2008.  
These figures may differ slightly from those published 
previously due to ongoing updating of notification data 
on CIDR. 
EU data are available at www.euvac.net and WHO 
European data are available at http://data.euro.who.int/
CISID/.
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Figure 2. Number of notified measles cases in 2007 by age group and 
case classification
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Figure 3. The age specific incidence rate of notified measles cases by 
case classification in 2007 
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Age group (years)
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In 2007, 179 cases (4.2/100,000) cases of invasive 
meningococcal disease (IMD) were notified in Ireland. 
This was a notable decrease from the previous two 
years when 209 cases (4.9/100,000) and 203 cases (4.8 
/100,000), were notified in 2006 and 2005, respectively 
(figure 1). When compared with rates reported in 1999 
and 2000, incidence rates have substantially declined in 
recent years (figure 1).
Based on the meningococcal disease case definition, 
161 of the 179 cases (90%) notified in 2008 were 
classified as definite, one (1%) as presumed and 17 
(9%) as possible.  Ninety-one percent (162/179) of the 
cases were laboratory confirmed. Most cases were 
confirmed by PCR alone (48.6%, n=87). Confirmation 
of the remaining 75 cases was by culture only (n=9), by 
PCR and/or culture (n=66), and none by serology or 
microscopy exclusively.
In 2007, male cases (n=97) exceeded female cases 
(n=82), resulting in a male to female ratio of 1.2:1.0.  
Cases ranged in age from one month to 83 years, with 
a median age of three years. The incidence of IMD 
was highest in infants and young children. Age specific 
incidence rate (ASIR) was highest among  infants <1 
year of age (78.6 per 100,000), followed by children in 
the 1-2 year age groups (32.2/100,000), and the 3-4 
year age groups (15.8/100,000) (table 1).  
Neisseria meningitidis serogroup B was the pathogen 
most commonly associated with IMD in 2007 and 
accounted for 157 (88%) of the 179 notifications (figure 
1). Each year since 2003 serogroup B has accounted for 
80% or more of the IMD notifications (figure 1).  
IMD due to serogroup C has remained at very low levels 
over the last five years with no more than five cases 
occurring annually. In 2007, just two (0.04/100,000) 
serogroup C cases arose (figure 1).  Both cases occurred 
in adults (age range 17-33 years), one of whom was 
vaccinated.  One MenC vaccine failure also occurred in 
2006 and again in 2005, while no failures arose in either 
2004 or 2003.
1.3 Meningococcal Disease
Summary
Number of cases, 2007: 179
Number of cases, 2006: 209
Number of cases, 2005: 203
Crude incidence rate, 2007: 4.2/100,000
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Figure 1.  Number of invasive meningococcal disease notification in 
Ireland by serogroup, 1999-2007
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These low incidence rates highlight the huge impact 
the introduction of the MenC conjugate vaccine in 
October 2000 has had in almost eliminating IMD due to 
serogroup C (figure 1). Prior to the introduction of this 
vaccine, the serogroup C incidence rate in 1999 was 3.7 
per 100,000 total population.  
There were seven IMD related deaths in 2007 (case 
fatality ratio of 3.9%) compared to six in 2005 and 6 in 
2005.  The case fatality ratio (CFR) was highest amongst 
cases 1-2 years of age (10.3%) as a result of four deaths 
from 39 cases (table 1).  The next highest CFR occurred 
in young adults aged 15-19 years (5%) and adults aged 
25 years or more (4.8%). Six of the seven deaths in 
2007 were due to serogroup B disease; no organism 
was identified for the seventh. Five of the deaths (71%) 
occurred in children <=2 years of age and the remaining 
two were in adults (age range 18-83 years) (table 1).  
No serogroup C deaths occurred between 2005 and 
2007, while one occurred in both 2003 and 2004 in 
adults over 55 year of age.  In 2001 one death from 
serogroup C disease occurred in a child <15 years of 
age, but since then there have been no deaths reported 
in Ireland in this age bracket. Thus, the introduction of 
the MenC vaccine in October 2000 has also substantially 
reduced mortality due to serogroup C disease in Ireland.
Despite a reduction in the overall incidence of IMD in 
recent years, this disease continues to be treated as a 
serious public health concern due to its severity, high 
mortality rate and serious adverse sequelae associated 
with it. 
Effective vaccination is necessary for the complete 
prevention and control of meningococcal disease. 
Although effective vaccines are available against 
serogroups A, C, W135 and Y forms of the disease, 
a suitable vaccine against serogroup B disease, the 
most common form of the disease in Ireland, is not 
yet available.  Until such time that an effective MenB 
vaccine, suitable for use in infants, is on the market, IMD 
remains a significant cause of morbidity and mortality in 
children and young adults in Ireland.
Table 1.  Number of cases, deaths, incidence rates and case fatality 
ratios, by age group, of invasive meningococcal disease in Ireland, 
2007
No. Cases ASIR No. Deaths CFR (%)
<1 48 78.6 1 2.1%
1-2 39 32.2 4 10.3%
3-4 19 15.8 0 0%
5-9 14 4.9 0 0%
10-14 13 4.7 0 0%
15-19 20 6.9 1 5%
20-24 5 1.5 0 0%
25+ 21 0.8 1 4.8%
All ages 179 4.2 7 3.9%
ASIR, age specific incidence rate of cases
CFR, case fatality ratio
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) system on 15th August 2008.  
These figures may differ slightly from those published 
previously due to ongoing updating of notification data 
on CIDR.
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There were 142 (3.3/100,000) mumps cases notified 
during 2007.  This is a three-fold decrease compared to 
2006 (n=427, 10.1/100,000) and a decrease of nearly 
eight-fold compared to 2005 (n=1,079, 25.4/100,000).  
Mumps notifications were high in recent years following 
a national mumps outbreak that started at the end of 
2004.  In contrast, in the six years prior to 2004 there 
were on average 43 mumps notifications each year 
(figure 1).   
In 2007, of the 142 mumps cases notified 68 (48%) 
were classified as confirmed, one (1%) was classified as 
probable and 73 (51%) were classified as possible. 
Sixty-eight cases were laboratory positive for mumps in 
2007.  For 24 cases the laboratory tests were negative 
for mumps, however, for 13 (54%) of these cases the 
specimen was not taken at the optimal time following 
disease onset or the date of specimen collection in 
relation to disease onset was not reported.  (The 
optimal time for collecting specimens for mumps IgM 
testing following onset of symptoms is greater than 
seven days to two months for oral fluid specimens and 
greater than four days to two-three months for serum 
specimens).  All cases with laboratory negative mumps 
tests were classified as possible mumps cases.  
In 2007, cases ranged in age from 11 months to 86 
years, with a mean age of 25 years and a median age 
of 22 years.  A breakdown of mumps cases by age 
group and the age specific incidence rates per 100,000 
population from 2003 to 2007 are presented in table 
1.  There were fewer cases in most age groups in 2007 
compared to 2006, except among those aged 35-54 
years (table 1).  Of the 142 mumps cases 84 (59%) were 
male and 58 (41%) were female.
Of the 90 mumps cases where vaccination status was 
reported 50% (n=45/90) were unvaccinated, 27% 
1.4 Mumps
Summary
Number of cases, 2007: 142
Number of cases, 2006: 427
Crude incidence rate, 2007: 3.3/100,000
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Figure 1. Number of notified mumps cases by year and year of introduction of the measles-mumps-rubella (MMR) vaccine in Ireland
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(n=24/90) had one dose of the measles-mumps-rubella 
vaccine (MMR) and 21% (n=19/90) were reported to 
have received two doses of MMR.  An additional two 
percent (n=2/90) had at least one dose of MMR.  The 
vaccination date was reported for 83% (n=20/24) 
of cases reported to have received one dose of 
MMR.  Both vaccination dates were reported for 63% 
(n=12/19) of cases vaccinated with two doses of MMR.  
Only 21% (n=4/19) of the cases reported to have 
received two doses of MMR were laboratory confirmed. 
Information on hospitalisation status was available for 
93 cases.  Twelve cases were hospitalised, representing 
13 percent of all cases with known hospitalisation 
status.  
Reported complications of mumps included orchitis 
(17%, n=9/54), deafness (7%, n=6/88), meningitis (1%, 
n=1/91), encephalitis (1%, n=1/91) and mastitis (1%, 
n=1/89).  
Three localised outbreaks of mumps were notified 
during 2007.  The outbreak locations included a school 
(with three ill), a community (with 5 ill) and a private 
house (with two ill).
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) system on 4th September 
2008.  These figures may differ slightly from those 
published previously due to ongoing updating of 
notification data on CIDR.  
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Table 1.  Number of mumps cases notified by age group and the age specific incidence rate per 100,000 population (ASIR) by year from 
2003-2007
Age Group
(Years)
2003 2004 2005 2006 2007
Number ASIR Number ASIR Number ASIR Number ASIR Number ASIR
0-4 11 4.0 23 7.6 49 16.2 33 10.9 24 7.9
5-9 8 3.0 8 2.8 86 29.8 33 11.4 13 4.5
10-14 3 1.1 24 8.8 108 39.4 60 21.9 10 3.7
15-19 6 1.9 115 39.6 323 111.3 99 34.1 16 5.5
20-24 3 0.9 129 37.7 299 87.3 89 26.0 17 5.0
25-34 4 0.6 44 6.1 135 18.7 64 8.9 18 2.5
35-44 1 0.2 17 2.7 32 5.1 20 3.2 22 3.5
45-54 1 0.2 6 1.1 22 4.2 11 2.1 12 2.3
55-64 0 0.0 4 1.0 8 2.0 8 2.0 7 1.7
65+ 1 0.2 2 0.4 5 1.1 8 1.7 3 0.6
Unknown 2 - 48 - 12 - 2 - 0 -
Total 40 1.0* 420 9.9* 1079 25.4* 427 10.1* 142 3.3*
*Crude incidence rate per 100,000 total population
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Apart from Neisseria meningitidis, which is considered 
the most common cause of bacterial meningitis in 
Ireland, other forms of the disease do occur.  Details 
of these are presented below. For details on invasive 
meningococcal disease (which includes N. meningitidis 
meningitis), see a separate chapter within this report.
Streptococcus pneumoniae
In 2007, 35 cases of pneumococcal meningitis were 
notified, compared to 24 in 2006 and 19 in 2005.  Cases 
in 2007 ranged in age from one month to 74 years.  
There were five pneumococcal meningitis related 
deaths, all but one were in children under two years of 
age.  See a separate chapter on invasive pneumococcal 
disease for further details.
Haemophilus influenzae
In 2007, two cases of meningitis due to H. influenzae 
were notified, both of whom recovered.  One case was 
in an infant <12 months and due to H. influenzae type b. 
The second case, age 36 years, was due to an untyped 
H. influenzae infection.  See a separate chapter on 
invasive H. influenzae disease for further details.
Listeria monocytogenes
One case of L. monocytogenes meningitis was notified 
in an elderly patient in 2007. 
1.5 Other forms of Bacterial Meningitis
Summary
Bacterial meningitis, Not Otherwise Specified
Number of cases, 2007: 31
Number of cases, 2006: 45
Number of cases, 2005: 29
Crude incidence rate, 2007: 0.7/100,000
Table 1. Annual notifications of bacterial meningitis other than meningococcal disease, in Ireland, 2005-2007
Notified under Causative Pathogen 2005 2006 2007
Streptococcus pneumoniae infection (invasive) S. pneumoniae 19 24 35
Haemophilus influenzae disease (invasive) H.  influenzae 9 4 2
Listeriosis L. monocytogenes 1 1 1
Streptococcus group A infection (invasive) S. pyogenes 1 1 0
Tuberculosis M. tuberculosis 9 7 7*
Bacterial meningitis NOS
(not otherwise specified)
E. coli 0 3 0
Gamella species 0 0 1
K. pneumoniae 0 1 0
P. aeruginosa 1 0 0
P. mirabilis 0 0 1
S. aureus 1 0 0
Staphylococcus
coagulase negative
0 1 0
S. agalactiae
(Group B streptococcus)
5 4 9
Streptococcus Group C 1 0 0
Unknown 21 36 22
Total BacMen (nos) 29 45 33
Other forms of bacterial meningitis                        Total 68 82 78*
* TB meningitis figures for 2007 are provisional
Streptococcus pyogenes (Streptococcus group A 
infection (invasive) (iGAS)
There was no reported case of iGAS causing meningitis 
in 2007, unlike in 2006 and 2005, when one case in each 
year was notified.
Mycobacterium tuberculosis
In 2007, seven M. tuberculosis meningitis cases were 
notified (provisional figure).  Cases ranged in age from 
38-78 years. One death was reported.
Group B streptococci
Nine cases of meningitis due to Streptococcus 
agalactiae were notified in 2007. All but one were 
neonatal cases.  No deaths were reported.
Other causative pathogens
Cases of bacterial meningitis due to other pathogens 
were also notified in 2007. One meningitis notification 
for each of the following was received: Gamella species 
and Proteus mirabilis, both of which were reported in 
neonates.  
Bacterial meningitis (not otherwise specified)
In total 33 cases of meningitis under this disease 
category were notified in 2007.  The causative 
pathogens were identified in 11 of these and are 
detailed above (see group B streptococci, Gamella 
species and Proteus mirabilis). No causative pathogen 
was identified for 22 of the notifications, a decrease 
compared to 2006 (n=36) and similarly to that reported 
in 2005 (n=21). 
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Seventy-eight cases (1.8/100,000) of pertussis were 
notified in 2007 compared to 62 in 2006.  Of the 78 
cases in 2007 47 were classified as confirmed, three as 
probable, 27 as possible while case classification was 
not specified for one (table 1).
In 2007, the majority of cases (n=46, 59%) and the 
highest age-specific incidence rate (75.3/100,000) were 
in children aged less than one year (table 1) with fifty-
five percent (n=43) of all cases in children less than six 
months of age.  Forty cases were male and 38 were 
female.
In Ireland it is recommended that children be vaccinated 
with a pertussis-containing vaccine at two, four and 
six months of age and a booster at four to five years 
of age.  An additional booster with low dose acellular 
pertussis for those 11-14 years of age will be included 
in the childhood immunisation schedule in the near 
future.  The vaccine provides protection in over 80% of 
recipients who are fully vaccinated.  However, protection 
declines over time, with little or no protection 10-12 
years after primary immunisation, without boosting.  
 
In 2007, the vaccination status was reported for 44 
(56%) pertussis cases.  Twenty-six (n=26/44, 59%) cases 
were unvaccinated.  Nine (n=9/44, 20%) cases were 
reported as incompletely vaccinated, but this included 
six cases who were less than six months of age and 
were therefore not eligible for three doses of pertussis 
vaccine in the Irish schedule.  Nine (n=9/44, 20%) cases 
were reported as completely vaccinated, with two of the 
nine cases reported to have received a booster dose.  
The two cases vaccinated with the booster dose were 
aged eight and 15 years.
 
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) system on 20th August 2008.  
These figures may differ slightly from those published 
previously due to ongoing updating of notification data 
on CIDR.
1.6 Pertussis
Summary
Number of cases, 2007: 78
Number of cases, 2006: 62
Crude incidence rate, 2007: 1.8/100,000
Table 1. Number of notified pertussis cases by age group and case classification and the age specific incidence rate per 100,000 population (ASIR) 
in 2007
Age Group
(Year/s)
Case Classification Total ASIR
Confirmed Probable Possible Not Specified
<1 31 1 14 0 46 75.3
1-4 8 2 6 1 17 7.0
5-9 2 0 1 0 3 1.0
10-14 3 0 1 0 4 1.5
15-19 2 0 1 0 3 1.0
20-24 0 0 2 0 2 0.6
25-34 0 0 0 0 0 0.0
35-44 1 0 1 0 2 0.3
45-54 0 0 1 0 1 0.2
55+ 0 0 0 0 0 0.0
Total 47 3 27 1 78 1.8*
*Crude incidence rate per 100,000 total population
In  2007, 19 cases (0.4/100,000) of rubella were notified 
in Ireland compared to 14 cases in 2006.
Three of the cases in 2007 were classified as confirmed 
giving a crude confirmed incidence rate of 0.1 per 
100,000 total population.  Two of these cases were 
in the age group 30-34 years and one was aged one 
year (table 1).  Sixteen cases in 2007 were classified as 
possible, 15 of these were less than three years of age 
(table 1).
Ten of the rubella cases were female and nine were 
male.
Rubella vaccine in Ireland is available as part of the 
combined measles-mumps-rubella (MMR) vaccine.  
In Ireland, vaccination with the first dose of MMR is 
routinely recommended at twelve months of age and 
the second dose at four to five years of age.   
Vaccination status was reported for ten of the rubella 
cases in 2007.  Six cases were unvaccinated; five of 
these were less than 12 months of age and one case 
was aged 21 months.  All six were classified as possible 
cases.  Four cases were reported as completely 
vaccinated for their age.  All four were between one and 
two years of age and were classified as possible cases.
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) system on 19th August 2008.  
These figures may differ slightly from those published 
previously due to ongoing updating of notification data 
on CIDR.
WHO European data are available at http://data.euro.
who.int/CISID/.
1.7 Rubella
Summary
Number of cases, 2007: 19
Number of confirmed cases, 2007: 3
Crude incidence rate, 2007: 0.4/100,000
Crude confirmed incidence rate, 2007: 0.1/100,000
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Table 1. Number of notified rubella cases by age group and case classification and the age specific incidence rate per 100,000 population (ASIR) 
in 2007
Age Group
(Year/s)
Case Classification
Total ASIR
Confirmed Probable Possible
<1 0 0 7 7 11.5
1-2 1 0 8 9 7.4
3-4 0 0 0 0 0.0
5-9 0 0 0 0 0.0
10-14 0 0 0 0 0.0
15-19 0 0 0 0 0.0
20-24 0 0 0 0 0.0
25-29 0 0 0 0 0.0
30-34 2 0 1 3 0.9
35+ 0 0 0 0 0.0
Total 3 0 16 19 0.4*
*Crude incidence rate per 100,000 total population
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Since 1st January 2004, invasive infections due to 
Streptococcus pneumoniae are notifiable.  For the 
purposes of this report the term invasive pneumococcal 
disease (IPD) will be used to describe these infections.
In 2007, 361 cases of IPD (8.5/100,000) were notified 
in Ireland. This is a 19% increase from 2006 (293 cases; 
6.9/100,000).  Although, the number of IPD notifications 
has steadily increased each year since 2004 (figure 1), 
this increase is believed to be a reflection of improved 
reporting of IPD through the notification system rather 
than an increase in disease burden. The fact that the 
number of invasive S. pneumoniae isolates reported 
through the European Antimicrobial Surveillance System 
(EARSS) has remained relatively stable over these years 
with between 400-438 cases reported per annum would 
support the above assessment (figure 1).  
In 2007, 310 IPD cases were classified as confirmed 
(86%) and 51 as probable (14%). The clinical diagnosis 
was reported for 158 of the notifications and the clinical 
manifestations included pneumonia (51%; n=81), 
septicaemia (24%; n=38), meningitis or meningitis & 
septicaemia (22%; n=35), others (3% n=4; 1 each of 
peritonitis, mastoiditis, muscoskeletal infection and soft 
tissue infection).  
Slightly more cases of IPD occurred in males (52%, 
n=189) than in females (48%, n=172).  Cases ranged 
in age from 1 week to 98 years, with a median age of 
58 years.  Sixty percent of the IPD cases notified were 
in the young and the old; 18.8% (n=68) of cases were 
in children <5 years of age and 41.6% (n=150) were in 
elderly adults 65 years of age and older (figure 2).
In children the incidence of IPD was highest in infants <1 
year of age (41/100,000) followed by 1 year old children 
(38/100,000).  Thereafter, the incidence declined and it 
was <10 cases per 100,000 for the age groups between 
5-54 years (figure 2).  In the elderly the incidence of IPD 
increased considerably with increasing age; from 22 
cases per 100,000 in the 65-74 year olds, to 38 cases 
per 100,000 in 75-84 year olds and reaching the highest 
1.8 Streptococcus pneumoniae (invasive)
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Number of cases in 2006: 293
Number of deaths in 2007: 18
Crude incidence rate, 2007: 8.5/100,000
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Figure 1.  Annual number of invasive pneumococcal disease cases 
reported through the infectious disease notification system and 
EARSS, 2004-2007
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Figure 2.  Number and age specific incidence rates of IPD notifications 
by age group, 2007 
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rate in those 85 years of age and older, at 69 cases per 
100,000 population (figure 2).
Outcome was reported for 35% (127/361) of 
IPD notifications in 2007 and although this is an 
improvement from the 10% reported in 2006, the 
figures presented here may underestimate mortality due 
to IPD in Ireland.  In 2007, 18 deaths associated with IPD 
were reported, involving five children (28%; all <2 years 
of age) and 13 adults (72%) ranging in age between 38 
and 98 years.  Cause of death was reported as follows: 
pneumonia (39%; n=7), meningitis or meningitis & 
septicaemia (28%; n=5), septicaemia (11%; n=2) and 
clinical diagnosis not reported (22%; n=4).  
In April 2007 a collaborative project commenced 
between the RCSI Beaumont Hospital, the Children’s 
University Hospital Temple Street and HPSC on the 
typing of invasive S. pneumoniae isolates submitted by 
Irish microbiology laboratories.  A primary objective of 
this project was to determine the serotype distribution 
of IPD isolates in circulation in Ireland prior to the 
introduction of the pneumococcal conjugate 7-valent 
vaccine (PCV7, Prevenar) to the infant immunisation 
schedule.  Based on data from the first 12 months 
of the project (April 2007 – March 2008) the most 
common serotypes in circulation are 14, 4, 9V, 7F, 19A; 
accounting for 45% of the isolates typed. The seven 
serotypes contained in PCV7 occur in the top 10 most 
prevalent serotypes associated with IPD in Ireland.  
Eighty four percent of isolates from children aged <2 
years had serotypes covered by PCV7.  Further details 
and results from this typing project are presented in the 
August 2008 edition of Epi-Insight, available at www.
hpsc.ie.
On 1st September 2008, PCV7 was introduced in Ireland 
to the infant immunisation schedule, offering three 
doses at 2, 6 and 12 months of age, to those born on 
or after 01/07/2008.  A catch-up campaign for those 
born between 02/09/2006 and 30/06/2008 is also 
being undertaken.  The monitoring of S. pneumoniae 
serotype distribution needs to continue in order to 
assess the impact of introducing PCV7, to investigate 
vaccine failures and to inform future public health policy 
regarding immunisation schedules and the value of 
introducing expanded valency IPD conjugate vaccines 
as they become available.  To ensure this work can 
continue in the long term, provision of a permanently 
resourced reference facility is an absolute priority.
The IPD notification figures presented in this report 
are based on data extracted from the Computerised 
Infectious Disease Reporting (CIDR) system on 29th 
August 2008.  These figures may differ slightly from 
those previously published due to ongoing updating of 
notification data on CIDR.  EARSS data were obtained 
from the Whonet database at HPSC.
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One case of tetanus was notified in 2007.  The case 
was aged greater than 70 years and had received a 
wound injury 11 days prior to onset of symptoms.  A 
tetanus booster was given at the time of injury, however, 
information on previous tetanus vaccines, if any, are not 
known/were not reported.
In total, 10 cases of tetanus were reported since 
tetanus became notifiable in November 1981.  Age was 
reported for eight of these cases, the mean age was 
55.5 years and the median age was 60.5 years (range 
15-84 years).  The number of tetanus notifications 
by age group is shown in figure 1.  Two deaths were 
reported in cases aged >60 years.  
The childhood immunisation schedule recommends 
children receive a dose of tetanus-containing vaccine 
at two, four and six months of age and booster doses 
at four-five years and 11-14 years of age. The vaccine 
provides protection in 90-95% of children who are fully 
vaccinated.   However, as protection declines over time 
up to 50% of 20-year-olds and up to 70% of 70-year-
olds may be unprotected if they have not received 
boosters.  Vaccination data were reported for three of 
the 10 notified cases.  One case, in the age group 15-19 
years, was reported to have received three doses of 
tetanus vaccine as a child and a booster at four years 
and again at five-six years of age.  A second case was 
reported to have received a tetanus vaccine around 40 
years prior to infection.  The third case (case notified in 
2007) received a tetanus vaccine at the time of injury 
but information on tetanus vaccines prior to injury was 
not known/not reported.
The following known/suspected wound injuries (n=5) 
were reported among the 10 notified cases: wound 
associated with dog bite (n=1), wound from kitchen 
knife (n=1), gardening associated leg wound (n=1), 
leg scratches in an avid gardener (n=1), hand wound 
associated with a clean piece of wood (n=1) and a 
farming associated hand wound (n=1).  
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) system on 20th August 2008.  
These figures may differ slightly from those published 
previously due to ongoing updating of notification data 
on CIDR.
1.9 Tetanus
Summary
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Figure 1.  Tetanus notifications (n=10) from 1982 to 2007 by age group
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HPSC is working in collaboration with the NVRL, the 
ICGP and the Departments of Public Health on the 
influenza sentinel surveillance project. Fifty-two general 
practices (located in all HSE-areas) were recruited to 
report electronically, on a weekly basis, the number of 
patients who consulted with influenza-like illness (ILI). 
Sentinel GPs were requested to send a combined nasal 
and throat swab on at least one ILI patient per week to 
the NVRL. Other indicators of influenza activity include a 
network of sentinel hospitals reporting admission levels, 
sentinel schools reporting absenteeism and enhanced 
surveillance of hospitalised influenza cases in 0-14 year 
olds.  
Influenza activity in Ireland peaked slightly earlier in 
the 2007/2008 season compared to the previous two 
seasons. Activity was mild, peaking during week 1 2008 
at 49.1 per 100,000 population (figure 1). During the 
peak of activity, the majority of ILI cases reported were 
in the 15-64 year age group. 
The NVRL tested 342 sentinel specimens for influenza 
virus during the 2007/2008 season. One hundred 
and fifty (43.9%) sentinel specimens were positive for 
influenza: 78 influenza A (74 A H1N1, 1 A H3N2 and 3 A 
unsubtyped) and 72 influenza B. 
Influenza A (H1N1) was the predominant subtype 
detected from week 48 2007 to week 7 2008 and 
influenza B predominated in the latter part of the 
season. Influenza A (H1N1), accounted for 98.7% of 
subtyped positive sentinel specimens. The majority of 
positive influenza sentinel cases were in the 15-64 year 
age group (87.9%). The NVRL tested 2,207 non-sentinel 
respiratory specimens during the 2007/2008 season, 
61 (2.8%) of which were positive: 32 influenza A and 
29 influenza B. The majority of non-sentinel influenza 
(56.1%) specimens were in the 15-64 year age group. 
Based on antigenic or genetic characterisation of 70 
2.1 Influenza
Summary
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2007/2008 Influenza Season
Number of influenza-like illness cases: 927
% of influenza positive sentinel specimens: 43.9
Dominant circulating (sub)type: A (H1N1) & B
% specimens oseltamivir resistant: 11.1
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Figure 1. GP ILI consultation rate per 100,000 population and the number of positive influenza specimens detected by the NVRL by week and 
season, 2003/2004 - 2007/2008
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influenza viruses, 59 were A/Solomon Island/3/2006 
(H1N1)-like, seven were A/Wisconsin/67/2005 
(H3N2)-like and four were B/Florida/4/2006-like (B/
Yamagata/16/88 lineage). 
The NVRL conducted nucleotide sequencing on 
specimens taken by sentinel GPs between November 
2007 and February 2008. Seven of 63 specimens 
(11.1%) tested were resistant to oseltamivir (brand name 
Tamiflu). These viruses retain sensitivity to zanamivir, 
amantadine and rimantadine. 
Of the 150 positive influenza virus detections from 
sentinel specimens, 131 (87.3%) were unvaccinated, 
5 (3.3%) were vaccinated and vaccination status was 
unknown in 14 (9.3%) cases. Of the five vaccinated 
cases, influenza A (H1N1) was detected in two cases and 
influenza B in three cases.  
Overall, influenza activity was most intense in HSE-E 
during the 2007/2008 season. Two ILI/influenza 
outbreaks were reported to HPSC this season, both 
from HSE-E, one during week 12 2008 in a long term 
care facility associated with influenza A (H3N2) and one 
during week 16 2008 on a coach tour from Dublin to 
Clare associated with influenza B. 
Hospital respiratory admissions (as a proportion of total 
hospital admissions) in sentinel hospitals peaked during 
week 52 2007 (figure 2), one week prior to the peak in 
sentinel GP ILI consultation rates. However, ILI visits to 
GPs are often artificially reduced in Christmas week. 
Absenteeism in several sentinel schools was also at 
elevated levels during peaks in ILI consultation rates. 
A total of 299 influenza notifications were reported 
on CIDR during the 2007/2008 influenza season. Fifty-
five of these notifications were patients aged between 
0 to 14 years and six were hospitalised (between 
December 2007 and March 2008). Enhanced data were 
completed for all six cases. One enhanced case was 
in the 5-14 year age group and five cases were under 
one year of age. Four cases were notified from HSE-E 
and two from HSE-M. Three enhanced cases were 
positive for influenza A and three were positive for 
influenza B. Symptoms included fever (5/6), cough (6/6), 
gastrointestinal manifestations (2/6) and fatigue (2/6). 
Complications included bronchitis, croup and other 
respiratory complications. The mean number of days 
hospitalised was 13.6 (ranging from 5-30). One case was 
in an at-risk category for influenza vaccine. No cases 
were vaccinated. Outcome was recorded in all cases; 
four recovered and outcome was unknown in two cases. 
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Figure 2. Respiratory admissions as a percentage of total hospital admissions in ten sentinel hospitals and GP ILI consultation rate per 100,000 
population by week for the 2007/2008 influenza season 
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During the 2007/2008 influenza season, two deaths 
attributed to influenza were registered with the General 
Register Office. These deaths were both in adults over 
65 years of age, one in HSE-NW registered in week 8 
2008 and one in HSE-S registered in week 14 2008. It 
should be noted that the death registered in HSE-S was 
not a laboratory confirmed case of influenza. It should 
also be noted that deaths caused by influenza are rarely 
attributed to influenza per se.
For the forthcoming season, a number of additional 
measures have been put in place in Ireland to improve 
surveillance of ILI/influenza. The NVRL will undertake 
further development of genetic characterisation 
testing to include both influenza A and B strains. They 
will also continue monitoring oseltamivir resistance. 
Current Irish national guidance on the use of antivirals 
for treatment and prophylaxis of influenza remain in 
place though they are being kept under review in light 
of increased resistance to oseltamivir. Other activities 
being developed include surveillance of influenza 
vaccine uptake in those aged 50 years and older. 
Baseline threshold levels for influenza activity will be 
used for the first time in Ireland during the 2008/2009 
season. Case based reporting of avian influenza is now 
operational on CIDR and an interim MS Access database 
for contacts of avian influenza cases is in the final stages 
of development. Data from these projects will in turn 
inform continuing national progress on pandemic 
preparedness and will be vital in the event of an 
influenza pandemic for planning and control measures.
Further information on influenza is available on the 
HPSC website www.hpsc.ie 
European data are available at www.eiss.org/index.cgi
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In 2007, 16 cases of legionnaires’ disease were notified 
in Ireland, a rate of 3.8/million population. This was the 
highest rate recorded to date but the numbers are small 
(Table 1). One death was recorded in 2007. Ten cases 
were notified from HSE East, three from HSE Midlands, 
two from HSE North East and one case from HSE Mid-
West. 
The majority of cases (56.3%) were male. The median 
age was 47 years, with a range from 18 to 77 years.
There were fourteen confirmed cases and two 
probable cases. The organism involved was Legionella 
pneumophila serogroup 1 in fourteen cases while the 
Legionella species was unknown in two cases. Urinary 
antigen testing was the method of diagnosis in thirteen 
cases, serology in two cases and culture in one case. 
With increasing use of urinary antigen testing it can be 
anticipated that numbers of cases notified will continue 
to increase.
Of the 16 cases, eleven were travel-associated, four 
were community-associated and one was hospital-
associated. Countries of travel included Italy (3), France 
(2), Thailand (2), Spain (1), Germany (1), China (1), and 
USA (1). A case of legionnaires’ disease is defined 
as travel-associated if the patient spent one or more 
nights away from home in accommodation used for 
commercial purposes (hotels, holiday apartments) in the 
10 days before onset of illness. Travel-associated cases 
may involve travel within Ireland or abroad.
2.2 Legionellosis
Summary
Number of cases in 2007: 16
Crude incidence rate: 3.8/million
Number of deaths in 2007: 1
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Age group 
(years)
2000 2001 2002 2003 2004 2005 2006 2007
<30 1 0 0 1 0 0 0 1
30-39 2 1 2 0 0 2 0 4
40-49 1 1 3 0 1 4 8 4
50-59 1 0 0 1 1 1 2 2
60-69 2 1 1 2 1 1 1 3
70+ 2 0 0 3 1 1 2 2
Total 9 3 6 7 4 9 13 16
CIR 2.3 0.8 1.5 1.8 0.9 2.1 3.1 3.8
Table 1. Number of legionnaires’ disease cases per million population notified in Ireland, 2000-2007
Notifications
There were 57 cases (1.3 cases per 100,000 population) 
of invasive Group A streptococcal (iGAS) disease 
notified in 2007, compared to 61 cases (1.4 per 100,000) 
in 2006.  All 57 cases in 2007 were confirmed, defined 
as patients with group A Streptococcus (GAS), or 
Streptococcus pyogenes, isolated from a sterile site.
Patient demographics
Of the 57 cases, 26 (46%) were males and 31 (54%) 
were females. The age and sex specific rates of iGAS 
cases are shown in Figure 1. Children aged up to 4 years 
and adults aged over 65 years were most affected with 
smaller peaks in females aged 25-34 years and males 
aged 35-44 years.
Geographic spread and seasonal variation
Table 1 outlines the numbers and crude incidence rates 
(CIRs) of iGAS disease by HSE area from 2004-2007. Of 
note, the highest number of cases in 2007 occurred in 
the HSE-E (n=28) and the highest CIR in the HSE-SE (2.2 
per 100,000 population). 
Although the numbers of iGAS cases notified to date 
have been low and it is not possible to discern any 
distinct seasonal variation, the months with the highest 
numbers of notifications for each of the four years of 
surveillance have been either February, March or April 
(data not shown). 
Enhanced data
Enhanced data fields were entered for 40 (70%) of the 
57 cases reported in 2007. Fifteen laboratories were 
identified as the source for 39 cases. 
Isolate details
GAS was isolated from a sterile site from 33 of 40 cases 
for which enhanced data were available, primarily from 
blood cultures (30, or 91%) but also joint, bone and 
deep tissue (one isolate each). 
No serological typing data, based on the detection of M 
and T-proteins, were available. This may be due to the 
absence of a streptococcal reference laboratory in this 
country and thus laboratories are required to send their 
isolates to reference facilities abroad.
Clinical details
As in 2006, bacteraemia (32 cases) and cellulitis (10) 
were the most common clinical presentations, followed 
by pneumonia (6), streptococcal toxic shock syndrome 
(STSS) (5), necrotising fasciitis (2), puerperal sepsis (2), 
peritonitis (1) and myositis (1). Note that cases could 
have more than one clinical presentation.  The following 
clinical syndromes were associated with 34 cases for 
which data on clinical presentation were provided: 
•  bacteraemia, myositis, necrotising fasciitis and STSS (1)
•  bacteraemia, pneumonia, necrotising fasciitis and 
STSS (1)
2.3  Invasive Group A Streptococcal 
 Disease
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Summary
Number of cases, 2007: 57
Crude incidence rate, 2007:1.3 per 100,000 population
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Figure 1.  Age and sex specific rates of iGAS disease in 2007
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•  bacteraemia, cellulitis and STSS (2)
•  bacteraemia, pneumonia and STSS (1)
•  bacteraemia and cellulitis (7)
•  bacteraemia and pneumonia (4)
•  bacteraemia and puerperal sepsis (1)
•  cellulitis (1)
• peritonitis and puerperal sepsis (1)
• bacteraemia without a focus (15)
Risk factors
Risk factors associated with iGAS disease included: 
skin and wound lesions (11 cases), age over 65 years 
(14), intravenous drug use (IVDU) (5), steroid use (2), 
alcoholism (2),  malignancy (2), non-steroidal anti-
inflammatory drugs (1) and varicella infection (1). Note 
that cases could have one or more associated risk 
factors. No risk factors were identified for 9 cases. 
Among the five cases with STSS, IVDU was identified 
as a risk factor in two cases, alcoholism in one and skin 
lesions in three. No risk factors were identified for 
two cases. 
Clinical management
Surgical intervention was required for two patients and 
admission to the intensive care unit for five patients. 
Other epidemiological information
None of the cases were hospital-acquired. No outbreaks 
were identified in 2007.
Outcome
Outcome at 7-days following GAS isolation was 
reported for 26 cases: 21 were still alive, four died due 
to iGAS (ages 65, 82, 84 and 90 years) and one died due 
to an unknown cause (age 72 years). The case fatality 
rate (CFR) for outcome reported at 7-days was 19%. 
Of the five STSS cases, three died resulting in a CFR of 
60%.
Conclusion
The number of cases notified in Ireland is low compared 
to other Northern European countries and the US. 
Data reported to the Strep-Euro Program for 2003 and 
2004 showed that the highest rates of iGAS disease 
were in Northern Europe with age-standardised rates 
of 3.31, 3.10, 2.58 and 2.46 per 100,000 population in 
the UK, Sweden, Denmark and Finland, respectively. 
The estimated rate of iGAS disease in the US in 2007 
[provisional data from CDC’s Active Bacterial Core 
Surveillance (ABCS) Program] was 3.75 per 100,000 
population while the mortality rate was 0.43. Certain 
serotypes of GAS are more virulent than others, e.g. 
serotypes M1 and M3, but with the absence of a 
streptococcal reference laboratory in this country, no 
serological typing data were available. While enhanced 
data were available for 70% of cases, improved 
completion of the enhanced questionnaire for all cases 
will further augment our understanding of iGAS disease 
in Ireland.
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Diseases Reporting (CIDR) System on 22nd August 
2008. 
Further information on iGAS disease in Ireland 
is available at: www.ndsc.ie/hpsc/A-Z/Other/
GroupAStreptococcalDiseaseGAS/
Table 1. Numbers (n) and Crude Incidence Rates (CIRs) per 100,000 population of iGAS disease by HSE Area, 2004-2007
HSE Area 2004 2005 2006 2007
 n CIR  n CIR n  CIR   n   CIR    
HSE-E 25 1.7 19 1.3 37 2.5 28 1.9
HSE-M 0 0.0 1 0.4 2 0.8 0 0.0
HSE-MW 1 0.3 3 0.8 2 0.6 2 0.6
HSE-NE 1 0.3 3 0.8 5 1.3 3 0.8
HSE-NW 0 0.0 3 1.3 1 0.4 3 1.3
HSE-SE 7 1.5 1 0.2 4 0.9 10 2.2
HSE-S 1 0.2 1 0.2 3 0.5 4 0.6
HSE-W 0 0.0 18 4.3 7 1.7 7 1.7
IRELAND 35 0.8 49 1.2 61 1.4 57 1.3
 
In 2006, 465 cases of tuberculosis were notified in 
Ireland, corresponding to a crude notification rate of 
11.0 per 100,000 population. This is slightly higher 
than the rates reported between 2000 and 2005, 
which ranged from 9.7/100,000 to 10.6/100,000 
population, but is lower than the crude incidence rates 
reported between 1991 and 1999, which ranged from 
11.5/100,000 to 18.2/100,000.  A summary of the 
epidemiology of TB in Ireland during 2006 is shown in 
table 1. Number of cases and crude incidence rates 
from 1991 to 2007* with three-year moving averages 
are also shown in figure 1.
The highest crude incidence rate was reported in HSE S 
at 15.3 per 100,000 population. The next highest rates 
were reported in HSE E (12.9) and HSE SE (11.1). HSE 
NW (3.8) reported rates that were significantly lower 
than the national incidence rate. 
Differences in age-standardised TB incidence rates were 
also found between HSE areas with HSE S having the 
highest rate (15.3/100,000) in 2006 followed by HSE E 
(12.6) and HSE SE (11.1). HSE NW had the lowest rate 
in 2006 at 4.0/100,000.The highest age-specific rate in 
2006 occurred among those aged 65 years and over 
(17.7/100,000 population). This was similar to the rate 
observed in this age group between 2001-2005. 
Rates among males were higher than females for all 
age groups except in the 15-24 year age group. The 
highest rates among males (25.6/100,000) were among 
those aged 65 years and over while the highest rates 
in females (16.6/100,000) were in the 25-34 year age 
group. The male to female ratio (1.5:1) reported in 2006 
was consistent with the rate reported in 2005 (1.5:1). 
During 2006, 34.6% of TB cases notified were born 
outside Ireland. This compares to 33.8% in 2005, 30% in 
2004, 21.9% in 2003, 30.1% in 2002 and 16.5% in 2001. 
In 2006, among countries in the EU and Western Europe 
who reported data to the EuroTB network, 20% of 
notifications were in foreign-born patients. There was a 
notable difference in age between those born in Ireland 
and those born outside Ireland, with a median age of 45 
years and 31 years respectively.
2.4 Tuberculosis, 2006
Summary
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Number of cases, 2006: 465
Crude incidence rate, 2006: 11.0/100,000
Number of TB deaths, 2006: 10
Number of cases, 2007*: 478 
Crude incidence rate, 2007*: 11.3/100,000
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Figure 1: Notified cases of TB in Ireland with crude rates per 100,000 population, 1991 to 2007* and 3-year moving averages, 1992-2006
* Provisional data which may change significantly following validation.
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There were seven cases of TB meningitis in 2006, a 
rate of 0.2/100,000 population (2/million population). 
Between 1998 and 2006, a total of 57 cases of TB 
meningitis have been reported with five of the cases 
reported among 0-4 year olds.
There were 27 drug resistant cases notified in 2006, 
including four cases of MDR-TB. Mono-resistance to 
isoniazid was recorded in 14 cases, to rifampicin in two 
cases, to ethambutol in one case, to pyrazinamide in 
one case and to streptomycin in four cases. Resistance 
to isoniazid, ethambutol and streptomycin was also 
documented in one further case. Nine of the 27 (33.3%) 
drug resistant cases, including three (75%) of the MDR-
TB cases, were born outside Ireland.
In 2006, information on treatment outcome was 
provided for 78.9% of cases which is a marked decrease 
on the proportion in 2005 (87.1%). This compares to 
84.3% in 2004, 84.8% in 2003, 77.2% in 2002 and 59.8% 
in 2001. It is of critical importance to TB control in 
Ireland that surveillance of TB and reporting of outcome 
data be maintained at a high level especially with the 
global threat of resistant strains. 
The Global Plan to Stop TB 2006-2015 was launched in 
January 2006 and aims to reduce the global prevalence 
of, and deaths due to TB by 50% in 2015 relative to 
1990.  In addition it proposes to eliminate TB as a 
public health problem (<1 case per million population) 
by 2050. This strategy calls on countries to strengthen 
health systems for TB treatment and control and to 
address MDR-TB, TB/HIV and other challenges e.g. 
high risk groups and areas where TB rates are high. 
The importance of good surveillance data cannot be 
underestimated in this context as they will help guide 
where resources should be directed in order to ensure 
the effective prevention and control of TB in Ireland and 
in order to reach the elimination target by 2050. 
Provisional 2007 data
There were 478 cases of TB provisionally notified 
in 2007. It is important to note that these data are 
provisional and may change significantly following 
validation. 
Of the 478 cases provisionally notified in 2007, 
Pulmonary TB was diagnosed in 317 cases (66.3%), •	
extrapulmonary TB in 121 cases (25.3%) and 
pulmonary and extrapulmonary TB in 30 cases (6.3%)
Of the 347 cases with a pulmonary disease •	
component, 186 (53.6%) were culture positive and 
151 (43.5%) were smear positive
There were seven cases of TB meningitis provisionally •	
notified corresponding to a rate of 0.2/100,000 
population (2/million population)
Table 1. Summary of the epidemiology of TB in Ireland, 2006
Parameter 2006
Total number of cases 465
Crude notification rate per 100,000 11.0
Cases in indigenous population** 294
Cases in foreign-born persons** 161
Culture positive cases 317
Smear positive pulmonary cases 155
Multi-drug resistant cases 4
Mono-resistant to isoniazid 14
Deaths attributable to TB 10
Outcomes reported in cases 367 
TB meningitis cases 7
* Provisional data which may change significantly following validation.
**Country of birth not reported for 10 cases
There were 277 (57.9%) cases born in Ireland and 181 •	
(37.9%) were foreign-born. Country of birth was not 
reported for 20 cases
There were 293 cases (61.3%) notified in males, 183 •	
cases (38.3%) in females and the mean age of cases 
was 40.8 years (range 1 to 94 years)
Resistance was reported in 10 cases, three were •	
mono-resistant to isoniazid and five were MDR-TB. 
Eight of the 10 resistant cases, including four of the 
MDR cases, were born outside Ireland
A comprehensive report on 2006 data and a provisional 
report on 2007 data can be found at www.ndsc.ie/hpsc/
A-Z/Vaccine Preventable/TuberculosisTB/Publications/
AnnualReportsontheEpidemiologyofTBinIreland/ 
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Infectious Intestinal Diseases
03
Campylobacter is the commonest bacterial cause 
of gastroenteritis in Ireland.  In 2007, 1891 cases of 
Campylobacter infection were notified (44.6/100,000 
population). There is a continuing increase in the 
number of cases notified (up by 76 cases in 2007).  This 
is reflected in the crude incidence rate which increased 
from 42.8 in 2006 to 44.6 in 2007, which is the highest 
rate reported in Ireland since 1999 (table 1). 
Campylobacter became a notifiable disease in Ireland in 
2004.  Prior to this, data on laboratory-confirmed cases 
of Campylobacter infection in humans were collected 
nationally as part of the EU Zoonoses Regulations.
Regionally, the HSE-W and HSE-M continue to 
experience high incidence rates. The HSE-W region 
had a rate of 62.7 in 2007, which is an increase of 12.6 
over 2006 levels. Similarly the HSE-M region had a rate 
of 58.0,  an increase of 8.6 over 2006 levels.  The HSE-
NE region reported the lowest rate of 35.8 in 2007 
(figure 3).
Campylobacter has a well documented seasonal 
distribution with a peak in early summer.  The highest 
number of cases were reported in May with 254 in the 
month. Seventy four cases were notified in December.
In 2007, the highest burden of illness was seen in 
children less than five years of age, with 25.6 % of 
cases occurring in this age-category  (An age-specific 
incidence rate of 159.8 cases/100,000 was reported in 
the 0-4 age group).  This is also noted in previous years 
and is a well-reported feature of campylobacteriosis.
Analysis of age-sex adjusted rates show a predominance 
of male cases in every age category, except the 15-19 
and 25-34 age groups. Males accounted for 53.5% of all 
cases, females for 45.8% and the gender is unknown in 
0.7% of cases.
Due to the absence of a Campylobacter reference 
facility in Ireland, routine typing of human 
Campylobacter isolates is not conducted.  Information 
on species type was available for 37% (695/1891) of 
3.1 Campylobacter 
Summary
-40-
Number of cases in 2007: 1891
Number of cases in 2006: 1815
Crude incidence rate: 45/100,000
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Table 1.  Annual number of cases of campylobacteriosis in Ireland, 
1999-2007
Year Number of cases
Crude incidence rate 
(95% CI)
1999 2085 57.5 [55.0 – 60.0]
2000 1613 41.2 [39.2 – 43.2]
2001 1286 32.8 [31.0 – 34.6]
2002 1336 34.1 [32.3 – 35.9]
2003 1568 40.0 [38.0 – 42.0]
2004* 1710 40.3 [38.4 - 42.2]
2005* 1801 42.5 [40.5 - 44.4]
2006* 1815 42.8 [40.8 - 44.8]
2007* 1891 44.6 [42.6 - 46.6]
*rates based on 2006 Census data
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isolates. Of these, 91% (n=630) were reported as C. 
jejuni; 9% (n=62) as C. coli, one reported case of C. 
fetus and two reported cases of C. upsaliensis. C. 
upsaliensis was not reported in Ireland between 2004 
and 2006. 
In 2007 there were eight family outbreaks and 
one general outbreak in a residential home of 
campylobacteriosis notified. A total of 21 cases of illness 
were associated with these outbreaks. These were all 
small clusters of illness with no more than three people 
reported ill in any outbreak.
Information on country of infection was only provided 
in 14% (257/1891) of cases.  Of these, the majority were 
reported to have been acquired within Ireland (n=229), 
with just 11% associated with foreign travel.  Spain (n=6) 
and France (n=3) were the most commonly reported 
countries.  There were 16 different countries (excluding 
Ireland) cited as a country of infection. However the 
cases reported with known country of infection is 
considered to be an underestimate of the true burden 
of travel-associated cases.
In October 2007, co-ordination of European surveillance 
of Campylobacter via the Enter-net network ceased. The 
role was assumed by the European centre for Disease 
Prevention and Control (ECDC). It is one of the six 
priority diseases covered by the Food and Water Borne 
Diseases (FWD) network.
In a community summary report on zoonoses, published 
by European Food Safety Authority (EFSA) on data 
submitted in 2006, campylobacteriosis remained the 
most frequently reported zoonotic disease in humans. 
Campylobacter was determined to be the causative 
agent in 6.9% of all reported foodborne outbreaks. 
The EU incidence rate in humans was 46.1 per 100,000 
population, however, there is large variation in the 
incidence of campylobacteriosis reported between 
member states.
See www.hpsc.ie for more a detailed Campylobacter 
epidemiology report for 2007
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Figure 1. Seasonal distribution of Campylobacteriosis in Ireland, 
2004-2007
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Figure 2. Age standardised incidence rates (ASIR) of human 
campylobacteriosis in Ireland, compared to crude incidence rates (CIR) 
in each health board, 2007.
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Cryptosporidiosis
In 2007, 609 cases of cryptosporidiosis were notified 
in Ireland, a crude incidence rate of 14.4 per 100,000 
population (table 1). This was a 66% increase on the 
number of cases notified in 2006, and was the highest 
annual number of cases since the disease became 
notifiable in 2004. 
The crude incidence (CIR) and age standardised 
incidence (ASIR) rates by HSE area for 2007 are reported 
in table 1. The main reason for the increased incidence 
in 2007 was the very high number of notifications in the 
HSE-W associated with a large outbreak in the spring 
of 2007. As in previous years, the HSE E reported the 
lowest crude incidence rate. 
Disease incidence peaked slightly earlier than in 
previous years (figure 1), however, this was strongly 
influenced by the HSE-W outbreak. When notifications 
from the HSE-W are excluded, the seasonal pattern was 
comparable to previous years.
Typically, the highest reported incidence rates are in 
children under 5 years, and this year, the trend was 
similar. Overall, there were more males (n=327) than 
females (n=278) reported. 
A crude indicator of disease severity can be obtained 
from reviewing rates of hospitalisation among cases. 
This information is available for cases reported in those-
areas whose data is recorded live on CIDR. Using data 
from these 6 HSE-areas (244 notifications), 33% of cases 
were reported as hospital inpatients, 2% as day or 
outpatients, 52% as GP patients, and this information 
was unknown or not specified for 11% of cases.
An interesting development in 2007 has been the 
routine referral of positive Cryptosporidium specimens 
for speciation by a small number of hospital 
laboratories. Prior to this, typing of positive human 
specimens was only rarely undertaken except in the 
event of outbreaks. The results of these studies provide 
the first systematic evidence of the relative importance 
of different Cryptosporidium species here. In the United 
Kingdom, speciation of human isolates, in conjunction 
with case control studies and other surveillance 
3.2 Cryptosporidiosis
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Summary
Number of cases, 2007: 609
Number of cases, 2006: 367
Crude incidence rate, 2007: 14.4/100,000
HSE area
Number of 
notifications
CIR (95% CI)* ASIR (95% CI)*
ER 22 1.5 (0.9-2.1) 1.4 (0.8-2.0)
M 34 13.5 (9.0-18.1) 12.8 (8.5-17.1)
MW 57 15.8 (11.7-19.9) 16.0 (11.9-20.2)
NE 24 6.1 (3.7-8.5) 5.6 (3.3-7.8)
NW 25 10.5 (6.4-14.7) 10.6 (6.4-14.7)
SE 79 17.1 (13.4-20.9) 16.9 (13.1-20.6)
S 60 9.7 (7.2-12.1) 9.9 (7.4-12.4)
W 308 74.4 (66.1-82.7) 75.8 (67.3-84.2)
Total 2007 609
14.4 (13.2-
15.5)
-
Total 2006 367 8.7 (7.8-9.5) -
Total 2005 570
13.4 (12.3-
14.5)
-
Total 2004 431 10.2 (9.2-11.1) -
*Rates calculations based on CSO census 2006, and may differ from 
rate published previously based on 2002 census
Table 1. Number of notified cases, crude incidence rate and age-
standardised incidence rate cryptosporidiosis by HSE area, 2007, and 
annual number of cryptosporidiosis notifications and crude incidence 
rate, Ireland 2004-2006
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Figure 1. Seasonal distribution of cryptosporidiosis cases 2004-2007 
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data, has proved invaluable in understanding the 
epidemiology of cryptosporidiosis. 
In 2007, information was available on species for 370 
cases, largely from the HSE-SE, HSE-NW and HSE-W 
areas. There were 131 C. parvum, 134 C. hominis, four 
non-typeable and one cervine infections reported, with 
the species not known/not reported for the remaining 
339 cases. The large outbreak in Galway strongly 
skewed this species distribution data. Over 80% of the 
C. hominis cases were reported from the HSE-W, while 
for non-HSE-W areas, C. parvum was more common, 
suggesting that C. parvum is probably more common 
among sporadic cases. 
Sixteen outbreaks of cryptosporidiosis were reported 
in 2007: six general outbreaks and ten family outbreaks 
(table 2). Three hundred and fifty eight people 
were reported ill as a result of these outbreaks. The 
suspected mode of transmission for nine outbreaks was 
person-to-person, and for three outbreaks, water was 
suspected to have played a role in transmission. Three 
general outbreaks were community outbreaks and two 
small general outbreaks were reported in crèches.
The waterborne outbreak of cryptosporidiosis in Galway 
was the largest such outbreak reported in Ireland since 
surveillance for outbreaks began. In all, 304 laboratory-
confirmed cases were reported. A preliminary report 
on the outbreak showed that it was primarily due to 
C. hominis. Cases were clustered in areas supplied by 
water treatment plants which used water from Lough 
Corrib. Boil water notices were issued for four water 
supplies in March 2007, and were lifted in July and 
August 2007 following closure of two older plants, and 
upgrading of the two newer plants. No specific point 
source of contamination was identified. 
In April 2008, the EPA published a Remedial Action 
List (www.epa.ie/news/pr/2008/april/name,24320,en.
html) – a list of public water supplies which they 
consider require examination from source to consumer 
to determine whether replacements or upgrades were 
needed, or whether operational practices should 
be improved. Several supplies have been placed on 
the list on the basis that they may have inadequate 
treatment for Cryptosporidium. The work arising 
from this prioritisation exercise and the ongoing 
work on upgrading Group Water Schemes under 
the Rural Water Program (www.nfgws.ie/f/fckeditor/
File/RuralWaterNewsautumn08.pdf) should lead to a 
reduction in waterborne illness in Ireland in the coming 
years. 
See www.hpsc.ie for a more detailed report on Cryp-
tosporidiosis 2007
Month HSE-area Transmission route Location Type No. ill
Jan SE Waterborne Community outbreak General 7
Mar W Waterborne Community outbreak General 304
Apr SE Unknown Private house Family 3
Apr SE Unknown Private house Family 2
May SE Person-to-person Private house General 3
May SE Person-to-person Private house Family 2
May SE Person-to-person Private house Family 2
May SE Person-to-person Private house Family 5
Jun SE Person-to-person Community outbreak General 14
Jun S Person-to-person Private house Family 2
Jul MW Unknown Creche General 4
Jul S Waterborne Private house Family 2
Aug NW Person-to-person Private house Family 2
Oct E Not Specified Private house Family 2
Oct S Person-to-person Creche General 2
Nov SE Person-to-person Private house Family 2
Table 2. Cryptosporidiosis outbreaks Ireland 2007
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Verotoxigenic E. coli 
In 2007, 167 confirmed and probable cases of VTEC 
were notified to HPSC, a crude incidence rate (CIR) of 
3.9 per 100,000 (table 1). It should be noted however, 
that this includes 52 probable cases associated with a 
single outbreak, and that there were only 115 confirmed 
cases notified this year. 
As in previous years, the most common serogroup 
reported among confirmed cases was VTEC O157 
(n=94), followed by VTEC O26 (n=13), and there were 
eight additional non-O157 cases. One VTEC O157 case 
was co-infected with a VTEC O103 strain and one VTEC 
O26 case was co-infected with a VTEC O113 strain. 
Although not notifiable, an additional (HUS) case was 
reported as a suspected VTEC case. 
Regional variation was noted in the numbers of cases 
reported (table 2). The highest incidence rate for VTEC 
overall was reported in the HSE-NW (in part due to 
the 52 probable cases reported associated with an 
outbreak during August 2007), however, even when 
only confirmed cases are included, the incidence rate 
there was 7.2 per 100,000. The HSE-M also reported a 
relatively high incidence rate of 7.2 per 100,000. The 
HSE-E and HSE-NW reported the highest numbers of 
non-O157 VTEC infections (table 2).
Disease incidence was highest among young children 
(median age=10 years), which is consistent with previous 
years, and there were similar numbers of male (n=81) 
and female (n=86) cases. 
Information on symptoms was available for 158 
notified cases, of whom 136 (86%) were reported as 
symptomatic. Reported symptoms included bloody 
diarrhoea in 40 cases, and haemolytic ureamic syndrome 
(HUS) in 5 cases. This is a decrease on the number of 
VTEC-associated HUS cases reported in the last 2 years. 
HUS cases ranged in age from 1 to 7 years, and notably,
two HUS cases were associated with non-O157 VTEC 
(one VTEC O145 and one Ungroupable strain). 
3.3 Verotoxigenic E. coli 
Summary
Number of cases, 2007: 167
Number of cases, 2006: 158
Crude incidence rate, 2007: 3.9/100,000
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Table 1. Number and crude incidence rates confirmed and probable 
VTEC, Ireland 2004-2007
Year
Confirmed 
cases 
Probable 
cases 
Total 
VTEC 
CIR VTEC* 
(95% CI) 
2004 61 0 61 1.4 (1.1-1.8)
2005 125 0 125 3.0 (2.4-3.5)
2006 153 5 158| 3.7 (3.2-4.3)
2007 115 52 167 3.9 (3.3-4.5)
* Data from the 2006 census were used to calculate rates 
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In 2007, 117 human VTEC isolates were referred to the 
HSE PHL Dublin Mid Leinster, Cherry Orchard Hospital 
(table 3). As in previous years, PT32 was the commonest 
phage type reported (n=44), accounting for 47% of 
the confirmed VTEC O157 reported. The second most 
common phage type this year was PT51. 
The verotoxin profiles of VTEC strains were typical. 
Eighty-two per cent of VTEC O157 strains carried the 
genes for VT2 only while 18% carried the genes for both 
VT1 and VT2 (table 3). In contrast, 61% of non-O157 
VTEC isolates carried the genes for VT1 only, 35% for 
VT2 only, and 4% VT1 and VT2.
Twenty-one VTEC outbreaks were reported this year, 
comprising 67 of the 115 confirmed cases notified. 
Four outbreaks were described as general outbreaks 
and 17 as family outbreaks. Sixteen were due to VTEC 
O157, three due to VTEC O26, one was caused by 
an Ungroupable strain and one was a mixed strain 
outbreak. The suspected modes of transmission 
reported are listed in table 4. 
Person-to-person spread is an important mode of VTEC 
transmission in households, child-care facilities and 
institutions, and was suspected to have played a role 
in nine VTEC outbreaks in 2007. These included two 
outbreaks associated with crèches.
One general VTEC outbreak in 2007 was linked to 
a hotel in the HSE-NW. There were four confirmed 
cases (one from the Republic of Ireland and three from 
Northern Ireland) and an additional 52 probable cases 
identified through case finding among hotel guests. 
Foodborne transmission was suspected although no 
specific food was implicated during investigations. 
During this incident, PFGE performed by HSE DML-
PHL was invaluable in distinguishing outbreak cases 
from other sporadic cases reported in Ireland around 
this time, supporting the results of public health 
investigations. 
For one general outbreak and for one sporadic case in 
2007, examination of water from the private wells of 
the affected households confirmed the presence of the 
E. coli O157. For the general outbreak, the separate 
Table 2. Number of confirmed and probable VTEC cases by quarter and HSE area, crude incidence rate and age-standardised incidence rate 
by HSE area, Ireland 2007
Quarter E M MW NE NW SE S W Total
Q1 2 0 0 2 4 0 0 2 10
Q2 4 5 6 4 1 3 2 0 25
Q3 6 12 9 5 59‡ 4 9 3 107‡
Q4 7 1 2 1 5 2 3 4 25
VTEC O157 11 18 15 11 60‡ 8 13 9 145‡
Non-O157 VTEC 8 0 1 3 9 1 1 0 20
Mixed infection 0 0 1 1 0 0 0 0 2
Total 19 18 17 12 69‡ 9 14 9 167
CIR VTEC*
(95% CI)
1.3 
(0.7-1.8)
7.2 
(3.9-10.5)
4.7 
(2.5-7.0)
3.0 
(1.3-4.8)
29.1 
(22.2-36.0) ‡
2.0 
(0.7-3.2)
2.3 
(1.1-3.4)
2.2 
(0.8-3.6)
3.9 
(3.3-4.5)
*Rates calculated using CSO census 2006 
‡ Includes 52 probable cases linked to VTEC O157 outbreak
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private wells of adjacent homes were contaminated. 
Drinking water from untreated private water supplies 
remains a very important risk factor for VTEC infection in 
Ireland.
See www.hpsc.ie for a more detailed report on VTEC 
2007
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Table 3. Verotoxin and phage typing results for VTEC isolates referred 
to the PHL HSE Dublin Mid Leinster, Cherry Orchard Hospital in 2007
Serogroup PT
VT1 
only
VT2 
only
VT1 & 
VT2
Total
O157 2 0 5 0 5
4 0 5 0 5
8 0 0 9 9
14 0 7 0 7
31 0 1 0 1
32 0 37 7 44
33 0 1 0 1
34 0 1 0 1
43 0 1 0 1
51 0 12 0 12
21/28 0 5 1 6
RDNC 0 1 0 1
N/K 0 1 0 1
O26 - 12 0 1 13
O ungroupable - 1 4 0 5
O103 - 0 1 0 1
O111 1 0 0 1
O113 - 0 1 0 1
O128 - 0 1 0 1
O145 - 0 1 0 1
Total - 14 85 18 117
Note that for fifty-two probable cases reported on the basis of 
epidemiological linkage, isolates were not available for typing. Table 3 
includes all strains isolated from mixed VTEC infections. 
Table 4. VTEC outbreaks in Ireland 2007 by suspected mode of 
transmission
Suspected mode of 
transmission
Number of 
outbreaks
Number 
confirmed 
cases*
Number 
ill
Animal contact 1 4 1
Foodborne 1 4 56
Person-to-person 9 34 27
Waterborne 2 10 8
Unknown/Not specified 8 19 11
Total 21 71 103
* Confirmed cases include asymptomatic laboratory confirmed cases.
Hepatitis A virus causes an acute, usually self-limiting 
disease of the liver. It is primarily transmitted from 
person to person via the faecal-oral route and is 
associated with poor hygiene and sanitation. Common 
source outbreaks due to contaminated food or water 
may also occur.
The incidence of hepatitis A in Ireland has been low in 
recent years and remained low in 2007, with 32 cases 
notified. This corresponds to a crude notification rate of 
0.8/100,000 population and represents an 18% decrease 
compared to 2006, when 39 cases were notified (figure 
1). Case classification was reported for all cases. Twenty 
nine cases were laboratory confirmed, one was classified 
as probable and two were classified as possible.
Fifty three percent of cases were male (n=17) and 47% 
were female (n=15). All age groups were affected, 
but the highest rates were in children aged 5-14 years 
(figure 2). Eleven cases were associated with travel 
outside of Ireland, nine cases were infected in Ireland 
and the country of infection was not specified for the 
remaining 12 cases.
Three family outbreaks were reported in 2007. Each 
involved two siblings and the ages ranged from three to 
11 years. Two were travel associated.
The figures presented in this summary are based on 
3.4 Hepatitis A
Summary
Number of cases in 2007: 32
Crude notification rate: 0.8/100,000
Number of cases in 2006: 39
Number of cases in 2005: 56
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Figure 1. Number of cases of hepatitis A notified annually, 1982-2007
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data extracted from the Computerised Infectious 
Disease Reporting (CIDR) System on 1st September 
2008. These figures may differ slightly from those 
published previously due to ongoing updating of 
notification data on CIDR.
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Figure 2.  Age and sex-specific notification rates/100,000 population for hepatitis A, 2007
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Rotavirus is the commonest reported cause of acute 
gastroenteritis in children under five years of age in 
Ireland. In 2007, there were 2520 notifications of acute 
infectious gastroenteritis (AIG).  Rotavirus was the 
causative organism identified in 2326 (92%) of these, 
giving a crude incidence rate (CIR) of 54.9 cases per 
100,000 population (table 1).  This is the highest rate 
recorded since rotavirus became notifiable in 2004. The 
CIR increased to 54.9 in 2007 from 50.0 in 2006.
AIG became a statutorily notifiable disease in 2004.  
Only cases of rotavirus and ‘gastroenteritis unspecified’ 
are notifiable under this disease category.  Prior to 
2004, rotavirus was only notifiable as a generic disease 
category of ‘gastroenteritis in children less than two 
years of age’.  Data for this report were extracted and 
analysed from the CIDR system. 
Rotavirus is primarily a paediatric illness, with children 
generally affected in the first 2-3 years of life, with peak 
incidence of clinical disease in the 6-24 month age 
group. Examination of the distribution of cases in 2007 
and previous years by age group illustrates this. In 2007 
the highest burden of illness was in children less than 
five years, as seen in previous years.  The majority of 
infections (n=1780) occurred in children less the two 
years of age.  There has been a continuous increase 
in the number of cases affecting this age group over 
recent years (figure 1).  
Regional variation was observed in the number of cases 
reported (table 1). The HSE-W and HSE-M had the 
highest incidence rates. The lowest rate reported was 
by the HSE-MW region.  HSE-E, HSE-SE and 
HSE–W regions noted a decrease in the rate of rotavirus 
infection compared to 2006. An increased rate was 
reported in all other regions. Such regional variation 
almost certainly reflects differences in diagnosis and 
reporting rather than true variation in disease incidence.
With regard to sex distribution, males accounted for 
1186 cases (51%); females 1116 (48%), with 1% of cases 
unknown.  This represented a ratio of males: females of 
1.1:1.  This was similar to previous years.
3.5 Rotavirus
Summary
Number of cases in 2007: 2326
Number of cases in 2006: 2112
Number of cases in 2005:  2251
Crude incidence rate: 50/100,000
-49-HPSC Annual Report 2007 3. Infectious Intestinal Diseases
Table 1. Number of notified cases, crude incidence rate of rotavirus 
infections in Ireland by HSE area, 2007, and total number with crude 
incidence rate for 2004-2007.
HSE Area No. of cases *CIR incl. 95% C.I.
E 637 42.5 [39.2 - 45.8]
M 243 96.6 [84.4 - 108.7]
MW 74 20.5 [15.8 - 25.2]
NE 106 26.9 [21.8 - 32.0]
NW 176 74.2 [63.3 - 85.2]
SE 353 76.6 [68.6 - 84.6]
S 265 42.7 [37.5 - 47.8]
W 472 113.9 [103.7 - 124.2]
Total 2007 2326 *54.9 [52.6 - 57.1]
Total 2006 2112 *50.0 [48.0 - 52.0]
Total 2005 2251 *53.1 [50.9 – 55.3]
Total 2004 1600 *37.8 [35.9 – 39.6]
*Rates calculated using 2006 census data and may differ from 
previously published rates
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Figure 1: Number of cases of rotavirus in children less than two years 
of age by year, 2001 to 2007
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Rotaviral infection has a well documented seasonal 
pattern with peaks in cases occurring each year in later 
winter/ early spring.  Analysis of the data by week of 
notification from 2004 to 2007 is shown in figure 2. 
However in 2007, there was a change to this pattern.  
The usual upsurge did not appear until week 12, a full 
four weeks later than is usual, and the plateau continued 
for a month longer than usual.  This delay was also 
seen in Germany. In 2007, a peak was observed in both 
weeks 15 and 18 (162 and 176 cases reported). This is 
different from 2005 and 2006 where in week 17, in both 
years, a peak occurred.  (There is a ‘false’ second peak 
seen in 2005 during week 33, which is attributable to 
bulk uploading of notifications for the HSE-W region). 
In 2007, there were seven rotavirus outbreaks and 
one mixed norovirus/rotavirus outbreak notified on 
CIDR. These eight outbreaks resulted in 47 cases of 
illness. The mixed outbreak was the largest rotaviral 
outbreak reported with 17 people ill. This outbreak 
occurred within a crèche with spread being from 
person to person. The second largest  outbreak was 
a pure rotavirus outbreak occurring within a hospital. 
Ten patients were affected via a person-to-person 
transmission route.
See www.hpsc.ie for more a detailed report on the epi-
demiology of rotavirus in Ireland in 2007
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Figure 2: Seasonal distribution of rotavirus events by week, 2004-2007 (CIDR)
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In 2007, 456 cases of salmonellosis were notified in 
Ireland. Of these, 440 cases were laboratory confirmed. 
Probable cases are notifiable under the amended 
Infectious Disease Regulations (2003) if clinical 
symptoms or epidemiological links are identified. This 
resulted in 16 probable cases notified in 2007. All 
probable cases were linked to Salmonella outbreaks on 
CIDR. Four hundred and fifty seven Salmonella isolates 
from humans were referred to the National Salmonella 
Reference Laboratory (NSRL).
In 2007 there was a slight preponderance of cases in 
males, unlike 2006. The female: male ratio in 2007 was 
1:1.1.  In terms of age distribution, the highest number 
of cases was seen in children under five years of age, 
with 23.7% of cases occurring in this age category.  This 
is likely to be a reflection of the greater likelihood of 
clinicians seeking clinical samples in children under five.
An outbreak of S Enteritidis involving 52 cases in HSE-S 
produced a peak in figures in weeks 29 and 30. Analysis 
of remaining cases not associated with this outbreak 
showed seasonal trends as seen in previous years, with a 
plateau from mid-August to early October.  
Analysis of serotyping data provided from NSRL in 
2007 show 64 different serotypes were identified from 
the 457 isolates tested by the reference laboratory.  As 
has been the trend in recent years, the predominant 
serotype causing human illness in 2007 was S. Enteritidis 
(n=179), followed by S. Typhimurium (n=114).  After  
S. Enteritidis and S. Typhimurium, the next most 
commonly isolated serotypes were S. Newport (n=13) 
and S. Kentucky n=9) (table 1).  
There were eight cases of S. Typhi and five isolates of 
S. Paratyphi A detected in 2007, compared to just one 
case of S. Paratyphi A in 2006.  Six of the eight S. Typhi 
cases reported a history travel. Visited countries include 
Pakistan (n=2), India (n=2), Asia (n=1) and Nepal (n=1). 
In the seventh case the patient gave no history of travel 
outside of Ireland. However one relative tested positive 
and it is likely that person to person spread resulted 
in acquisition of the disease in Ireland. No travel 
information was available in the eighth case. All cases of 
S Paratyphi A reported a history of travel to either India 
(n=3) or Pakistan (n=2).
3.6 Salmonella
Summary
Number of confirmed cases in 2007 (CIDR): 440
Number of probable cases in 2007 (CIDR): 16
Number of cases in 2006 (CIDR): 422
Number of human isolates referred to NSRL 
(2007): 457
Crude incidence rate: 10.76/100,000
Year
0
5
10
15
20
25
30
35
40
1982 1983 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
C
IR
Figure 1. Crude rate of Salmonellosis Notified in Ireland per 100,000 population, 1982-2007
CIR, crude incidence rate per 100,000 population
Phage typing was conducted by the NSRL on all S. 
Enteritidis and S. Typhimurium isolates. Among S. 
Enteritidis isolates PT4 as the most prevalent phage 
type identified (n=71), largely due to an outbreak during 
July. PT8 was the second most widespread  S. Enteritidis 
phage type identified (n=35). Among S. Typhimurium, 
DT104 was the most common phage type (n=21), 
followed by S. Typhimurium DT120 (n=19).
One hundred and seventy four out of 457 isolates (38%) 
reported to NSRL in 2007 have a known history of travel 
outside of Ireland. This is almost double the number 
reported during 2006 (21%).  The most commonly 
reported countries were Spain (n=27), Turkey (n=15), 
Thailand (n=12), Canary Islands (n=11), Portugal (n=10), 
India (n=10) and Nigeria (n=6). Although in previous 
years underestimation of foreign history travel was 
evident, the figures for 2007 shows more detailed 
information is being reported. 
In 2007, there were 10 outbreaks of salmonellosis 
notified via CIDR to the HPSC; three general and 
seven family outbreaks.  Of the seven family outbreaks, 
one was travel associated and the remaining six were 
located in private houses. The three general outbreaks 
had a total of 65 ill. There were two smaller outbreaks, 
one located in a crèche and the other in a community 
with 13 associated cases. 
The third outbreak was notified in mid-July of 2007 in 
HSE-S. There were 52 cases with a 31% hospitalisation 
rate. The cases were notified from the 2nd week of July 
until the 1st of August. The peak onset of illness was 
6th-9th July. The outbreak phage type was identified as 
S Enteritidis PT4. The outbreak was epidemiologically 
linked to a local bakery, bakery X. Results from the 
analytical study indicated a strong statistical association 
between illness and eating food from bakery X and/or 
eating food from outlets supplied by bakery X  
Investigators concluded that it was not possible to 
definitively state how Salmonella Enteritidis was 
introduced to Bakery X. However, the evidence 
appeared to support the introduction of S. Enteritidis by 
either pigeons or by foodhandlers.  Once introduced, 
conditions and practices in the premises could then 
have contributed to the spread of infection within the 
premises. Department of Agriculture and Food trace 
back to the supplying flocks revealed no evidence of 
supply of contaminated raw eggs to the premises. The 
bakery closed voluntarily.
See www.hpsc.ie for a more detailed Salmonella epide-
miology report for 2007
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Table 1. Salmonella serotype distribution 2005-2007 (NSRL)
2005 2006 2007
Rank Serotype No. (%) Serotype No. (%) Serotype No. (%)
1 Enteritidis 145 (41%) Enteritidis 158 (37%) Enteritidis 179 (39%)
2 Typhimurium 85 (24%) Typhimurium 101 (23%) Typhimurium 114 (25%)
3 Agona 10 (3%) Hadar 11 (3%) Newport 13 (3%)
4 Virchow 9 (3%) Infantis 11 (3%) Kentucky 9 (2%)
5 Hadar 8 (2%) Virchow 10 (2%) Typhi 8 (2%)
6 Goldcoast 7 (2%) Newport 9 (2%) Java 8 (2%)
7 Java 7 (2%) Saintpaul 8 (2%) Infantis 8 (2%)
8 Stanley 6 (2%) Typhi 7 (2%) Panama 7 (2%)
9 Dublin 5 (1%) Bredeney 6 (1%) Virchow 5 (1%)
10 Newport 5 (1%) Stanley 6 (1%) Paratyphi A 5 (1%)
 Others 70 (19%) Others 103 (24%) Others 101 (21)%
357 (100%) 430 (100%) 457 (100%)
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Shigellosis
Forty-three cases of shigellosis were notified in 2007 
compared to 54 in 2006 and 36 in 2005 (Figure). 
Cases ranged in age from less than one year to 60 years 
(mean age=27 years, median age=26 years), with more 
females (n=27) than males (n=16). 
As in previous years, Shigella sonnei was the most 
common species reported (n=23). There were also 14 
S. flexneri, three S. boydii, one S. dysenteriae, and two 
cases for which the species was not reported. 
Information on travel history is improving, with eighteen 
cases (42%) reported associated with foreign travel. 
The countries of infection reported were India (n=6), 
Pakistan (n=3), Egypt (n=2), and there was one case 
associated with travel to each of Afghanistan, Gambia, 
Ghana, Mexico, Morocco, occupied Palestine Territories, 
and United Kingdom. Three cases were reported 
as being acquired in Ireland, and for the remaining 
22 cases, country of infection was unknown or not 
specified. The number of cases by species and country 
of infection is reported in the table below. 
In the last decade, the number of cases of shigellosis 
has remained low in comparison to the number of cases 
notified in the early 1990s.
While no shigellosis outbreaks were notified in Ireland 
in 2007, typing of Shigella isolates can provide useful 
information on the relatedness of strains which can be 
used by public health to outrule/include cases during 
investigations of case clusters. The National Salmonella 
Reference Laboratory in University College Hospital, 
Galway can provide services for serotyping, and where 
appropriate, Pulsed Field Gel Electrophoresis (PFGE) of 
Shigella isolates.
3.7  Less common gastrointestinal 
 infections
Table. Number of notifications shigellosis by species and country of infection, Ireland 2007
Species Ireland Africa Asia Other Not known/ not 
reported
Total
S. boydii 0 1 1 0 1 3
S. dysenteriae 0 0 1 0 0 1
S. flexneri 0 2 4 1 7 14
S. sonnei 2 2 5 1 13 23
Not reported/not known 1 0 0 0 1 2
Total 3 5 11 2 22 43
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Figure 1.  Annual number of notifications shigellosis, Ireland 1991-2007    
Giardiasis
In 2007, there were 62 cases of giardiasis notified, a 
slight decrease on the number notified in 2006 (n=65).
Cases ranges in age from 1-93 years (mean age=24 
years, median age=24 years), with more males (n=36) 
than females (n=23) reported; sex unknown for three 
cases.
Six cases were reported as being associated with 
foreign travel: the countries of infection reported were 
France, Republic of Korea, Russian Federation (n=2), 
Spain, and the United States. One case was reported 
as being acquired in Ireland, and for the remaining 
55 cases, country of infection was unknown or not 
specified.
In 2007, there were three small family outbreaks 
reported. The mode of transmission for one was 
reported as person-to-person spread, and unknown for 
the remaining two outbreaks. 
Yersiniosis
In 2007, there were six cases of yersiniosis, compared to 
one notification in 2006 and three in 2005. 
Cases ranged in age from one month to 79 years; four 
females and three males were notified. 
Five cases were reported as Y. enterocolitica and one as 
Y. pseudotuberculosis.
-54- HPSC Annual Report 20073. Infectious Intestinal Diseases
-55-HPSC Annual Report 2007 3. Infectious Intestinal Diseases
3.8 Listeriosis 
Twenty-one listeriosis cases (CIR 0.5 per 100,000 
population) were reported in Ireland in 2007, three 
times the number of cases that were notified in 2006. 
This is against a backdrop of increased reporting of 
human listeriosis across the EU over the last eight years. 
Overall the reported incidence of listeriosis across the 
EU in 2006 was 0.3 per 100,000 (range 0.0-1.0 per 
100,000).
Cases were distributed throughout Ireland, with higher 
number of cases than usual reported in Quarters 3 and 
4 (table 1). 
In particular, there was a significant increase in the 
reported number of pregnancy-associated and neonatal 
cases. Nine pregnancy-related/neonatal cases were 
notified in 2007 -an estimated rate of 14.0 notifications 
per 100,000 live birthsa- compared with five pregnancy-
related/neonatal cases for the entire period 2004-2006 
(Table 2). Of particular note was the fact that five of the 
pregnancy-related cases in 2007 were non Irish-born 
women; three from Eastern Europe, one from Asia and 
one from Africa. In addition, one of the neonatal cases 
was born to an Eastern-European mother. This increase 
in the number of pregnancy-associated cases in Ireland 
contrasts with recent rises in human listeriosis incidence 
noted in Germany and in England & Wales, where 
elevated numbers of non-pregnancy associated adult 
cases were reported.
There were also 12 non-pregnancy associated adult 
cases notified in 2007, all except one of which were 
reported as elderly (>65 years) and/or suffering from an 
underlying illness which predisposed them to listeriosis; 
the remaining adult case was >55 years. Seven cases 
were male (58%) and five were female, age range 30-79 
years (median=71 years). 
There were no adult fatalities due to listeriosis in 2007, 
however, two women were reported as having suffered 
late miscarriages. 
Summary
Number of cases in 2007: 21
Number of cases in 2006: 7
Crude incidence rate, 2007: 0.5/100,000
Table 1. Listeriosis notifications by quarter and year, Ireland 2004-2007
 Quarter 2004 2005 2006 2007 Total
Q1 2 2 5 2 12
Q2 3 3 0 1 7
Q3 4 5 1 11 21
Q4 2 2 1 7 12
Total 11 12 7 21 51
CIR (CI) per 100,000* 0.26(0.11-0.41) 0.28(0.12-0.44) 0.17(0.04-0.29) 0.50(0.28-0.71) -
*CSO data from census 2006 as denominator in incidence rates
aRate was calculated using an the number of births reported by CSO for 2006 as an estimate of the number which occurred in 2007 as data not 
yet published for 2007.
-56- HPSC Annual Report 20073. Infectious Intestinal Diseases
Isolates for sixteen human cases notified in 2007 were 
serotyped at NSRL (Table 3). While the predominant 
serotype from patients was 4b, 1/2 was the predominant 
Listeria monocytogenes serotype isolated from food. 
Listeria isolates can be further characterized by 
molecular typing methods to investigate possible links 
between cases. During the upsurge in cases in 2007, 
isolates were examined by the National Salmonella 
Reference Laboratory (NSRL) using pulsed field gel 
electrophoresis (PFGE), and by Waterford Regional 
Hospital (WRH) using ribotyping. Only two isolates were 
indistinguishable both by ribotyping and PFGE. From 
these results, it appears that the upsurge in cases was 
not caused by a single common strain, with evidence for 
a possible unrecognized common link only between two 
cases.
Typing of human Listeria monocytogenes isolates during 
the upsurge in cases was invaluable, as it supported the 
results of public health investigations which suggested 
an increased incidence of sporadic disease rather than a 
large common source outbreak. 
In consequence of the rise in the number of pregnancy-
associated/neonatal cases in 2007, efforts have been 
made to develop appropriate messages for pregnant 
women, in particular those whose first language is not 
English. A leaflet highlighting ways to minimize the risk 
of listeriosis has been developed for pregnant women 
by Safefood (www.safefood.eu/article.asp?article=2377). 
This leaflet has been translated into several languages. 
Table 2. Listeriosis notifications by case type, Ireland 2004-2007
Case type 2004 2005 2006 2007 Total
Adult or 
juvenile
8 12 5 12 37
Pregnancy-
related
3 0 1 6 10
Neonatal 0 0 1 3 4
Total 11 12 7 21 51
Table 3. Serotypes of Listeria monocytogenes isolates from 2007 
referred to the NSRL
Serotype Human Food
1/2 4 15
4b 12 3
Untypeable 0 1
Total 16 19
Vectorborne and Zoonotic Diseases
04
Leptospirosis
Twenty-two cases of leptospirosis were notified in 
2007, compared to 20 in 2006 and 15 in 2005.  All 
except one case this year was male. Age range 20-73 
years (mean age =41 years, median age=38 years). Ten 
cases required hospitalization, four were reported as 
GP patients, and patient type was not available for the 
remaining 8 patients. Over three quarter of all cases 
(n=17) were notified in the last half of the year.
Ten cases were believed to have acquired their 
illness occupationally –through contact with farm 
environments. Seven cases were reported as having 
recent contact with river water including three cases 
who were exposed in Asia (Laos for one case and 
Thailand for two cases). No risk factor information was 
available for the remaining 5 cases. 
Four cases in 2007 were infected with Leptospira 
interrogans hardjo, including three farming-related 
cases. One occupational case who had worked on a 
farm silage pit was reported as being infected with 
Leptospira interrogans icterohaemorrhagiae. Species 
was not reported for the remaining 17 cases.
Activities that have been associated with leptospirosis 
risk include farming, occupations that involve contact 
with wet rodent-infested environments, recreational 
activities such as water sports, and flooding. 
In the last 2 years, travel to Asia (in particular Thailand) 
has emerged as a risk factor for leptospirosis in Ireland. 
This has been noted previously in the United Kingdom.
4.1 Non-IID Zoonotic Diseases
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Figure 1. Annual number of leptospirosis notifications, Ireland 1991-2007 
(data source: CIDR)
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Toxoplasmosis
During 2007, 49 cases of toxoplasmosis were notified 
compared to 44 in 2006 and 45 in 2005.  
Two cases were reported as congenital cases.  
Congenital cases were identified through a pilot 
toxoplasmosis screening program which commenced in 
July 2005, and was coordinated at the Rotunda Hospital 
in conjunction with the National Newborn Screening 
Laboratory. The pilot program was completed in July 
2007.
The remaining 47 cases ranged in age from 4 years to 
63 years (median, 32 years).  Of the 47 cases, 32 were 
female and 15 were male. The high number of cases 
reported among women of child-bearing age may 
reflect enhanced testing during pregnancy. 
 
Brucellosis
During 2007, 28 cases of brucellosis were notified 
compared 29 in 2006 and 53 notifications in 2005. 
Twenty-five cases (89%) were male while three (11%) 
were female. The cases ranged in aged from 27 years 
to 80 years (mean age, 53 years; median age, 55 years). 
The age and sex distribution for brucellosis in recent 
years in Ireland suggests that occupational exposure is 
likely to be the main transmission route for this disease. 
In 2007, seven cases were reported as confirmed, and 
21 as were classified as probable. The case definition 
permits inclusion of acute and chronic cases. In 2007, 
22 cases were reported as chronic cases; acute/chronic 
status was not reported for the remaining 6 cases. 
 
Table.Toxoplasmosis notifications by age and sex, Ireland 2007
Age group Male Female Total
<1 yr 2 0 2
1-4 yrs 1 0 1
5-14 yrs 2 0 2
15-24 yrs 3 2 5
25-44 yrs 5 26 31
45-64 yrs 4 4 8
65+ yrs 0 0 0
Total 17 32 49
Table. Brucellosis notifications by age and sex, Ireland 2007
Age group Male Female Total
<5 yr 0 0 0
5-14 yrs 0 0 0
15-24 yrs 0 0 0
25-44 yrs 3 1 4
45-64 yrs 18 2 20
65+ yrs 4 0 4
Total 25 3 28
Q Fever
Seventeen cases of Q fever were notified during 2007 
compared to 12 in 2006 and ten in 2005. 
Six cases occurred in males and eleven in females. The 
cases ranged in age from three years to 83 years (mean 
age, 41 years; median age, 37 years). 
Four cases were classified as confirmed and thirteen as 
probable.
The disease is commonly acquired through occupational 
exposure to infected sheep, e.g. farmers, veterinarians, 
and abattoir workers. In 2006, the United Kingdom 
reported a large outbreak of Q fever associated with a 
slaughterhouse in Scotland . 
Donaghy M, Prempeh H, Macdonald N. Outbreak of Q fever 
in workers at a meat processing plant in Scotland, July 2006. 
Euro Surveill. 2006;11(34): 3031. Available online: http://www.
eurosurveillance.org/ViewArticle.aspx?ArticleId=3031
Trichinosis
Two linked cases of trichinosis were reported in Ireland 
in 2007. These were the first cases of trichinosis 
notified in Ireland since the disease became notifiable 
in 2004. The cases had travelled to Poland during their 
incubation period where they consumed lightly smoked 
sausages.1 They were linked to a large outbreak which 
was reported in Poland at that time.2
McHugh G, Low J, Healy ML, Clarke S, Kiely D, Hayes C,.1.  2007. 
Two Cases of Trichinosis in Polish Nationals living in Ireland. Epi-
insight 8:1
Golab E, Szulc M, Wnukowska N, Rozej W, Fell G, Sadkowska-2. 
Todys M. Outbreak of trichinellosis in north-western 
Poland – Update and exported cases, June-July 2007. Euro 
Surveill. 2007;12(29):pii=3238. Available online: http://www.
eurosurveillance.org/ViewArticle.aspx?ArticleId=3238
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Table. Q fever notifications by age and sex, Ireland 2007
Age group Male Female Total
<5 yr 0 1 1
5-14 yrs 0 0 0
15-24 yrs 1 0 1
25-44 yrs 3 6 9
45-64 yrs 1 2 3
65+ yrs 1 2 3
Total 6 11 17
In 2007, 71 cases of malaria were notified (figure 1). This 
is a decrease of 26% on the number reported in 2006, 
and equates to a crude annual incidence rate of 1.7 per 
100,000 (95% C.I. 1.3-2.1). 
Cases ranged in age from 1 to 85 years, and male cases 
(n=43) were more common than female cases (n=26); 
for two cases, sex was unknown/unspecified. Notably, 
there were 17 paediatric cases (24%) and 37 cases (52%) 
in the 25-44 years age range. 
The highest number of cases were reported by the 
HSE-E (n=32). There were also 8 cases in the HSE-M, 3 
in the HSE-MW, 6 in the HSE-NE, 9 in the HSE-SE, 6 in 
the HSE-S and 7 in the HSE-W. 
Species data were reported for 92% of cases in 2007. 
As in previous years, the most common species 
reported was P. falciparum, accounting for 70% of all 
cases notified (n=50). There were also seven P. vivax, 
five P. ovale, three P. malariae and six cases where the 
species was not specified. This is similar to the species 
distribution reported by the United Kingdom and in 
Europe for cases of imported malaria.
Information on patient type was available for 70% of 
patients (n=50), with 37 cases reported as hospital in-
patients, seven as hospital out-patients, three as GP 
patients, one as a hospital day patient, and two as 
patient type=other. No deaths due to malaria were 
reported to HPSC in 2007.
Country of infection was recorded for 54 cases, the 
majority of whom were exposed in sub-Saharan Africa; a 
smaller number of cases were associated with exposure 
in Asia and South America (table 1). One P. vivax case 
was reported as a relapsed infection.
Reason for travel was recorded for 53 cases. The largest 
subgroup identified in 2007 was people who had 
travelled to visit family in their country of origin -  over 
half of those for whom the information was available 
(n=38). New entrants made up a further 6 cases.  Other 
reasons reported for travel were holidays (n=5), business 
travellers (n=1), armed services (n=1), other (n=2) and 
not specified (n=18).  
Of the 38 cases whose reason for travel was reported 
4.2 Malaria 
Summary
Number of cases, 2007: 71
Number of cases, 2006: 96
Crude incidence rate, 2007: 1.7/100,000
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Figure 1. Number of malaria notifications, Ireland 1982-2007
as ‘visiting family in country of origin’, five were born 
in Ireland and all five were less than six years of age, 
presumably representing the children of immigrants. 
In comparison to their parents who may retain some 
immunity from previous exposure (although this fades 
when they no longer live in endemic areas), these 
children are likely to be more susceptible than their 
parents.
Excluding new entrants (those who had spent their 
lives to date living in an endemic region would not be 
expected to be taking chemoprophylaxis), information 
on malaria prophylaxis was available for 46 of the 
remaining 65 cases. Of these, 36 took no prophylaxis, 
and eight took prophylaxis but failed to continue for 
the required period. Only two cases reported full 
compliance with prescribed course of prophylaxis. 
In two instances, more than one member of the same 
family was affected after a visit to a malarious region.
With increasing holiday travel to malarious destinations, 
and a growing immigrant community who regularly 
travel home, it is now becoming more likely that 
malarial patients will present to the health services. 
Given the potential for fatal complications in severe 
cases, it is important for clinicians to consider malaria 
as a diagnosis when presented with patients with 
compatible symptoms who have history of travel to a 
malaria endemic country within the preceding year.
International information on malaria is available at 
www.who.int/malaria/ 
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Table 1. Malaria notifications, Ireland 2007 by country of exposure
Country of exposure Number 
notifications
% notifications
Sub-saharan Africa 48 68%
   Nigeria 37 52%
   Other than Nigeria 11 15%
Asia 5 7%
South America 1 1%
Not reported 17 24%
Total 71 100%
05
Blood-borne and 
Sexually Transmitted Infections
Hepatitis B is a vaccine preventable disease which 
is transmitted through contact with the blood or 
body fluids of an infected person. The main routes of 
transmission are mother to baby, sexual contact and 
unsafe injections. Over 90% of people infected as 
adults clear the virus, but there is a high probability of 
developing chronic infection if hepatitis B is acquired in 
infancy (90%) or early childhood (20-50%).
Notification rates for hepatitis B in Ireland have 
increased dramatically over the past decade but appear 
to be levelling off over the past few years. The number 
of cases reported increased slightly in 2007, with 863 
notifications (20.4/100,000 population) compared 
to 811 in 2006 (figure 1). Sixty percent (n=521) of 
notifications were from the HSE-E, corresponding to 
an age-standardised notification rate of 32.6/100,000 
population.
All cases were laboratory confirmed. Eighty eight 
percent contained information on the acute/chronic 
status. Where status was known, 93% of cases were 
chronic (n=705) and 7% were acute (n=52).
Acute cases
Seventy nine percent (n=41) of acute cases were male, 
19% (n=10) were female and sex was not known for one 
case. The highest rates were among young to middle 
aged adults, with 73% of cases (n=38) aged between 20 
and 44 years (figure 2). 
Some risk factor data were available for 83% (n=43) of 
acute cases. The predominant mode of transmission 
was sexual, with 63% (n=27) likely to have been sexually 
acquired. Fifteen of these were heterosexuals, ten were 
men who have sex with men and sexual orientation was 
not available for two. A further eight cases (19%) were 
born in a country of intermediate (2-7%) or high (≥8%) 
hepatitis B endemicity. Where reason for testing was 
5.1 Hepatitis B
Summary
-64-
Number of cases in 2007: 863
Crude notification rate: 20.4/100,000
Number of acute cases in 2007: 52
Number of chronic cases in 2007: 705
Number of cases in 2006: 811
HPSC Annual Report 2007  5 Blood-borne and Sexually Transmitted Infections
-65-HPSC Annual Report 2007 5 Blood-borne and Sexually Transmitted Infections
known (n=45), 69% (n=31) were tested because they 
were symptomatic. 
Country of birth was known for 45 acute cases and 78% 
(n=35) were born in Ireland. Where country of infection 
was known (n=41), 73% (n=30) were infected in Ireland.
Chronic cases
Fifty two percent of chronic cases were male (n=364), 
43% were female (n=307) and sex was not known for 5% 
(n=34). Eighty one percent (n=574) were aged between 
20 and 44 years. The median age for males (34) was 
higher than that for females (29.5) (figure 2).
Risk factor data were very limited for chronic cases, but 
some data were available for 42% (n=297). Of these, 
85% (n=252) were identified as asylum seekers or as 
having been born in a country with high or intermediate 
hepatitis B endemicity. Where country of birth was 
known, 34% (n=84) were born in Sub-Saharan Africa, 
25% (n=62) were born in Eastern or Central Europe and 
23% (n=58) were born in Asia. Only 14% (n=34) of the 
chronic cases with country of birth data were born in 
Ireland.  
Reason for testing was known for 371 chronic cases. 
Thirty four percent (n=127) were identified through 
antenatal screening programmes, 24% (n=89) were 
identified through asylum seeker screening programmes 
and 14% (n=52) were diagnosed as a result of testing in 
sexually transmitted infection settings.
Eight Irish-born chronic cases were residents of 
intellectual disability institutions. Their ages ranged 
from 43 to 52 years. Most were diagnosed as a result of 
routine screening and may have been infected for some 
time.
Discussion
The number of cases of hepatitis B identified is 
influenced by screening programmes and these have 
expanded over the past decade. The vast majority of 
hepatitis B notifications in 2007 were chronic cases. 
Available data indicate  that most were born in countries 
where hepatitis B is endemic and were infected outside 
of Ireland. The number of acute cases notified was low 
and sexual acquisition was the predominant mode of 
transmission. 
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Figure 1. Number of hepatitis B notifications by accute/chronic status, 1988-2007 
 
*Case definitions, which differentiate between acute and chronic cases of hepatitis B, and mandatory laboratory reporting of notifiable 
infectious diseases were introduced in 2004
1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004* 2005 2006 2007
Acute Chronic Unknown
Hepatitis B vaccine was added to the routine childhood 
immunisation schedule in September 2008 (www.ndsc.
ie/hpsc/A-Z/VaccinePreventable/Vaccination/Guidance/). 
This universal infant vaccination programme will be run 
in parallel with the pre-existing targeted immunisation 
programme, which recommends hepatitis B vaccination 
for individuals who are at increased risk of infection 
because of their lifestyle, occupation or other factors. 
This includes individuals who change sex partner 
frequently, injecting drug users, healthcare workers, 
haemophiliacs, renal dialysis patients and close contacts 
of cases.
Antenatal screening for hepatitis B is now carried out  in 
all Irish maternity hospitals. Administration of hepatitis 
B immunoglobulin and vaccine to babies of infected 
mothers soon after birth can prevent infection being 
transmitted.
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) System on 15th August 2008. 
These figures may differ slightly from those published 
previously due to ongoing updating of notification data 
on CIDR.
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Figure 2. Age and sex-specific notification rates/100,000 population for hepatitis B by acute/chronic status, 2007
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The hepatitis C virus is primarily transmitted through  
sharing contaminated equipment when injecting 
drugs or through the receipt of unscreened blood or 
blood products. Sexual, occupational and perinatal 
transmission can also occur but are less common. 
Infection is initially asymptomatic in approximately 90% 
of cases, but between 60 and 85% of those infected fail 
to clear the virus and develop chronic infection.
Hepatitis C became a notifiable disease in Ireland in 
2004 and the number of cases reported each year since 
then has been high. Notifications increased by 28% to 
1,558 in 2007, compared to 1,220 in 2006 (figure 1). This 
corresponds to a crude notification rate of 36.7/100,000 
population. All cases were laboratory confirmed. 
The sex distribution of cases was very similar to previous 
years with a strong predominance of male cases (figure 
1).  In 2007, 63% (n=979) of cases were male, 35% 
(n=551) were female and sex was not known for 28 
cases. The age profile was similar for both sexes, with 
the highest notification rates in young to middle aged 
adults. Seventy two percent (n=1,124) of cases were 
aged between 25 and 44 years and 92% (n=1,427) were 
aged between 20 and 54 years. The median age for 
females was younger (31) than that for males (34)
(figure 1).
The geographic distribution of cases was skewed, with 
the HSE-E reporting 77% of all cases (n=1,206). Their 
age-standardised notification rate, of 73.8/100,000 
population, was approximately four times that of the 
next highest area (figure 2).
An enhanced surveillance system for hepatitis C was 
implemented in 2007 and some risk factor data were 
identified for 42% of cases (n=658). The most likely risk 
factor for 75% (n=496) was injecting drug use.  A further 
3.8% (n=25) were either prison inmates or homeless. 
Although mode of transmission was not reported for 
these cases, both groups have high prevalences of 
injecting drug use. 
5.2 Hepatitis C
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Summary
Number of cases in 2007: 1,558
Crude notification rate: 36.7/100,000 population
Number of cases in 2006: 1,220
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Figure 1.  Number of hepatitis C notifications and median age by sex, 2004-2007
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Thirty four cases (5.2%) were reported as likely to 
have been infected through receipt of blood or blood 
products. Of these, 19 were infected in Ireland. There 
were no further data for one of these 19, but the 
remainder were all infected through anti-D or blood 
transfusions acquired many years in the past, but were 
notified for the first time in 2007. 
Hepatitis C notification rates may not accurately reflect 
incidence trends in Ireland as it is likely that a significant 
proportion of cases notified do not represent newly 
acquired infections. Infection is frequently asymptomatic 
initially and a large proportion of cases are diagnosed 
as a result of screening of people identified as being 
at risk. Some may have been infected for years prior to 
diagnosis.
In addition, current notifications may include some 
cases that were diagnosed before 2004 (when hepatitis 
C first became notifiable), for whom repeat testing has 
been carried out now.  Two hundred and thirty four of 
the cases notified in 2007 were known to have been 
previously diagnosed.
There is also likely to be some duplication of 
notifications as Departments of Public Health do not 
always receive full names and thus cannot always 
identify if a patient has been notified previously.
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) System on 1st September 
2008. These figures may differ slightly from those 
published previously due to ongoing updating of 
notification data on CIDR.
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Figure 2.  Age standardised notification rates/100,000 population for hepatitis C by HSE area, 2004-2007
ME MW NE NW SE S W
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
2006 200720052004
-69-HPSC Annual Report 2007 5 Blood-borne and Sexually Transmitted Infections
HIV and AIDS in Ireland, 2007
A total of 362 newly diagnosed HIV infections were 
reported to the HPSC during 2007. This compares to 
337 diagnosed in 2006 and represents a 7.4% increase. 
The rate of newly diagnosed HIV infection in Ireland in 
2007 was 85.4 per million population. The cumulative 
total number of HIV infections reported in Ireland since 
surveillance began to the end of December 2007 is 
4,781. 
No reporting forms were received for 106 of the cases 
(29.3%) reported in 2007. This makes the analysis of 
data and interpretation of trends difficult. It is also 
important to note that the figures do not represent 
the numbers of people infected with HIV in Ireland 
but rather provide information on the number of new 
diagnoses in a given time period. The number of new 
diagnoses reported is dependent on patterns of testing 
and reporting.
Of the 362 newly diagnosed cases, 146 were 
heterosexually acquired. This compares to 176 in 
2006, 168 in 2005 and 178 in 2004. There were 75 new 
diagnoses among MSM (men who have sex with men) 
during 2007 compared to 85 in 2006, 57 in 2005 and 
64 in 2004. There were 54 new diagnoses among IDUs 
(injecting drug users) during 2007 compared to 57 in 
2006, 66 in 2005 and 71 in 2004.However, these data 
should be interpreted with caution as information on 
risk group is unavailable for 75 (20.7%) of the cases 
newly diagnosed in 2007. Figure 1 shows probable 
route of transmission for newly diagnosed cases among 
the three major risk groups since 1994.
HIV infection was newly diagnosed in eight children in 
2007. The probable route of transmission for six cases 
was mother to child transmission (MCT), transfusion 
related in one case (transfusion received in sub-Saharan 
Africa) and heterosexually acquired in one case. Of 
the six MCT cases, five of the mothers were born in 
5.3 HIV and AIDS
Summary
Number of HIV cases: 362
Crude HIV incidence rate: 8.5 per 100,000 population
Number of AIDS cases: 29
Number of deaths in AIDS cases: 5
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Figure 1: Newly diagnosed HIV infections in Ireland among heterosexuals, MSM and IDUs (1994 to 2007)
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countries with generalised HIV epidemics. Two of the 
mothers were diagnosed after the birth of the children 
and one was diagnosed while pregnant with the child. In 
addition, there were 117 babies born to a HIV infected 
mother in Ireland during 2007: 91 are not infected, 25 
remain of indeterminate status (i.e. do not meet the 
criteria for HIV infection and are <18 months at time of 
test) and one was infected. The country of birth for the 
mother of the infected baby was not known. The mother 
tested negative during the pregnancy and later tested 
positive post-natally.
Most of the newly diagnosed cases (75.4%) were 
aged between 20 and 39 years. The mean age at HIV 
diagnosis was 32.5 years. The mean age among females 
was 30.4 years and among males was 33.9 years, a 
difference of 3.5 years. The mean age at HIV diagnosis 
was 30.7 years in IDUs, 31.7 years in heterosexuals and 
35.5 years in MSM.
Of the 362 cases, 209 (57.7%) were male and 130 
(35.9%) were female. Gender was unknown for 23 
(6.4%) cases. Of the 130 newly diagnosed cases 
among females, the majority (66.2%) were acquired 
heterosexually and 29 (22.3%) were reported to be 
pregnant at HIV diagnosis.  Of the newly diagnosed 
cases among males, 35.4% were among MSM and 
23.9% were among heterosexuals. 
Of the 251 cases where geographic origin* was known, 
107 were born in Ireland, 96 were born in sub-Saharan 
Africa and 17 were born in other countries in Western 
Europe (figure 2). Information on geographic origin 
is unavailable for 111 (30.7%) of the newly diagnosed 
cases. Of the 146 cases acquired through heterosexual 
contact, 87 were born in sub-Saharan Africa (58 female, 
22 male and seven cases where sex was unknown) and 
28 were born in Ireland (10 female, 17 male and one 
case where sex was unknown). Information on stage 
of infection at time of HIV diagnosis was available 
for 244 of the 362 cases. Of the 244 cases, 187 were 
asymptomatic and 28 were diagnosed with AIDS at the 
time as HIV diagnosis. Of the 28 late diagnoses, 14 were 
heterosexual (seven male, five female and two cases 
where sex was unknown), four were MSM, eight were 
IDUs (five female, two male and one where sex was 
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Figure 2: Newly diagnosed HIV infections in Ireland by probable route 
of transmission and geographic origin (2007)
* Geographic origin is based on country of birth as used by EuroHIV.
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not known), one was due to MCT and for one route of 
transmission was unknown. 
By the end of 2007, 957 cases of AIDS were reported 
in Ireland since surveillance began. Of these, 405 are 
reported to have died. A total of 461 deaths have been 
reported in HIV infected individuals in Ireland since 
surveillance began.  Information on cause of death has 
been supplied since the introduction of HIV case based 
reporting in 2001. Of the 37 deaths that occurred 
among AIDS cases between 2002 and 2007, the cause 
of death was reported as AIDS in 31 cases (83.8%), 
HIV/AIDS related in three cases (8.1%), non-AIDS in 
two cases (5.4%) and unknown in one case (2.7%). Five 
deaths in AIDS cases were reported during 2007.
A more detailed report on the epidemiology of HIV and 
AIDS in Ireland in 2007 is available on the HPSC website 
www.hpsc.ie under Topics A-Z.
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Clinicians and laboratories notify their respective 
departments of public health of anonymised probable 
and confirmed cases of sexually transmitted infections 
(STIs).  These notifications are then reported to HPSC in 
aggregate form on a quarterly basis. Because of delays 
in STI reporting, annual data are not always available 
nationally in a timely manner. Consequently, this report 
focuses on STIs notified to HPSC in 2006. The figures 
presented in this chapter are based on those in the 
Annual STI Report for 2006, published in April 2008. 
In 2006, 9,892 STIs were reported in Ireland, a 3% 
decrease compared to 2005 when 10,144 STIs were 
reported (table 1). This decline is largely attributable 
to a drop in the number of Chlamydia trachomatis 
notifications between 2005 and 2006.  In addition, 
figures were further reduced by the fact that one STI 
clinic in the HSE-MW Area was unable to provide 
returns. Three infectious diseases accounted for 89% 
of all STI notifications in 2006: ano-genital warts, C. 
trachomatis and non-specific urethritis. Between 2005 
and 2006, notifications for chlamydia, trichomoniasis, 
syphilis and hepatitis B (acute or chronic) decreased 
by 6%, 37%, 53% and 75%, respectively. However, 
notifications of ano-genital warts, non-specific urethritis, 
herpes simplex (genital) and gonorrhoea increased by 
1%, 3%, 3% and 26%, respectively (table 1).
STIs in males accounted for 62.7% of all notifications; 
36.9% were in females. Gender data were not reported 
for 0.4% of notifications (table 2). The number of 
notifications among males generally exceeded that 
of females for all STI diseases with the exception of 
5.4  Sexually Transmitted Infections  
 (STIs), 2006
Table 1. Notifiable sexually transmitted infections from 1999 to 2006
Summary
Total number of STI notifications in 2006: 9,892
 Three most common STIs reported in 2006:
1.  Ano-genital warts: 3,494 cases (82.4/100,000)
2.  Chlamydia trachomatis infection (genital): 3,144 
cases (74.2/100,000)
3.  Non-specific urethritis: 2,161 cases (51/100,000)
Sexually Transmitted Infection 1999 2000 2001 2002 2003 2004 2005 2006
Ano-Genital warts 3049 3735 3993 3932 3981 4174 3456 3494
Chancroid 1 16 1 1 0 1 0 1
Chlamydia trachomatis infection (genital) 869 1343 1649 1922 2258 2803 3353 3144
Gonorrhoea 175 290 349 214 186 270 342 431
Granuloma inguinale 1 0 0 0 0 1 0 0
Hepatitis B (acute or chronic) 2 15 39 57 112 85 80 20
Herpes simplex (genital) 275 269 331 358 375 411 441 455
Lymphogranuloma venereum 2 0 0 1 0 0 1 0
Non-specific urethritis 1265 1726 1634 2025 2332 2746 2106 2161
Syphilis 6 46 279 303 235 144 282 134
Trichomoniasis 47 78 64 73 59 60 83 52
Total 5692 7518 8339 8886 9538 10695 10144 9892
C. trachomatis, herpes simplex and trichomoniasis. In 
2006, the highest number of notifications was in the 
20-29 year age group, accounting for 64.5% of all STIs 
notified. This age group also had the highest number of 
notifications for each of the STI diseases except syphilis 
and trichomoniasis (table 2).
During 2006, over 50% (n=4,992) of all STI notifications 
were from the HSE-E. Four areas (HSE-E, HSE-SE, HSE-S 
and HSE-W) accounted for 90% of the STI notifications 
in 2006 (table 3). The breakdown of STI data by 
geographical area should, however, be interpreted 
with caution, as figures are largely a reflection of the 
area where cases availed of STI services rather than a 
reflection of the burden of STIs in the population in that 
area. 
Summary Statistics on Selected STIs, 2006
Ano-genital warts
In 2006, 3,494 cases of ano-genital warts were notified 
(82.4/100,000 population) which accounted for 35% of 
all STI notifications reported.  This number represents 
an increase of 1% since 2005. More cases were notified 
among males than females (1,993 versus 1,498) and in 
the 20-29 year old age group which had 66% of all such 
cases reported.  
Chlamydia trachomatis infection (genital)
The crude incidence rate in 2006 for C. trachomatis 
infection was 74.2/100,000 (3,144 notifications). 
Chlamydia notifications constituted 32% of all STI 
notifications reported in 2006 and represent a decrease 
of 6% since 2005. More cases were notified among 
females than males (1,659 versus 1,454) and 70% of 
cases were reported in the 20-29 year old age group.  
Non-specific urethritis
In 2006, 2,161 cases of non-specific urethritis were 
notified (51.0/100,000), an increase of 2.6% since 
2005. These notifications constituted 22% of all STI 
notifications reported.  Considerably more cases were 
notified among males than females (2,044 versus 115). 
Sixty percent of cases were reported in the 20-29 year 
old age group.  
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Table 2 . Notified sexually transmitted infections by age group and gender, 2006
Sexually Transmitted Infection 0 - 19 20 - 29 30 - 39 40+
Age 
Unknown
Male Female
Gender 
Unknown
Total
Ano-genital warts 425 2320 548 198 3 1993 1498 3 3494
Chancroid 0 1 0 0 0 1 0 0 1
Chlamydia trachomatis infection 
(genital)
434 2193 415 95 7 1454 1659 31 3144
Gonorrhoea 42 254 86 48 1 380 48 3 431
Granuloma inguinale 0 0 0 0 0 0 0 0 0
Hepatitis B (acute or chronic) 0 10 8 2 0 11 9 0 20
Herpes simplex (genital) 51 232 109 63 0 210 244 1 455
Lymphogranuloma venereum 0 0 0 0 0 0 0 0 0
Non-specific urethritis 148 1297 493 218 5 2044 115 2 2161
Syphilis 1 51 51 30 1 102 30 2 134
Trichomoniasis 5 18 18 11 0 3 49 0 52
Total 1106 6376 1728 665 17 6198 3652 42 9892
(% of  Total) 11.2 64.5 17.5 6.7 0.2 62.7 36.9 0.4 100
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Table 3. Notified sexually transmitted infections by HSE area, 2006
Sexually Transmitted Infection
HSE-
E
HSE-
M
HSE-
MW*
HSE-
NE
HSE-
NW
HSE-
SE
HSE-
S
HSE-
W
Total
Ano-genital warts 1445 0 0 3 199 508 605 734 3494
Chancroid 0 0 0 0 0 1 0 0 1
Chlamydia trachomatis infection (genital) 1598 164 189 90 80 321 402 300 3144
Gonorrhoea 320 8 14 6 10 25 18 30 431
Granuloma inguinale 0 0 0 0 0 0 0 0 0
Hepatitis B (acute or chronic) 0 0 0 0 1 0 17 2 20
Herpes simplex (genital) 277 2 0 0 9 24 57 86 455
Lymphogranuloma venereum 0 0 0 0 0 0 0 0 0
Non-specific urethritis 1262 0 0 0 181 244 290 184 2161
Syphilis 74 7 0 1 1 11 26 14 134
Trichomoniasis 16 3 5 12 0 0 12 4 52
Total 4992 184 208 112 481 1134 1427 1354 9892
% of Total 50.5 1.9 2.1 1.1 4.9 11.5 14.4 13.7 100.0
*  Data not available from STI Clinic in HSE-MW.  Above data based on lab-confirmed reports provided by the laboratory to public health.
Herpes simplex (genital)
The crude incidence rate for genital herpes in 2006 
was 10.7/100,000 (455 notifications). The notifications 
constituted 5% of all STI notifications reported in 2006 
and represent an increase of 3% since 2005. More cases 
were notified among females than males (244 versus 
210) and in the 20-29 year old age group (51% of all 
such cases notified).
Gonorrhoea
In 2006, 431 cases of gonorrhoea were notified 
(10.2/100,000), an increase of 26% since 2005. These 
notifications constituted 4% of all STI notifications 
reported in 2006. More cases were notified among 
males than females (380 versus 48) and most frequently 
in the 20-29 year old age group (59% of all such cases 
reported).  
Hepatitis B
The data presented here reflect only those cases 
notified through STI services.  Further information 
on the epidemiology can be found in the Hepatitis B 
chapter of this report. 
A more detailed report on STIs is available at www.hpsc.
ie under the disease name in Topics A- Z.
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Other infections
In 2007, eight cases of viral encephalitis were notified 
in Ireland, which is a crude incidence rate of 0.2 
per 100,000 total population.  The number of viral 
encephalitis notifications in 2007 is half that which 
was reported in 2006, but comparable to the six cases 
notified in 2005 and five in 2004.  The decrease in viral 
encephalitis in 2007, compared to 2006 is particularly 
related to a decrease in varicella zoster virus associated 
encephalitis notifications.
Of the eight cases notified in 2007, more cases occurred 
in males (n=6) than in females (n=2) giving a ratio of 
3.0:1.0.
Cases ranged in age from two to 83 years (table 1). One 
quarter of the cases (n=2) occurred in children <10 years 
of age and 63% were in adults ≥45 years of age (table 
1). The highest incidence rates were in children aged 
1-4 years and also in elderly adults ≥65 years of age 
(0.4/100,000 each) (table 1).
The causative agent was identified in all eight cases of 
viral encephalitis notified; herpes simplex virus (n=5) 
and varicella zoster virus (n=3). Two of the cases due to 
herpes simplex occurred in children under 10 years of 
age while the remaining three cases occurred in adults 
aged ≥45 years. All three cases due to varicella zoster 
occurred in adults ≥15 years of age. No deaths from 
viral encephalitis were reported between 2004 and 
2007.
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) system on 21st August 2008.
               
6.1 Viral Encephalitis
Summary
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Number of cases, 2007: 8
Number of cases, 2006: 16
Number of cases, 2005: 6
Crude incidence rate, 2007: 0.2/100,000
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Table 1.  Number, crude incidence rates and proportion of viral 
encephalitis cases by age group, 2007
Number Proportion (%) ASIR
<1 0 0 0.0
1-4 1 13 0.4
5-9 1 13 0.3
10-44 1 13 0.0
45-64 3 38 0.3
65+ 2 25 0.4
All ages 8 100 0.2
ASIR, age specific incidence rate per 100,000
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In 2007, 46 cases (1.1/100,000 total population) of viral 
meningitis were notified in Ireland.  Most of the cases 
were classified as confirmed (76%, n=35), 10 (22%) as 
probable and for one (2%) the case classification was 
possible. More cases occurred in males (n=28) than in 
females (n=18) giving a ratio of 1.6:1.0.  One death due 
to viral meningitis was notified in a 33 year old man.  
Cases ranged in age from 1 month to 59 years with 
a median age of 7 years.  Eighty percent (n=37) of 
all cases were <35 years of age.  Children <1 year of 
age had the highest incidence rate: 27.8 per 100,000, 
followed by the 1-4 year olds, 1.7/100,000 (table 1). Of 
the 46 cases reported in 2007 the causative agent was 
identified as enterovirus (n=27;59%), herpes simplex 
virus (n=4;9%), varicella zoster virus (n=2;4%), echovirus 
(n=1;2%), parechovirus (n=1;2%) and unknown (n=11; 
24%) (table 1).
In Ireland, viral meningitis activity tends to be highest 
from June to October. In 2007 the numbers of cases 
peaked in July (n=9) and again in October (n=7) with an 
average of five cases per month (n=22) between June 
and October. In contrast, viral meningitis was low during 
the rest of the year with a monthly average of three 
cases (n=21).  
The number of cases notified in 2007 represents a 
substantial return to the yearly average since 1997 
during which the annual number of notifications ranged 
from 23-161 (figure 1). In 2006, there were 148 cases 
reported, but in 2005 and 2004, the numbers were 35 
and 23, respectively. 
High numbers of cases occurred in 2000 (n=98), 
2001 (n=161) and 2006 (n=148). These upsurges in 
notifications coincided with an increase in reports by 
the National Virus Reference Laboratory (NVRL) of 
laboratory confirmed non-polio enterovirus isolates. The 
predominant strains were echovirus type 13 in 2000 and 
echovirus type 30 in 2001. 
Towards the end of 2005 NVRL introduced PCR testing 
of CSF samples for enteroviral nucleic acid. This was in 
addition to the routine method of viral isolation from 
6.2 Viral Meningitis
Summary
Number of cases, 2007: 46
Number of cases, 2006: 148
Number of cases, 2005: 35
Crude incidence rate, 2007: 1.1/100,000
6. Oth  Inf ctions
Table 1.  Number and age specific incidence rates of viral meningitis notifications, 2007
 Enterovirus
Herpes 
simplex 
virus
Varicella 
zoster 
virus
Echovirus Parechovirus Unknown Total ASIR
<1 12 0 0 1 1 3 17 27.8
1-4 2 0 0 0 0 2 4 1.7
5-9 1 0 0 0 0 2 3 1.0
10-14 1 0 0 0 0 1 2 0.7
15-19 3 0 0 0 0 0 3 1.0
20-24 2 0 0 0 0 1 3 0.9
25-34 2 1 0 0 0 2 5 0.7
35-44 4 1 1 0 0 0 6 1.0
45+ 0 1 1 0 0 0 2 0.1
All ages 27 4 2 1 1 11 46 1.1
ASIR, age specific incidence rate per 100,000
HPSC Annual Report 2007
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stool samples.  The number of viral meningitis cases 
attributable to enterovirus isolates in 2006 was 117, 
compared to 27 cases reported in 2007. No single strain 
predominated in 2007, as was also the case in 2006. 
However, in 2007 Coxsachie B4 and Echovirus type 11 
were the strains most commonly isolated.
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) system on 21st August 2008.  
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Figure 1. Annual number of viral meningitis notifications in Ireland, 
1997-200
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Three cases of Creutzfeldt-Jakob disease (CJD) were 
notified in 2007 compared to six cases in 2006.  All 
three cases in 2007 were aged greater than 54 years 
and two cases were female.  All three were reported as 
sporadic CJD.   
In total, 41 cases of CJD were notified since CJD was 
first specified as a notifiable disease in December 1996, 
giving an average of approximately four notifications 
each year.  Figure 1 shows the 41 CJD notifications by 
age group.  Over 80% (n=34) of the cases were aged  
greater than 54 years.  Of the 41 cases, 22 were male 
and 19 were female. Thirty-eight cases were sporadic 
CJD, two were familial CJD and one was iatrogenic 
CJD.
Variant CJD (vCJD) is specified as a separate notifiable 
disease.  No cases of vCJD were notified in 2007.  
Four cases of vCJD were notified since vCJD became 
notifiable in December 1996.  A summary of these four 
cases was provided in the 2006 HPSC annual report. 
Data presented in this summary are based on 
notifications from HSE Areas and from the Irish National 
Creutzfeldt-Jakob Disease Surveillance Unit. The figures 
were extracted from the Computerised Infectious 
Disease Reporting (CIDR) system on 13th August 2008 
and may differ slightly from those published previously 
due to ongoing updating of notification data on CIDR. 
6.3 Creutzfeldt-Jakob disease  
Summary
Number of cases, 2007: 3
Number of cases, 2006: 6
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Figure 1.  Number of CJD notifications (n=41) from December 1996 to 2007 by age group
Age group (years)
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07
Infectious Disease Outbreaks
During 2007 there were 260 outbreaks of infectious 
disease notified on CIDR. These outbreaks resulted in 
4715 associated cases of illness. Eight hundred and 
ninety cases were reported to have been hospitalised.  
   
The regional distribution of all outbreaks of infectious 
disease in 2007, and those specifically infectious 
intestinal disease (IID), are detailed in table 1. HSE-SE 
had the highest outbreak rate of 10.4 per 100,000. 
HSE-S reported the greatest number of outbreaks 
(n=56). Of note, in 2006 HSE-M had an outbreak rate 
of 13.9 per 100,000. In 2007 this rate significantly 
decreased to 5.2 per 100,000.
 
General outbreaks accounted for 73.9% (n= 192) of 
all outbreaks notified. The remaining outbreaks were 
considered family/household outbreaks (26.1%, n= 68). 
One hundred and seventy eight (or 68.5%) of outbreaks 
were gastrointestinal/ infectious intestinal disease (IID).  
These resulted in at least 4595 people becoming ill. 
Norovirus/suspected viral outbreaks continue to be the 
most prevalent cause of IID outbreaks, continuing the 
trend observed in previous years. Figure 1 shows the 
causative origin of outbreaks by year since 1998. 
The number of general and family outbreaks of IID 
by pathogen and numbers ill are outlined in Table 
2.  Norovirus/ suspect viral outbreaks, accounted for 
60.7% of all IID outbreaks reported in 2007 (figure 1). 
Norovirus was responsible for the largest outbreak of 
2007. This occurred within a hospital with approximately 
407 cases of illness. 
After norovirus (n=111), the next most commonly 
reported IID outbreaks were acute infectious 
gastroenteritis (n=53), EHEC (n=21), cryptosporidiosis 
(n=16), salmonellosis (n=10) and campylobacter (n=9).
There were 21 EHEC outbreaks reported in 2007, 10 
less than 2006. These outbreaks can be subdivided into 
17 family outbreaks and four general (two in crèche, 
one in a hotel and one in a private house).  Sixteen 
outbreaks were due to VTEC O157, three due to 
7. Outbreaks
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Table 1. All outbreaks of ID, number of IID and non-IID outbreaks, and total numbers ill in all outbreaks reported by health region (2007)
HSE Region No. of Outbreaks Outbreak Rate No. ill in all outbreaks No. of IID outbreak
No. of Non IID 
outbreaks
E 71 4.7 1627 67 4
M 13 5.2 136 13 0
MW 14 3.9 192 12 2
NE 21 5.3 442 21 0
NW 22 9.3 315 20 2
SE 48 10.4 862 44 4
S  56 9.0 840 50 6
W 14 3.4 412 10 4
HPSC 1 ~ 8 1 0
Total 260 6.1 4833 238 22
Summary
Number of  outbreaks in 2007: 260
Number of IID outbreaks: 238
Number of non-IID outbreaks: 22
VTEC O26, one was caused by an un-groupable strain 
and one was a mixed strain outbreak.  One general 
VTEC outbreak in 2007 was linked to a hotel, with 56 
associated cases of illness. Foodborne transmission was 
suspected as a mode of transmission in this outbreak 
although no specific food was implicated during 
investigations. E. coli O157 was isolated from the 
private water supplies associated with one outbreak and 
one sporadic case in 2007.
In 2007, there were 10 outbreaks of salmonellosis 
reported via CIDR to the HPSC; three general and 
seven family outbreaks.  Of the seven family outbreaks, 
one was travel associated and the remaining six were 
located in private houses. The three general outbreaks 
resulted in a total of 65 persons ill. One of these 
general outbreaks had 52 associated cases with a 31% 
hospitalisation rate This was notified in mid-July of 2007 
in HSE-S. Results from the analytical study indicated a 
strong statistical association between illness and eating 
food from bakery X and/or eating food from outlets 
supplied by bakery X. Investigators concluded that it 
was not possible to definitively state how Salmonella 
Enteritidis was introduced to Bakery X. The bakery 
closed voluntarily. In the two smaller general outbreaks, 
one involved a crèche while the other was a more 
generalised community outbreak resulting in thirteen 
cases.
In 2007, there were nine campylobacteriosis outbreaks, 
eight family outbreaks and one general, resulting in 21 
cases of illness. These were all small clusters of illness 
with no more than three people reported ill in any one 
outbreak.
Sixteen outbreaks of cryptosporidiosis were reported in 
2007: six general outbreaks and ten family outbreaks. 
Three hundred and fifty eight people were reported ill 
as a result of these outbreaks. The suspected mode of 
transmission for nine outbreaks was person-to-person, 
and for three outbreaks, water was suspected to have 
played a role in transmission. The Galway outbreak of 
cryptosporidiosis had 304 laboratory confirmed cases 
associated.  A preliminary report on the outbreak 
showed that it was primarily due to C. hominis. Cases 
were clustered in areas supplied by water treatment 
plants which used water from Lough Corrib.  Boil water 
notices were issued for four water supplies in March 
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Table 2.  Number of general and family outbreaks of IID by pathogen, 2007
Disease
No General 
Outbreaks
No Family 
Outbreaks
Total No 
Outbreaks
No ill
Noroviral Infection 107 4 111 3307
Acute Infectious Gastroenteritis 49 4 53 719
Campylobacter infection 1 8 9 21
Clostridium difficile 3 0 3 60
Cryptosporidiosis 6 10 16 358
EHEC 4 17 21 104
Giardiasis 0 3 3 4
Hepatitis A (acute) 0 3 3 6
Norovirus & Rotavirus 1 0 1 17
Rotavirus 4 3 7 30
Salmonellosis 3 7 10 85
Trichinosis 0 1 1 2
Total 178 60 238 4781
2007 and were lifted in July and August 2007 following 
closure of two older plants and upgrading of two newer 
plants.  No specific point source of contamination was 
identified.
Twenty-two outbreaks of non-IID/gastroenteric diseases 
were notified in 2007.  Table 3 outlines the responsible 
pathogens and numbers ill.  Tuberculosis was the most 
common cause of non-IID outbreaks notified.  The most 
significant outbreak of tuberculosis reported in Ireland 
in recent years was notified by HSE South in March 
2007.  The outbreak resulted in 21 cases of tuberculosis 
(18 children and 3 adults) and involved two crèches. The 
vast majority of child cases were toddlers (children aged 
2 to 3 years).  A symptomatic crèche worker (index case) 
was diagnosed with sputum positive pulmonary TB in 
March 2007. This case had worked in two large crèches 
and worked primarily with toddler children at both 
locations. None of the 18 paediatric cases had BCG 
vaccination. The M. tuberculosis strain isolated from the 
index case was reported as being pan-sensitive. 
Similar to previous years, person-to-person spread was 
the mode of transmission reported for the majority 
(49%) of outbreaks of IID in 2007 (n=117).  Most of 
these outbreaks were due to norovirus/ suspect viral.  
Person-to-person was also cited in 14% of IID outbreaks 
(n=34) as a associated mode of transmission.  
Healthcare settings were the commonest location for 
outbreaks - 54.6% of all reported IID outbreaks occurred 
in hospitals and residential institutions.  A further 22.2% 
occurred in private homes, 5.5 % occurred in hotels and 
5.5% in crèches.
When the IID outbreaks are analysed by month of 
onset the majority occurred in the first three months 
of the year.   This peak is attributable to the number 
of norovirus outbreaks that occurred at this time.  This 
seasonality was also evident in 2006.
The information gathered from this National Outbreak 
Surveillance Systems is used to inform public health 
professionals on the causes and factors contributing 
to outbreaks, to target prevention strategies and to 
monitor the effectiveness of prevention programmes.
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Figure 1. Number of outbreaks by year and by pathogen, 1998-2007 (Data prior to 2001 provided by FSAI outbreak surveillance system)
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Disease
Total No 
Outbreaks
No ill
Hepatitis B (acute & chronic) 4 10
Influenza 1 13
Measles 3 13
Meningococcal disease 1 2
MSSA (methicillin sensitive staph aureus) 1 4
Mumps 3 10
Outbreak 1 20
Suspected Scarlet Fever 1 3
Suspected Varicella 1 4
Tuberculosis 2 25
Varicella 4 16
Total 22 120
Table 3. Non–IID outbreaks notified in 2007
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Immunisation Uptake
iurerc
In 2007, each HSE Area provided HPSC with quarterly 
immunisation uptake data for their Area and for 
each of the Local Health Offices (LHOs) in their Area.  
HPSC collated these data and quarterly reports were 
produced which are available on the HPSC website.  
The annual immunisation uptake rates presented 
here represent the collation of the 2007 quarterly 
data.  The proportion of children who completed the 
recommended childhood immunisation schedule by 12 
months (born between 01/01/2006 and 31/12/2006) or 
24 months (born between 01/01/2005 & 31/12/2005) of 
age in 2007 is reported.
The Irish childhood immunisation schedule during the 
years 2005-2007 recommended that babies receive 
one dose of vaccine against tuberculosis (BCG vaccine) 
at birth or by one month of age and three doses of 
vaccines against diphtheria (D3), tetanus (T3), pertussis 
(P3), Haemophilus influenzae type b (Hib3), polio (Polio3) 
and meningococcal group C (MenC3) with one dose of 
each given at two, four and six months of age.  Between 
12 and 15 months of age children were recommended 
to receive the first dose of the measles-mumps-rubella 
vaccine (MMR1) and from September 18
th 2006 a Hib 
booster (Hibb) was recommended at the same time as 
MMR1, this followed the national Hib campaign from 
November 2005 to May 2006 among children less than 
four years of age.  A booster dose of DTaP/Polio was 
scheduled for children at four to five years of age, as 
was a second dose of MMR vaccine.  A booster dose of 
tetanus and diphtheria was recommended for children 
at 11 to 14 years of age.  To effectively control these 
vaccine preventable diseases at least 95% of children 
should complete the childhood immunisation schedule. 
The immunisation uptake rates were reported by LHO 
for the first time in 2007.  While there are 32 LHOs the 
immunisation uptake rates for the LHOs of North Lee 
and South Lee are reported as a combined figure.
8. Immunisation Uptake
-86- HPSC Annual Report 20078. Immunisation Uptake
Summary
At 12 months uptake of:
D3, T3, P3, Hib3, Polio3 and MenC3 was 87%
At 24 months uptake of:
D3, T3, P3, Hib3 and Polio3 was 92%
MenC3 was 91%
MMR1 was 87%
Table 1.  Annual immunisation uptake rates by HSE Area for children 12 and 24 months of age in 2007
HSE Area % Uptake at 12 months
Cohort born 01/01/2006 - 31/12/2006
% Uptake at 24 months
Cohort born 01/01/2005 - 31/12/2005
D3 P3 Hib3 Polio3 MenC3 BCG D3 P3 Hib3 Hibb Polio3 MenC3 MMR1
HSE-E 86 86 86 86 86 na 89 89 89 69 89 89 84
HSE-M 92 92 92 92 92 91 97 97 97 90 97 97 94
HSE-MW 89 89 89 89 89 97 92 92 92 85 92 92 90
HSE-NE 90 90 90 90 88 na 93 93 93 88 93 93 90
HSE-NW 92 92 91 92 90 94 97 97 95 87‡ 97 93 92
HSE-SE 86 86 86 86 85 92 91 91 90 62‡ 91 90 86
HSE-S 84 84 84 84 84 90* 94 94 94 74 94 94 88
HSE-W 86 86 86 86 87 na 93 93 93 68‡ 93 93 85
Ireland 87 87 87 87 87 93† 92 92 92 74‡ 92 91 87
Since T3 uptake identical to D3 uptake only D3 uptake figures presented
*HSE-S part coverage of neonatal BCG (i.e. Kerry only)
†Based on data from five of the eight HSE Areas
‡The national Hibb figure is incomplete, as the HSE-W data for Quarter 1 2007 and the HSE-NW data for Quarter 3 2007 were not available.  
The national Hibb figure also includes the HSE-SE data which are an underestimate due to data extraction methods
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Immunisation uptake rates at 12 months
National immunisation uptake rates for D3, T3, P3, Hib3, 
Polio3 and MenC3 in children 12 months of age in 2007 
were 87%.   Compared to 2006 this was an improvement 
of one percent for D3, T3, P3, Hib3 and Polio3 uptake and 
an improvement of two percent for MenC3 uptake.
Uptake rates for D3, T3, P3, Hib3, Polio3 and MenC3 
ranged from 84% in the HSE-S to 92% in the HSE-M 
(table 1).  Three HSE Areas had uptake rates of ≥90% for 
D3, T3, P3, Hib3 and Polio3 while two had uptake rates of 
≥90% for MenC3 (table 1).
Among the LHOs, uptake rates for D3, T3, P3, Hib3 and 
Polio3 ranged from 79% to 93% and the uptake rate for 
MenC3 ranged from 79% to 94%.  Ten of the LHOs had 
uptake rates of ≥90% for D3, T3, P3, Hib3 and Polio3 while 
eight had uptake rates of ≥90% for MenC3.
BCG uptake data were available from five of the 
eight HSE Areas (table 1).  These five areas represent 
approximately a third of the national birth cohort.  
Where data were available national BCG uptake was 
93% in 2007, unchanged compared to 2006.  Among 
the 12 LHOs that reported BCG data, uptake rates 
ranged from 90% to 98%.  The target uptake rate of 
95% was reached or exceeded in three of the 12 LHOs.
Immunisation uptake rates at 24 months
National immunisation uptake rates, in children 24 
months of age in 2007, for D3, T3, P3, Hib3 and Polio3 
were 92% and 91% for MenC3.  Compared with 2006 
the uptake rates for these vaccines increased by one 
percent in 2007 (figure 1).  
Uptake of D3, T3, P3, Hib3, Polio3 and MenC3 ranged from 
89% in the HSE-E to 97% in the HSE-M (table 1).  Seven 
HSE Areas had uptake rates of ≥90% for these vaccines 
(table 1).  The target uptake of 95% was reached or 
exceeded for D3, T3, P3, Hib3, Polio3 and MenC3 in the 
HSE-M and for D3, T3, P3, Hib3 and Polio3 in the HSE-NW 
during 2007 (table 1).
Among the LHOs, uptake rates for D3, T3, P3, Hib3, Polio3 
and MenC3 ranged from 82% to 98%.  D3 immunisation 
uptake rates, in those 24 months of age in 2007, are 
mapped by LHO in figure 2a. Only nine of the LHOs 
reached/exceeded the target uptake rate of 95% for D3 
(figure 2a), P3, T3 and Polio3.  Only eight LHOs reached/
exceeded the target uptake rate of 95% for Hib3 and 
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Figure 1.  National annual immunisation uptake rates at 24 months, 1999-2007
Since T3 uptake identical to D3 uptake only D3 uptake figures presented and since Polio3 uptake almost identical to Hib3 uptake only Hib3 
figures presented.
The 2006 MMR1 figure includes the Quarter-1 2006 HSE-E figure, which is an estimate only due to technical problems with extraction of MMR1 
data from the HSE-E database.
The 2005 MMR1 uptake figure is incomplete as the HSE-E was unable to provide MMR data for Quarter-4 2005, due to technical problems 
with extraction of MMR1 data from the HSE-E database. 
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 only five reached/exceeded the target for MenC3. 
 
During 2007 MMR1 uptake was 87% nationally; an 
increase of one percent when compared to 2006 (figure 
1).  In 2007, uptake rates for MMR1 ranged from 84% 
in the HSE-E to 94% in the HSE-M with just four HSE 
Areas reporting uptake of ≥90% (table 1).  None of the 
HSE Areas achieved the target uptake of 95% for MMR1 
for all of 2007; however, in Quarter 1 and Quarter 3 
2007 MMR1 uptake was 95% in the HSE-M.  
Among the LHOs, uptake rates for MMR1 ranged from 
76% to 95%.  Fourteen LHOs had uptake rates of ≥90%; 
however, only one reached the target uptake of 95% 
(figure 2b).  
Hibb national uptake statistics were reported for the 
first time in 2007.  These figures relate to children who 
received a dose of Hib after 12 months of age.  In 2007 
national uptake of Hibb, in those 24 months of age, was 
74% (table 1).  However, the Hibb figure is incomplete, 
as the HSE-W data for Quarter 1 2007 and the HSE-
NW data for Quarter 3 2007 were not available.  The 
figure also includes the HSE-SE data which are an 
underestimate due to data extraction methods.
Further improvements in uptake are necessary so 
that the 95% target rate is achieved nationally for all 
vaccines.  In 2007, national uptake rates at 24 months 
for D3, T3, P3, Hib3, Polio3 and MenC3 were three to four 
percent below the target rate while MMR1 was eight 
percent below the target rate.
A new routine childhood immunisation programme is 
effective from September 1st 2008.  Changes include 
the addition of pneumococcal vaccine and hepatitis B 
vaccine and a change in the recommended age of Hib 
booster and MenC vaccine.  
The 2007 immunisation uptake rates for each LHO are 
presented in tables in a separate report.  This LHO 
report and the immunisation reports for Quarters 1 to 4 
2007 are available on the HPSC website www.hpsc.ie in 
Topics A-Z under the heading vaccination.  
8. Immunisation Uptake
Figure 2.  D3 (A) and MMR1 (B) immunisation uptake rates (%) by Local Health Office (LHO) in those 24 months of age in 2007
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Antimicrobial Consumption 
and  Resistance 
Ireland participates in the European Surveillance of 
Antimicrobial Consumption (ESAC) which aims to collect 
systemic antibiotic usage data from the outpatient 
(ambulatory, community or primary care) setting and 
from the hospital (inpatient) setting. Consumption is 
measured in Defined Daily Dose (DDD), which is the 
assumed average maintenance dose per day for a 
drug used for its main indication in adults. Rates are 
calculated in DDD per 1000 inhabitants per day (DID) 
for outpatients and DDD per 1000 bed-days used (DBD) 
for inpatients.
Outpatient Antibiotic Consumption
The overall outpatient antibiotic consumption for Ireland 
in 2007 was 22.5 DID, a rise from the previous year’s 
rate of 21.1 DID, and has been rising steadily at 3% 
per year since 2000. In an ESAC report of outpatient 
antibiotic consumption from 29 EU countries with 
reliable data for 2005, the range of outpatient antibiotic 
usage was 9.2 DID (Russian Federation) to 34.7 DID 
(Greece). The median for all countries was 18.1 DID. 
Outpatient antibiotic usage in Ireland has been around 
19 - 23 DID over the last five years. Thus the overall 
rate in Ireland is mid-to-high in Europe. Furthermore, 
the ESAC report also highlighted that Ireland is one 
of only four countries where the trend in consumption 
is increasing, while six of the remaining 25 countries 
showed a decrease in usage.
In Ireland in 2007, outpatient consumption of penicillins 
accounted for the largest class used (50% of total at 
11.3 DID), followed by macrolides (18%, 4.0 DID), 
tetracyclines (14%, 3.3 DID), cephalosporins (9%, 1.9 
DID), quinolones (5%, 1.0 DID) and sulphonamides (4%, 
9.1 Antimicrobial Consumption 
 
Summary
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Outpatient antibiotic consumption, 2007: 22.5 DID
Outpatient antibiotic consumption, 2006: 21.1 DID
Median hospital antibiotic consumption, 2007: 
80.6 DBD
Median hospital antibiotic consumption, 2006: 
78.7 DBD
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Figure 1. Outpatient antibiotic consumption in Ireland by month, 2000-2007
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0.9 DID). Other antibiotic classes accounted for about 
1% of total use.
Penicillin in combination with beta-lactamase inhibitor 
(such as co-amoxiclav) accounted for the largest 
proportion of penicillins and showed a dramatic rise 
over last seven years (3.2 DID in 2000 to 5.5 DID in 
2007). Broad-spectrum penicillin (such as ampicillin and 
amoxicillin) usage was stable but high (3.5 DID).
There was considerable variability in the overall 
outpatient antibiotic usage at county level (18.5 to 
28.9 DID) as shown in figure 2. Furthermore, analysis of 
Primary Care Reimbursement data showed that those 
entitled to reimbursement (representing 30% of the 
population) are prescribed about 55% of the antibiotics 
in terms of cost.
Seasonal fluctuation (26% rise in DID from summer to 
winter, figure 1) has been seen every year in outpatient 
antibiotic consumption and is probably related to over-
prescribing of antibiotics for respiratory tract infections 
in winter months. In an analysis of recent Irish data, it 
was shown that outpatient antibiotic use is strongly 
associated with seasonal influenza activity.
The consistently increasing trend in outpatient antibiotic 
usage may lead to Ireland having among the highest 
rates of usage in Europe. Furthermore, strong seasonal 
fluctuations, over-reliance on broad-spectrum antibiotics 
and high density usage in some regions are factors that 
may work together to increase the pressure for selection 
of resistant variants of bacterial pathogens.
 
Hospital Antibiotic Consumption
Data for hospital antibiotic consumption for 2006 and 
2007 were published by named institution for the first 
time in April 2008. That publication was also the first 
time accurate acute in-patient antibiotic usage statistics 
were calculated, whereas in previous publications about 
10% of the volume of antibiotics included in hospital 
antibiotic usage analyses was accounted for by non-
acute or outpatient use.
18.5 - 21.9
22 - 23.1
23.3 - 23.6
24 - 25.2
26.1 - 28.6
Figure 2. Outpatient antibiotic consumption in Ireland by county, 2007.
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Thirty-five public acute hospitals provided valid 
antibiotic usage data for 2007. The median rate of 
antibiotic consumption usage was 80.6 DBD (range 17.1 
– 120.0 DBD). This was a rise from the previous year’s 
rate of 78.7 DBD. These levels are again mid-to-high in 
Europe.
Hospital function was the main driver for the differences 
in the rates of antibiotic consumption between 
hospitals. The rates for regional/tertiary and general 
hospitals (medians 81.9 and 88.2 DBD) centred just 
above the median for Ireland, while the rate for 
single specialist facilities (maternity, orthopaedic or 
paediatric) was much lower (median 54.2 DBD), though 
with a wider range (17.1 – 80.3). The lower median 
consumption in single speciality hospitals probably 
reflects differences in case mix, compared to other 
hospitals, but may also reflect the fact that DDDs are 
based on adult dosing and may therefore underestimate 
antibiotic consumption in paediatric settings. 
Differences in percentage injectable antibiotics over 
total (median 42.5%, range 23.8% – 62.2%), which is a 
measure of patient acuity, also reflected the category of 
hospital.
There was an increase in the consumption of some “high 
risk” antibiotics (fluoroquinolones and penicillins such 
as co-amoxiclav) and reserved antibiotics (vancomycin 
and teicoplanin) in 2007 as shown in table 1. This is one 
area where antibiotic stewardship programmes would 
help to limit the spread and development of drug-
resistant organisms that can cause healthcare-associated 
infections.
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Table 1. Key antibiotics and antibiotic groups, and the average consumption rate among all hospitals in DBD for 2007 compared with 2006. Also 
shown is the percentage change in consumption. 
Antibiotic 2006 2007 Change
Penicillin with beta-lactamase inhibitor 19.40 20.62 6%
Other Penicillins 16.25 17.23 6%
First-generation cephalosporins 0.34 0.35 4%
Second-generation cephalosporins 2.91 2.65 -10%
Third-generation cephalosporins 1.90 1.75 -8%
Macrolides 10.70 10.62 -1%
Fluoroquinolones 9.56 10.44 8%
Clindamycin 0.46 0.50 8%
Oral Vancomycin 0.01 0.02 45%
Injectable Vancomycin 1.10 1.39 21%
Teicoplanin 1.29 1.38 6%
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The detailed breakdown of antibiotic consumption for 
2006 and 2007 by individual hospital may be found 
at www.hpsc.ie in the “Publications” subsection, 
under “Healthcare Associated Infections”. The figures 
presented in this report may vary from previously 
published levels owing to methodological changes. 
More detailed analyses of antibiotic usage data can be 
found on the www.hpsc.ie website, through “Topics 
A-Z”, under “ESAC”.
EU Network: ESAC  www.esac.ua.ac.be 
9.2 Antimicrobial Resistance
Summary
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•   There were 1,394 reports of S. aureus bacteraemia 
submitted to the European Antimicrobial Resistance 
Surveillance System (EARSS), of which 537 (38.5%) 
were meticillin-resistant S. aureus (MRSA).  This rep-
resents a decrease {bordering on statistical signifi-
cance} from 41.9% reported in 2006.  Overall, the 
number of MRSA reports was down by 9.3% from 
592 in 2006
  For acute public hospitals only, the rate (and cor-
responding proportion) of MRSA bacteraemia was 
0.14 per 1,000 patient bed days used (39.3%), a 
decrease from 0.15 per 1,000 patient bed days used 
(42.5%) in 2006
  There was one report of vancomycin-intermediate 
S. aureus (VISA)
•   There were 438 reports of invasive S. pneumoniae 
infection, an increase of almost 8% from 407 in 
2006.  The national rate of invasive infection was 
10.5 per 100,000 population compared to 9.8 in 
2006
  The proportion of penicillin-non-susceptible 
S. pneumoniae (PNSP) has increased significantly 
over the past 3 years from 10.3% in 2004 to 17.4% 
in 2007; the proportion of isolates with high-level 
resistance to penicillin increased significantly from 
2.9% in 2006 to 5.7% in 2007
  A pilot project for serotyping pneumococci was 
established in 2007.  Overall, serotype data were 
available on 238 isolates and results indicate good 
coverage for both the 23-valent polysaccharide 
(PPV23) and 7-valent conjugate (PCV7) vaccines in 
their target populations: 86% (adults ≥65 years) and 
88% (children <2 years), respectively
•   There were 332 reports of E. faecium bacteraemia, 
an increase of 25% from 265 in 2006.  The 
proportions that were vancomycin-resistant 
E. faecium (VREfm) and multi-drug resistant (MDR) 
decreased from 37.1% and 25.6% to 33.5% and 
22.3%, respectively.  The number of VREfm isolates, 
however, increased by about 13% from 98 to 111 
over the same period
•   There were 1,784 reports of invasive E. coli 
infection, an increase of almost 8% from 1,656 
reports in 2006.  Resistance to gentamicin and third-
generation cephalosporins (3GCs) and extended-
spectrum beta-lactamase (ESBL)-production 
increased significantly in 2007.  Ciprofloxacin 
resistance increased only marginally but the overall 
trend was still upwards.  MDR E. coli increased from 
9.0% in 2006 to 11.4% in 2007
•   Resistance to most antibiotics increased for invasive 
K. pneumoniae and P. aeruginosa infections with 
MDR isolates accounting for  11.9% and 12.5%, 
respectively
•   See http://www.hpsc.ie for further details of EARSS 
and antimicrobial resistance in Ireland,  including  
quarterly and annual reports and more detailed 
slide presentations on the 2007 EARSS data for 
each of the pathogens under surveillance
•   European data are available at www.rivm.nl/earss/
database/ 
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Introduction
The European Antimicrobial Resistance Surveillance 
System (EARSS) in Ireland collects routinely-generated 
antimicrobial susceptibility testing data on seven 
important bacterial pathogens using the EARSS case 
definition. Participating laboratories submit data on the 
“primary” or first isolate from blood or CSF per patient 
per quarter.  EARSS does not distinguish clinically 
significant isolates from contaminants and primarily 
serves as a surveillance system to measure national 
levels of antimicrobial resistance (AMR).  By the end of 
2007, all 44 microbiology laboratories in Ireland were 
participating in EARSS representing 100% coverage of 
the Irish population.
Staphylococcus aureus
There were 1,394 reports of S. aureus bacteraemia from 
1,331 patients, of which 537 (38.5%) were meticillin-
resistant S. aureus (MRSA) (table 1).  This represents the 
lowest annual proportion since surveillance began in 
1999.  In 2006, the proportion was 41.9%.  The decrease 
observed in 2007 was bordering on significance 
(Chi2=3.4, P=0.07).  The proportion of MRSA in Ireland 
had been stable at approximately 42% for the previous 
four years (figure 1).  Overall, there was a 9.1% decrease 
in the number of MRSA bacteraemia reports compared 
with 2006 (n=592), however the total overall number of 
S. aureus bacteraemia reports remained at about the 
same level (1,412 in 2006 vs. 1,394 in 2007).  Despite 
the decrease in numbers and proportion of MRSA, 
Ireland still had one of the highest proportions of 
MRSA in Europe in 2007 (see http://www.rivm.nl/earss/
database/ for European data, including EARSS maps).  
One MRSA isolate with reduced susceptibility to 
vancomycin was detected at the National MRSA 
Reference Laboratory by the Etest® macromethod with 
a value of 12mg/L.  This isolate also had a vancomycin 
minimum inhibitory concentration (MIC) of 4mg/L, by 
which it was classified as vancomycin-intermediate 
S. aureus (VISA) according to the latest CLSI guidelines.  
The isolate was shown to be hetero-VISA by Population 
Analysis Profiling.
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Figure 1. Trends for S. aureus – total numbers of S. aureus/MRSA and percentage MRSA with 95% confidence intervals.
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R, Resistant; NS, Non-Susceptible [includes isolates with intermediate (Int) and high-level resistance (HLR)]            
MRSA, Meticillin-Resistant S. aureus; VISA, Vancomycin-Intermediate S. aureus            
HLG, High-Level Gentamicin; 3GC, 3rd-Generation Cephalosporin (includes cefotaxime, ceftriaxone, ceftazidime             
and cefpodoxime); ESBL, Extended-Spectrum Beta-Lactamase; MDR, Multi-Drug Resistant           
* Not all isolates tested
Pathogen 1999 2000 2001 2002 2003 2004 2005 2006 2007
Number laboratories by year-end 12 19 20 23 28 41 42 42 44
S. aureus         
    Number of isolates 510 639 815 1042 1140 1323 1424 1412 1394
    Number Meticillin-R (or MRSA) 198 249 337 445 480 553 592 592 537
    Meticillin-R (or MRSA) 38.8% 39.0% 41.3% 42.7% 42.1% 41.8% 41.6% 41.9% 38.5%
    Number VISA 0 0 0 0 0 0 0 2 1
    VISA* 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.1% 0.1%
S. pneumoniae         
    Number of isolates 157 201 245 278 364 400 401 407 438
    Penicillin-NS 19.1% 13.4% 12.2% 11.5% 11.8% 10.3% 11.7% 15.7% 17.4%
    of which:   HLR 0.0% 3.5% 1.6% 1.4% 2.2% 1.8% 3.0% 2.9% 5.7%
                      Int 16.6% 8.5% 10.6% 9.7% 8.8% 7.0% 8.7% 12.5% 11.0%
    Erythromycin-R* 14.0% 12.0% 12.5% 12.7% 11.6% 14.4% 12.1% 16.1% 16.4%
Number laboratories by year-end    21 27 40 41 42 44
E. faecalis         
    Number of isolates No data No data No data 168 218 242 290 294 281
    Ampicillin-R*    8.1% 5.1% 0.8% 3.5% 4.5% 2.2%
    Vancomycin-R    2.4% 1.4% 1.3% 2.5% 3.7% 2.8%
    HLG-R*    38.5% 33.9% 41.3% 43.1% 42.4% 37.2%
E. faecium         
    Number of isolates No data No data No data 85 135 187 224 265 332
    Ampicillin-R*    88.9% 91.0% 95.7% 92.3% 93.9% 93.1%
    Vancomycin-R    11.1% 19.4% 23.2% 31.7% 37.1% 33.5%
    HLG-R*    16.7% 53.8% 58.0% 51.4% 44.3% 34.9%
    MDR*    3.7% 11.4% 18.5% 25.6% 25.6% 22.3%
E. coli         
    Number of isolates No data No data No data 741 991 1256 1445 1656 1784
    Ampicillin-R*    62.2% 61.9% 65.0% 67.6% 70.7% 68.3%
    3GC-R*    3.0% 2.4% 2.4% 4.1% 4.1% 6.7%
    Ciprofloxacin-R*    5.4% 9.5% 12.6% 17.3% 21.5% 22.1%
    Gentamicin-R*    2.7% 3.9% 5.7% 8.5% 7.7% 9.9%
    ESBL-producers*    1.2% 1.3% 1.1% 2.4% 2.5% 4.1%
    MDR*    2.4% 3.8% 5.6% 7.7% 9.0% 11.4%
Number laboratories by year-end        36 39
K. pneumoniae         
    Number of isolates No data No data No data No data No data No data No data 217 244
    Ampicillin-R*        97.7% 99.2%
    3GC-R*        10.2% 9.9%
    Ciprofloxacin-R*        15.3% 18.1%
    Gentamicin-R*        7.8% 9.9%
    Imipenem/meropenem-R*        0.0% 0.6%
    ESBL-producers*        8.6% 3.7%
    MDR*        11.2% 11.9%
P. aeruginosa         
    Number of isolates No data No data No data No data No data No data No data 128 177
    Pipericillin/tazobactam-R*        10.2% 13.2%
    Ceftazidime-R*        10.6% 11.8%
    Imipenem/meropenem-R*        11.8% 12.2%
    Ciprofloxacin-R*        18.0% 22.9%
    Gentamicin-R*        10.2% 13.3%
    MDR*        9.5% 12.5%
                                           Year
Table 1. Summary of EARSS data by pathogen and year
         
The MRSA rate for acute public hospitals only was 
0.14 per 1,000 patient bed days used (calculated using 
acute public hospital activity data from the National 
Hospitals Office at the Health Services Executive).  The 
corresponding MRSA proportion was 39.3% (527 of 
1,340 isolates).  Both the MRSA rate and proportion for 
acute public hospitals decreased from 0.15 per 1,000 
patient days and 42.5% observed in 2006.
In patients with laboratory-confirmed S. aureus 
bacteraemia, the probability that the infecting organism 
was MRSA as compared to meticillin-susceptible 
S. aureus (MSSA) was almost 2-times greater in patients 
aged ≥65years than in those aged <65 years (RR=1.98, 
Chi2=96.4, P<0.0001).
Males were approximately 1.8-times more likely to get 
an invasive S. aureus infection (1.5-times for MRSA, 
z=4.3, P<0.0001; 2.1-times for MSSA, z=11.0, P<0.0001) 
than females (z=11.2, P<0.0001).  The frequency of 
invasive S. aureus infection increased with age, with 
the majority of infections (n=978; 70%) occurring in 
adults over 50 years.  The median age for patients with 
an MRSA infection was 71 years (95%CI, 70-72) while 
the median age for patients with MSSA was 58 years 
(95%CI, 56-60).  This was considered to be a significant 
difference as the confidence intervals did not overlap.
Streptococcus pneumoniae
There were 438 reports of invasive S. pneumoniae 
infection (423 from blood and 15 from CSF) from 
435 patients, an increase of 7.6% from 407 reports 
in 2006.  See table 1 for the annual proportions of 
S. pneumoniae isolates non-susceptible/resistant 
to penicillin and erythromycin by year since 1999 
when surveillance began.  Penicillin-non-susceptible 
S. pneumoniae (PNSP) accounted for 17.4% (n=76) of 
all isolates in 2007.  The proportion of PNSP in Ireland 
has increased significantly over the past four years from 
10.3% in 2004 (Chi2trend=11.1, P=0.0008) (figure 2).  The 
proportion of isolates with high-level resistance (HLR) 
to penicillin increased from 2.9% in 2006 to 5.7% in 
2007 but this was only borderline significant (Chi2=3.8, 
P=0.05).  Sixty-six (16.4%) of 403 isolates were resistant 
to erythromycin, which compares with 16.1% in 2006.  In 
2007, moderately high levels of PNSP and erythromycin 
resistance were seen in Ireland, similar to the situation 
observed in much of Southern and Central Europe.  
More notably, Ireland had one of the highest levels of 
HLR to penicillin in Europe. 
Of the 76 PNSP isolates, 48 were intermediately-
resistant (Int; MIC=0.1-1.0mg/L) and 25 were HLR 
(MIC >1.0mg/L) to penicillin.  No penicillin MICs were 
available for three non-susceptible (NS) isolates. 
Of isolates tested against both penicillin and 
erythromycin (n=403), 32 (7.9%) were simultaneously 
PNSP (22 Int, 9 HLR, 1 NS) and erythromycin-resistant in 
2007 compared with 7.4% in 2006. 
Prior to the introduction of the 7-valent pneumococcal 
conjugate vaccine (PCV7) into the childhood 
immunisation schedule in September 2008, a national 
pilot project was established early in 2007 as a result 
of a collaborative initiative between RCSI/Beaumont 
Hospital, Children’s University Hospital, Temple St and 
HPSC with the aim of providing baseline serotyping 
data on invasive S. pneumoniae isolates.  Serotype 
data were available on 219 pneumococcal isolates from 
26 laboratories (of 33 that reported pneumococcal 
isolates to EARSS in 2007) representing 81% of all 
pneumococcal isolates reported to EARSS, Quarters (Q) 
2-4 2007.  Serotype data were available on an additional 
19 isolates from Q1.  Overall for 2007, 203 (85%) 
and 113 (48%) of 238 isolates belonged to serotypes 
-97-HPSC Annual Report 2007 9. Antimicrobial Consumption and  Resistance 
Year
0 0%
Figure 2. Trends for S. pneumoniae – total numbers of S. pneumoniae/PNSP and percentage PNSP with 95% confidence intervals.
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covered by the pneumococcal polysaccharide (PPV23; 
target population: adults ≥65 years and at risk groups) 
and conjugate (PCV7; target population: children <2 
years) vaccines, respectively.  From adults ≥65 years, 80 
of 93 (86%) isolates would be covered by PPV23, while 
from children <2 years, 23 of 26 (88%) isolates would 
be covered by PCV7.  Of the 39 PNSP isolates, 16 of 
17 (94%) from adults ≥65 years were covered by PPV23 
while all four (100%) were from children <2 years were 
covered by PCV7.
The rate of invasive pneumococcal disease (IPD) in 
Ireland in 2007 was estimated to be 10.5 per 100,000 
population compared with 9.8 in 2006 (note: both 
calculated using the 2006 census data and adjusted 
for the estimated population coverage by EARSS for 
that year).  The highest rates of IPD were observed in 
children <1 year (37.7 per 100,000) and adults aged 75-
79 years (48.7) and adults >80 years (72.6).
Males were approximately 1.3-times more likely to 
have an invasive S. pneumoniae infection [1.6-times 
for PNSP, z=2.0, P=0.04; 1.2-times for penicillin-
susceptible S. pneumoniae (PSP), z=1.8, P=0.07] than 
females (z=2.5, P=0.02). Although these findings were 
significant for S. pneumoniae overall, they were at best 
approaching borderline significance for PNSP and PSP.  
The frequency of invasive S. pneumoniae infection 
was highest in children aged <1 year (n=23; 5.3% of 
all reported isolates) and 1-4 years (n=43, 9.8%) and in 
adults aged ≥65 years (n=196; 45%).   The median age 
was 62 years (95%CI, 58-64).
Enterococcus faecalis
There were 281 reports of E. faecalis bacteraemia from 
274 patients, a decrease from 294 reports in 2006.  See 
table 1 for the annual proportions of E. faecalis isolates 
resistant to the three “indicator” antibiotics (ampicillin, 
vancomycin and high-level gentamicin) by year since 
2002 when surveillance began.  Vancomycin-resistant 
E. faecalis (VREfa) accounted for 2.8% of isolates.  
Although this proportion was low, Ireland still had one 
of the highest proportions of VREfa in Europe in 2007.  
Six isolates were ampicillin-resistant, which suggests that 
these isolates were either misidentified as E. faecalis 
or misclassified as ampicillin-resistant, as resistance to 
ampicillin is rare in E. faecalis.
Males were approximately 1.3-times more likely to have 
an invasive E. faecalis infection than females but this 
was only of borderline significance (z=1.9, P=0.05).  The 
frequency of invasive E. faecalis infection increased 
with age with the majority of infections (n=216; 77%) 
occurring in adults over 50 years.  The median age was 
68 years (95%CI, 64-71).
Enterococcus faecium
There were 332 reports of E. faecium bacteraemia from 
324 patients, of which 33.5% were vancomycin-resistant 
E. faecium (VREfm).  This represents a decrease from 
37.1% in 2006.  See table 1 for the annual proportions 
of E. faecium isolates resistant to the three “indicator” 
antibiotics (as for E. faecalis above) by year since 2002.  
Between 2002 and 2006, the proportion of isolates 
that was VREfm increased significantly (Chi2trend=30.0; 
P<0.0001) (figure 3).  In 2007, Ireland had the second 
highest proportion of VREfm in Europe after Greece 
(37.7%).  In contrast to the proportion, the total number 
of VREfm isolates increased by about 13% from 98 in 
2006 to 111 in 2007.
Of 296 isolates tested against all three “indicator” 
antibiotics, 66 (22.3%) were resistant to all three and 
therefore classed as multi-drug resistant (MDR).  This 
represents a decrease from 25.6% in 2006.  In contrast 
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Figure 3. Trends for E. faecium – total numbers of E. faecium and percentage resistance to ampicillin (AMP), high-level gentamicin (HLG) and 
vancomycin (VAN) with 95% confidence intervals.
The numbers of participating laboratories by year-end are indicated above the bars
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to the proportion, the total number of MDR isolates 
increased from 63 in 2006 to 66 in 2007.
Males were approximately 1.6-times more likely to 
have an invasive E. faecium infection than females 
(z=3.0, P=0.0001).  The frequency of invasive E. faecium 
infection increased with age with the majority of 
infections (n=271; 82%) occurring in adults over 50 
years.  The median age was 65 years (95%CI, 63-68).
Escherichia coli
There were 1,784 reports of invasive E. coli infection 
(1,782 from blood and 2 from CSF) from 1,749 patients, 
an increase of 7.7% from 1,656 reports in 2006.  See 
table 1 for the proportion of E. coli isolates resistant 
to the four “indicator” antibiotics/antibiotic classes 
[ampicillin, third-generation cephalosporins (3GCs; 
cefotaxime, ceftriaxone, ceftazidime or cefpodoxime), 
fluoroquinolones (ciprofloxacin or ofloxacin) and 
aminoglycosides (gentamicin or tobramycin)] by 
year since 2002.  Ciprofloxacin resistance increased 
marginally from 21.5% in 2006 to 22.1% in 2007 
(non-significant; Chi2 =0.18, P=0.67).  Looking at 
the overall trend, the proportion of ciprofloxacin 
resistant isolates has increased significantly since 2002 
(Chi2trend=178.6, P<0.0001) (figure 4), although the rate 
of increase appeared to have slowed down in 2007.  
The proportions of isolates with resistance to 3GCs 
and gentamicin increased significantly from 4.1% and 
7.7% in 2006 to 6.7% (Chi2 =11.6, P=0.0007) and 9.9% 
(Chi2 =5.2, P=0.02), respectively, in 2007. Resistance to 
3GCs, ciprofloxacin and gentamicin in E. coli isolates 
have been increasing throughout most of Europe in 
recent years.  In 2007, ciprofloxacin resistance was at 
moderately high levels in Ireland compared to other 
European countries while resistance to 3GCs and 
gentamicin were both moderately low. 
Extended spectrum beta-lactamases (ESBLs) were 
detected in 68 (4.1%) of 1,669 isolates tested.  This 
represents a significant increase from 2.5% in 2006 (Chi2 
=5.7, P=0.02).  ESBLs are enzymes that confer resistance 
to most penicillins and cephalosporins (including 3GCs).  
ESBL-producing bacteria (including K. pneumoniae and, 
increasingly, E. coli) are often resistant to other classes 
of antibiotics and have emerged as important causes of 
infections in hospitals.
Of 1,751 isolates tested against all four “indicator” 
antibiotics, 199 (11.4%) were identified as MDR (defined 
as resistance to three or more of these), including 34 
with resistance to all four.  The proportion of isolates 
that are MDR has increased significantly (Chi2trend =94.1, 
P<0.0001) from 2.4% in 2002 when surveillance began.
Females were approximately 1.3-times more likely to 
have an invasive E. coli infection than males (z=4.8, 
P<0.0001), however, males were 1.3-times more likely 
to get an infection with ciprofloxacin-resistant E. coli 
(borderline significant; z=2.2, P=0.03) and 1.7-times 
more likely to get an infection with MDR E. coli (highly 
significant; z=3.4, P=0.0007).  The frequency of invasive 
E. coli infection increased with age with the majority of 
infections (n=1,382; 78%) occurring in adults over 55 
years.  The median age was 72 years (95%CI, 71-72).
Klebsiella pneumoniae
There were 244 reports of invasive K. pneumoniae 
infection (all from blood) from 237 patients (with 39 
of 44 laboratories participating in the surveillance 
of this pathogen).  See table 1 for the proportion of 
K. pneumoniae isolates resistant to the four “indicator” 
antibiotics (as for E. coli above) in 2006 and 2007.  In 
2007, 3GC resistance decreased slightly from that 
reported in 2006 while resistance to both ciprofloxacin 
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Figure 4. Trends for E. coli – total numbers of E. coli and percentage resistance to 3GCs, ciprofloxacin/ofloxacin (CIP/OFX) and gentamicin (GEN) 
with 95% confidence intervals.
The numbers of participating laboratories by year-end are indicated above the bars
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and gentamicin increased, however none of the 
differences were found to be significant. 
Two isolates were ampicillin-susceptible, which either 
represent isolates misidentified as K. pneumoniae or 
misclassified as ampicillin-susceptible, as all klebsiellae 
are inherently resistant to this antibiotic.
ESBLs were detected in 8 (3.7%) of 214 isolates 
tested.  This represents a decrease from 8.6% (11 of 
128 isolates) in 2006. However, a greater proportion of 
isolates were tested for ESBL production in 2007 (88% 
vs. 59%). 
Twenty-eight, or 11.9%, of 235 isolates tested against 
all four “indicator” antibiotics were identified as MDR, 
including nine with resistance to all four.  This compares 
with 11.2% in 2006. 
Males were approximately 1.6-times more likely 
to have an invasive K. pneumoniae infection than 
females (z=3.5, P=0.0005).  The frequency of invasive 
K. pneumoniae infection increased with age with the 
majority of infections (n=182; 75%) occurring in adults 
over 55 years.  The median age was 67 years (95%CI, 
62-69).
Pseudomonas aeruginosa
There were 177 reports of invasive P. aeruginosa 
infection (174 from blood and three from CSF) from 
172 patients (with 39 of 44 laboratories participating in 
the surveillance of this pathogen).  See table 1 for the 
proportion of P. aeruginosa isolates resistant to the five 
“indicator” antibiotics/antibiotic classes [piperacillin-
tazobactam, ceftazidime, carbapenems (meropenem or 
imipenem), fluoroquinolones (ciprofloxacin or ofloxacin) 
and gentamicin] in 2006 and 2007.  The resistance 
proportions observed in 2007 were all higher compared 
with the data for 2006. Notably, ciprofloxacin increased 
from 18.0% in 2006 to almost 22.9% in 2007, however, 
none of the differences were found to be significant.
Nineteen (12.5%) of 152 isolates tested against all five 
“indicator” antibiotics were MDR, including six (from 
five laboratories) with resistance to all five.
Males were approximately 1.7-times more likely to have 
an invasive P. aeruginosa infection than females (z=3.4, 
P=0.0006).  The frequency of invasive P. aeruginosa 
infection increased with age with the majority of 
infections (n=123; 70%) occurring in adults over 55 
years.  The median age was 66 years (95%CI, 61-70).
Conclusion
The proportion of MRSA decreased from approximately 
42% in 2006 (and similar levels in recent years) to 38.5% 
in 2007, with the corresponding number of reports 
decreasing by 9.3% from 592 to 537, respectively. 
However, the total overall number of S. aureus 
bacteraemia reports remained at about the same level.  
This may be related to infection prevention and control 
interventions selectively targeted at MRSA, or may 
indicate that some process is taking place whereby the 
prevalent MRSA strains causing bacteraemia are on the 
wane and are being replaced by MSSA strains, some of 
which can be as virulent, or more so, than MRSA.  It is 
hoped that the decrease in MRSA seen in 2007 will be 
sustained in 2008 and beyond.
Despite the encouraging MRSA trend, AMR continues 
to be a growing problem in other EARSS pathogens 
in this country.  PNSP has been increasing for the past 
four years and in 2007 for the first time the proportion 
of isolates with HLR has increased to over 5% with 
the result that Ireland now has one of the highest 
proportions of HLR in S. pneumoniae in countries 
reporting to EARSS.  The introduction of the 7-valent 
pneumococcal conjugate vaccine, PCV7, into the 
childhood immunisation program in September 2008 
may go some way to reduce the burden of invasive 
pneumococcal disease in children less than two years 
and also the general population as a whole as children 
are known to act as reservoirs for pneumococci.  
However, on-going surveillance of the predominant 
serotypes is required as strains with serotypes other 
than those in the vaccine have been reported to 
increase in prevalence following introduction of PCV7 
in other countries, hence the need for a fully resourced 
reference facility.  
The number of E. faecium isolates reported to EARSS 
rose by 25% between 2006 and 2007.  Over this period 
the proportion of isolates that were VREfm decreased 
from 37.1% to 33.5%, however, this belies that the total 
number of VREfm isolates actually increased by 13.2% 
from 98 to 111.
Resistance in E. coli and other Gram-negative 
pathogens is also becoming more problematic.  
Although the data for 2007 seem to indicate that the 
rate of increase in ciprofloxacin resistance slowed down, 
the overall trend was still upwards.  Gentamicin and 
3GC resistance plus ESBL-production also increased 
and consequently the proportion of MDR isolates now 
stands at 11.4% (up from 2.4% in 2002).  Resistance to 
most of the “indicator” antibiotics and MDR increased 
in K. pneumoniae and P. aeruginosa from the previous 
year but it is still too early to comment on trends as 
surveillance of these has been undertaken for just two 
years.
Recent improvements in infection prevention and 
control structures may have contributed to reducing 
the burden of MRSA bacteraemia in Ireland in 2007.  
However, the data for the other pathogens once again 
highlight the urgent need for full implementation of the 
recommendations included in the 2001 Strategy for the 
control of Antimicrobial Resistance in Ireland (SARI) to 
tackle the growing problems of AMR and HCAI in this 
country. In particular, measures to promote prudent 
antibiotic use in both hospital and community settings 
are required to reduce the burden of AMR in Ireland.
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The European Antimicrobial Resistance Surveillance 
System (EARSS) in Ireland has been enhanced to 
collect demographic, risk factor and clinical data since 
2004. The enhanced programme involves voluntary 
participation by hospitals that provide data on invasive 
pathogens causing bloodstream infections (BSI).
There were 1234 records of individual cases or 
isolates under the EARSS definition submitted from 11 
laboratories. This figure is down from the 2006 finalised 
figure of 1580, as at the time of writing this report 
data were outstanding from two laboratories. The total 
number of records thus far for 2007 represent 26% of 
the total core EARSS dataset.
Demographic and other basic data for the major 
resistance profiles of EARSS pathogens are shown 
in table 1. These and clinical features of the BSI 
are detailed in the rest of this section. Note that 
each patient may have more than one risk factor 
reported. Malignancies were noted in 23% and 
immunosuppression in 12% of all BSI, and these two risk 
factors are not mentioned again in relation to specific 
pathogens here. 
Staphylococcus aureus
There were 349 records for Staphylococcus aureus, 
152 (44%) of which were meticillin-resistance S. aureus 
(MRSA) and 197 were meticillin-sensitive S. aureus 
(MSSA). The majority of MRSA isolates (57%) were in 
those aged 65 or older. Common sources of the MRSA 
BSI were central venous catheter (CVC, 29%), skin/
soft tissue (12%) and respiratory tract infections (12%). 
Recent surgery (19%) and stay in intensive care unit 
(ICU stay, 10%) were risk factors specific to MRSA. The 
common origins of MSSA BSI were CVC (20%), and 
skin/soft tissue infections (19%). The most common risk 
factor specific to MSSA was recent surgery (11%) and 
4% had endocarditis.
The majority of MSSA BSI (51%) were detected <48 
hours after admission, meaning a large proportion 
were probably community-acquired, while 33% of 
MRSA BSI were detected <48 after admission. A closer 
examination of the records revealed that 37% of MSSA 
and 27% of MRSA BSI were recorded as “healthcare-
associated”, and 41% of MSSA and 61% of MRSA 
records were “hospital-acquired” within the hospital 
that made the notification.
Figure 1 shows how factors affecting S. aureus 
bacteraemia have changed over the last two years, 
2006 and 2007. The data were from six laboratories 
that contributed complete information for both years. 
The proportion of isolates that were MRSA from the 
six laboratories changed from 49% to 45%, and this 
9.3 Enhanced EARSS Surveillance
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Table 1. Age and gender breakdown by organisms with their major resistance profiles. Proportion of isolates detected <48 hours and >5 days 
post-admission is also shown. See text for abbreviations.
 
Total Number 
of isolates in 
2007
Proportion 
Female
Mean age in 
years
Proportion <5 
years old
Proportion 65 
years or older
Detected 
<48hrs after 
admission
Detected 
>5days after 
admission
MRSA 152 44% 63.8 1% 57% 33% 48%
MSSA 197 34% 54.3 6% 38% 51% 29%
PNSP 18 47% 54.0 11% 44% 89% 6%
PSSP 93 45% 55.9 6% 42% 76% 13%
FQREC 128 39% 68.3 0% 66% 45% 43%
FQSEC 337 61% 66.0 2% 62% 63% 22%
VRE 40 45% 59.8 0% 43% 10% 85%
VSE 142 43% 63.8 3% 54% 29% 55%
KPN 76 37% 66.1 0% 57% 46% 38%
PAE 51 49% 65.8 2% 61% 33% 53%
appears to reflect the decrease in the proportion of 
patients who were aged 65 years or older. However, 
other factors may also influence the likelihood 
of acquiring either MRSA or MSSA bacteraemia. 
Furthermore, significant factors may vary between 
institutions.
Other organisms
Of the 111 records for Streptococcus pneumoniae BSI, 
78% were isolated <48 hours after admission showing 
that these infections were mainly community-acquired. 
They tended to occur in younger patients (mean age 
55 year, compared to a mean age of 63 years for all of 
the pathogens), reflecting the bimodal age distribution 
of S. pneumoniae BSI (see table 1). The vast majority 
(96%) originated from respiratory tract infections. 
Eighteen records (16%) were penicillin non-susceptible 
S. pneumoniae (PNSP) BSI as compared to 93 penicillin 
susceptible S. pneumoniae (PSSP).
There were 465 records for Escherichia coli, 128 (28%) 
of which were fluoroquinolone-resistant E. coli (FQREC) 
and 337 were fluoroquinolone-sensitive E. coli (FQSEC). 
The majority of patients were 65 years or over (66% 
FQREC and 62% FQSEC). Urinary tract infections (35% 
FQREC and 49% FQSEC) and gastrointestinal tract 
infections (21% FQREC and 27% FQSEC) were common 
sources for these BSI. Urinary catheter was also a 
common source for FQREC BSI (21%), but only in 9% of 
FQSEC BSI.
There were 182 enterococcal BSI records, 80 
Enterococcus faecalis and 102 E. faecium. Of the 
enterococci BSI, 40 (22%) were vancomycin-resistant 
enterococci (VRE) and 142 vancomycin-sensitive 
enterococci (VSE). VRE BSI were associated with longer 
stay in hospital (85% detected >5 days after admission). 
CVC were a common source for these BSI (65% VRE and 
22% VSE), followed by gastro-intestinal tract (17% VRE 
and 46% VSE). Common pathogen-specific risk factors 
were ICU stay (28% VRE and 24% VSE) and recent 
surgery (13% VRE and 23% VSE).
There were 76 records for Klebsiella pneumoniae (KPN) 
BSI, originating mainly from gastro-intestinal tract 
sources (33%), CVC (20%), respiratory tract (15%) and 
urinary tract infections (11%). Common risk factors 
specific for KPN BSI were recent surgery (14%) and ICU 
stay (13%). 
There were 51 records for Pseudomonas aeruginosa 
(PNE) BSI, originating mainly from respiratory tract 
(21%) and urinary tract infection catheter (18%), and 
also from CVC, gastro-intestinal and urinary tracts (each 
15%). Common risk factors specific for PNE BSI were 
recent surgery (12%) and ICU stay (14%). 
Conclusion
Data from the enhanced EARSS surveillance programme 
shows that, with the exception of S. pneumoniae, 
the majority of the reported bloodstream infections 
occurred more than 48 hours after hospital admission 
and can, thus, be considered “hospital-acquired”. 
Bloodstream infections occurring less than 48 hours 
after hospital admission are traditionally considered to 
be “community-acquired”. However, a proportion of the 
latter may be related to prior healthcare exposure. As in 
previous reports, CVC were identified as the commonest 
modifiable risk factor for bloodstream infections, 
particularly for S. aureus. While not all healthcare-
associated, or hospital-acquired, bloodstream infections 
are preventable, these data underline the importance 
of ensuring interventions to reduce the occurrence of 
bloodstream infections are put in place, with particular 
emphasis on management of CVC. 
More information can be found at www.hpsc.
ie in “Topics A-Z”, under “Enhanced Bacteraemia 
Surveillance”.
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Figure 1. Factors affecting patients with Staphylococcus aureus 
bacteraemia in 2006 and 2007, in data from six laboratories that 
contributed complete information for both years. 
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Surveillance is one of the key elements in the control 
and prevention of healthcare-associated infection 
(HCAI). There are multiple examples from the literature, 
demonstrating reductions in HCAI rates following 
the implementation of surveillance programmes.  For 
surveillance to be effective, however, it needs to be 
standardised, timely and relevant to the institution 
providing the data. 
In 2007, the Health Protection Surveillance Centre 
(HPSC) established a multidisciplinary expert group 
under the auspices of the Strategy for the Control of 
Antimicrobial Resistance in Ireland (SARI) to evaluate 
methods for establishing surveillance in general 
surgery.  In August 2007, a questionnaire was sent 
to the infection prevention and control teams of 
59 acute national hospitals to capture the type of 
HCAI surveillance activities being carried out across 
the country. 45 hospitals responded and reported 
participating in a variety of surveillance activities (figure 
1). While all hospitals were using CDC definitions of 
surgical site infection, only three hospitals had access to 
an automated data entry system (Teleform / Formic) and 
only four hospitals are using standardised international 
protocols (HELICS / Pan Celtic)
41 (91%) hospitals expressed an interest in participating 
in national HCAI surveillance initiatives, however 
additional resources (IT and personnel) would be 
required in many centres to participate.  This gap in 
surveillance infrastructure was previously highlighted 
during the 2006 prevalence study of HCAI, when 
HSE-funded data collectors enabled 44 hospitals to 
participate. Without HSE support, the majority of 
hospitals would have been unable to participate in the 
survey, which is the only source of national HCAI data 
that Ireland has to date. 
A draft national protocol for surveillance of surgical site 
infection (SSI) in general surgery and recommendations 
on the development of a high quality national surgical 
site infection surveillance system that is standardised 
and internationally comparable were drafted and sent 
for consultation in late 2007.   In 2008 the group plan 
to produce similar protocols for surveillance in other 
surgical specialities.
The meticillin resistant Staphylococcus aureus (MRSA) in 
ICU Prevalence study was developed by members of the 
SARI Infection Control Sub-Committee in conjunction 
with HPSC. The objective of this study was to develop 
a simple surveillance protocol to collect a weekly 
snapshot of the problem of MRSA (both colonisation 
and infection) in the ICU setting that would require 
minimal if any additional resources. ICUs were chosen 
because the number of patients there is relatively 
9.4 Healthcare-associated infection 
surveillance
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Overview of current HCAI surveillance activities  
Surgical site infection surveillance:  13 (29%) 
HCAI surveillance in the intensive care unit:  17 (38%) 
Catheter-related bloodstream infection surveillance:  10 (22%)
Surveillance of pneumonia:  5 (11%)  
Surveillance of urinary tract infections:  5 (11%) 
Other surveillance activities:  15 (33%) 
Surgical site infection surveillance in 13 hospitals
Orthopaedic surgery  7 
Colon surgery  6
Cholecystectoy  6
Cardiac surgery  4
Caesarean section  2
Other surgical specialities  5 
Figure 1: HCAI surveillance activities in 45 acute hospitals in Ireland.
Table 1: National data on alcohol hand rub consumption in acute 
public hospitals in Ireland - 2006 and 2007.
2006* 2007**
Minimum Value 0.5 5.2
National Median 10.5 15.0
Maximum Value 29.0 47.1
*No data received from one hospital
** No data received from two hospitals
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small.  Data was to be collated nationally by the HPSC. 
A multidisciplinary steering group was established in 
2007 to oversee the survey and provide guidance in its 
development and implementation. 
In July 2007, HPSC commenced a nine month pilot 
study. During this time, several amendments were made 
to the protocol following valuable hospital feedback 
and the number of participating hospitals increased.  At 
the end of the pilot period, 31 hospitals (eight regional, 
20 general, one specialist and two private hospitals) 
were providing weekly MRSA surveillance data. The 
majority (17) of participating ICU’s contained between 
five and nine beds, with eight ICU’s containing less than 
four ICU beds.  During the course of the pilot study, 
three hospitals changed their policy to routinely screen 
all patients for MRSA upon admission to the ICU. Now 
100% (31/31) of participating hospitals routinely screen 
all patients. One of the most notable findings of the 
pilot study was the wide variation in isolation room 
facilities across ICU’s.   Many of the single rooms cannot 
be classified as isolation rooms as they lack many of 
the basic features of an isolation room such as a hand 
sink and anteroom. The average ratio of single rooms 
to available beds is 0.2 (i.e. one single bed for every 
five available beds) for general hospitals and 0.3 (i.e. 
1 single bed for every 3.3 available beds) for regional 
hospitals. Moreover, the appropriate specifications 
associated with an isolation room, i.e. a hand sink, 
anteroom and negative/positive pressure options, are 
more often found in ICUs within regional hospitals than 
general hospitals.
Alcohol-based hand rub consumption
Alcohol-based hand rubs have been shown to be 
an effective and rapid method of hand hygiene in 
healthcare settings, and are recommended as the 
primary means of hand hygiene in Irish national 
guidelines. Measurement of consumption of alcohol-
based hand rub, expressed as volume used per 1,000 
bed-days, has been shown to correlate with overall 
hand hygiene activity in hospitals. It is a recommended 
process measure of hand hygiene activity by both 
the World Health Organisation (WHO) and the US 
Centers for Disease Control (CDC). HPSC collated 
data on alcohol-based hand rub consumption in acute 
hospitals in 2006 and 2007.  This data represented the 
total volume of alcohol-based hand rub delivered or 
dispensed to wards, clinics and other hospital areas per 
quarter, excluding that used for pre-operative surgical 
‘scrub’. The rate of usage per hospital was calculated 
as the total volume of hand rub consumed (in litres) per 
1,000 bed-days used. (table 1)
There was a statistically significant (43%, excluding 
hospitals that only provided 2006 data) increase in the 
median rate of alcohol hand rub consumption, between 
2006 and 2007. The overall level of alcohol hand rub 
consumption is similar to levels reported from successful 
hand hygiene campaigns internationally.  The wide 
variation in levels of hand gel consumption between 
hospitals may be largely explained by differences in 
methodologies for collecting and reporting the data, 
and differences in types and range of hand hygiene 
agents used. 
The main limitations to be noted when examining the 
data in table 1 is that the data only refers to the use 
of alcohol-based hand rub, and does not take account 
of other hand hygiene agents (e.g. medicated liquid 
soap) that may also be in used in hospitals.  In addition, 
the data does not give an indication of the frequency 
with which hand decontamination is carried out at a 
given hospital nor distinguish between who has used 
the hand rub (visitor, patient and healthcare worker). 
There is clearly a need for better standardisation of data 
collection and reporting. However, even with better 
standardisation, the volume of alcohol-based hand rub 
consumed remains an inexact process measure of hand 
hygiene and additional outcome measures are required, 
including detailed audits of hand hygiene compliance. 
10
Computerised Infectious Disease 
Reporting System (CIDR)
Computerised Infectious Disease Reporting 
2007 represented the third full year of CIDR operation 
and demonstrated that CIDR continues to meet the 
ongoing and expanding needs of infectious disease 
surveillance in Ireland. Implementation of CIDR 
continued with two major academic teaching hospitals 
going ‘live’ – Cork University Hospital and St. Vincent’s 
University Hospital. The number of laboratory records 
uploaded or entered into CIDR continues to increase as 
more laboratories are using CIDR (see figure 1).
The CIDR application software was updated in 2007 
with the deployment of version 1.2.3. This version 
included a number of significant improvements to the 
system particularly in the area of laboratory results 
management. Similarly a significant number of reports 
were created or updated through 2007 to meet the 
developing needs of CIDR users.
A major achievement in 2007 was the migration of the 
existing CIDR accreditation for information security 
management from the old ISO 17799 standard to the 
new ISO 27001 standard. The new standard aligns 
more closely with other ISO standards such as the ISO 
9000 series and has an increased emphasis on security 
incident management and levels of service.
The operation and use of CIDR over the past three 
years has been underpinned by the CIDR Business Rules 
developed from the pilot implementation in 2004. It has 
become increasingly clear in the light of operation and 
further implementations since that time that these rules 
needed to be updated. Consequently a new national 
CIDR Business Rules Committee was formed in 2007 to 
review the existing document. This committee met three 
times through 2007 to update these rules to ensure that 
CIDR continued to be used appropriately and that the 
security of the system was maximised.
10. Computerised Infectious Disease 
 Reporting (CIDR)
Summary
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•  CIDR Application software and reports significantly 
enhanced
•  ISO 27001 Information Security Management 
certification achieved
•  Number of laboratory records in CIDR continue to 
increase significantly per year
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Figure 1. Number of laboratory records in CIDR per year.
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In parallel with the ongoing development of new 
Business Rules the number of active CIDR accounts was 
reviewed to ensure that these accounts continued to be 
needed. This also allowed the CIDR team to replace the 
security tokens needed to access the CIDR system which 
expired in September 2007.
The CIDR User Group met four times in 2007 
and continued to act as a valuable channel of 
communication between the CIDR team and CIDR 
users across the country. It also allowed CIDR users to 
share expertise and best practice amongst themselves. 
Subjects that were discussed included enhanced 
surveillance data items, particular problems in relation 
to hepatitis notifications, and data items in relation to 
outbreaks and hospital acquired infections.
CIDR training for CIDR users continued through 2007 
with 16 courses delivered to 59 trainees. The courses 
delivered included introductory courses for public health 
and for laboratory users, advanced courses for public 
health users, and introductory courses in the use of 
Business Objects software-based reporting in CIDR.
The CIDR helpdesk continued to support CIDR users in 
relation to business and technical support calls although 
the number of calls was slightly reduced compared 
with 2006 (figure 2). This reduction compared with 
2006 was primarily attributable to the fact that no new 
implementation of CIDR at public health level occurred 
in 2007.
International cooperation continued on several fronts 
through 2007. A member of the CIDR team was 
invited by the Netherlands School of Public Health to 
participate in an EU-funded Accession preparedness 
programme in Bulgaria. This involved two separate 
week-long missions to Bulgaria to investigate the 
requirements and opportunities for electronic infectious 
disease reporting in that country. The new TESSy 
infectious disease information system developed by the 
European Centre for Disease Prevention and Control 
in Stockholm was introduced to representatives from 
national surveillance institutes, including HPSC / CIDR 
and implications of this new information system for 
member states and their national infectious disease 
information systems such as CIDR were discussed. 
HPSC was visited for a week in June by a delegation 
from Uzbekistan, including public health specialists and 
information technology experts, who were interested 
in find out more about infectious disease surveillance 
in Ireland, including CIDR and to see how the system 
works.
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Figure 2. CIDR helpdesk calls per annum
Work continued through 2007 in preparation for the 
replacement of hardware approaching ‘end of life’ and 
the updating of third-party software applications used 
in CIDR to current up to date / supported versions. In 
parallel with this activity a public notice was published 
on eTenders.gov (the public sector tendering website) 
inviting suppliers to tender for a new information 
and communications technology framework support 
contract for HPSC, including maintenance, support and 
continued development of the CIDR system.
Two CIDR-associated presentations were made in 2007. 
Bernadette O’Connor from the Department of Public 
Health HSE South (SE) presented their experiences 
with CIDR at the annual Five Nations Health Protection 
Conference in Belfast, May 2007, concluding that ‘The 
implementation of CIDR in the HSE-South(SE) was 
successful, thus ensuring accurate and timely reporting 
of both clinical and laboratory notifiable infectious 
diseases. Integration of CIDR into the QMS (the Quality 
Management System) optimises the efficiency of the 
system.’ A presentation on the impact of CIDR on the 
quality of infectious disease information was made by 
John Brazil in February at the 4th Annual Data Quality 
Forum held in Dublin City University by the Irish 
Community of Practice of The International Association 
for Information and Data Quality (IAIDQ) in conjunction 
with the Irish Computer Society. 
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Appendix 1
Notifiable Infectious Diseases in Ireland
Notes:
Figures presented in this appendix were extracted from the Computerised Infectious Disease Reporting 
(CIDR) system on the 19th August 2008. These figures may differ from those published previously due to 
ongoing updating of notification data on CIDR.
Figures on EARSS pathogens, tuberculosis and sexually transmitted infections are not presented here. 
Separate databases are used to collate data on these diseases. Details on the epidemiology of these diseases 
can be found in separate chapters in this document.
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Table  A1.1
List of notifiable infectious diseases and their respective causative pathogens under Infectious Diseases (Amendment) (No. 3) Regulations 2003 
(S.I. No. 707 of 2003)
Infectious Disease Causative Pathogen(s)
Acute anterior poliomyelitis Polio virus
Acute infectious gastroenteritis
Ano-genital warts
Anthrax Bacillus anthracis
Bacillus cereus food-borne infection/intoxication Bacillus cereus
Bacterial meningitis (not otherwise specified)
Botulism Clostridium botulinum
Brucellosis Brucella species
Campylobacter infection Campylobacter species
Chancroid Haemophilus ducreyi
Chlamydia trachomatis infection (genital) Chlamydia trachomatis
Cholera Vibrio cholerae
Clostridium perfringens (type A) food-borne disease Clostridium perfringens
Creutzfeldt Jakob disease
Creutzfeldt Jakob disease (new variant)
Cryptosporidiosis Cryptosporidium parvum
Diphtheria Corynebacterium diphtheriae
Echinococcosis Echinococcus species
Enterococcal bacteraemia Enterococcus species (blood)
Enterohaemorrhagic Escherichia coli Escherichia coli of serogroup known to be toxin-producing
Escherichia coli infection (invasive) Escherichia coli (blood, CSF)
Giardiasis Giardia lamblia
Gonorrhoea Neisseria gonorrhoeae
Granuloma inguinale
Haemophilus influenzae disease (invasive) Haemophilus influenzae (blood, CSF or other normally sterile site)
Hepatitis A (acute) Hepatitis A virus
Hepatitis B (acute and chronic) Hepatitis B virus
Hepatitis C Hepatitis C virus
Herpes simplex (genital) Herpes simplex virus
Influenza Influenza A and B virus
Legionellosis Legionella species
Leptospirosis Leptospira species
Listeriosis Listeria monocytogenes
Lymphogranuloma venereum
Malaria Plasmodium falciparum, P. vivax, P. ovale, P. malariae
Measles Measles virus
Meningococcal disease Neisseria meningitidis
Mumps Mumps virus
Non-specific urethritis
Noroviral infection Norovirus
Paratyphoid Salmonella paratyphi
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Pertussis Bordetella pertussis
Plague Yersinia pestis
Q fever Coxiella burnetii
Rabies Rabies virus
Rubella Rubella virus
Salmonellosis Salmonella enterica
Severe Acute Respiratory Syndrome (SARS) SARS-associated coronavirus
Shigellosis Shigella species
Smallpox Variola virus
Staphylococcal food poisoning Enterotoxigenic Staphylococcus aureus
Staphylococcus aureus bacteraemia Staphylococcus aureus (blood)
Streptococcus group A infection (invasive) Streptococcus pyogenes (blood, CSF or other normally sterile site)
Streptococcus pneumoniae infection (invasive)
Streptococcus  pneumoniae (blood, CSF or other normally sterile 
site)
Syphilis Treponema pallidum
Tetanus Clostridium tetani
Toxoplasmosis Toxoplasma gondii
Trichinosis Trichinella species
Trichomoniasis Trichomonas vaginalis
Tuberculosis Mycobacterium tuberculosis complex
Tularemia Francisella tularensis
Typhoid Salmonella typhi
Typhus Rickettsia prowazekii
Viral encephalitis
Viral haemorrhagic fevers
Lassa virus, Marburg virus, Ebola virus, Crimean-Congo 
haemorrhagic fever virus
Viral meningitis
Yellow fever Yellow fever virus
Yersiniosis Yersinia enterocolitica, Yersinia pseudotuberculosis
Infectious Disease Causative Pathogen(s)
Table  A1.1 (continued)
List of notifiable infectious diseases and their respective causative pathogens under Infectious Diseases (Amendment) (No. 3) Regulations 2003 
(S.I. No. 707 of 2003)
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Table A1.2  Number of notifiable infectious diseases, 2005-2007 and crude incidence rates of diseases, 2007
Infectious Disease 2005 2006 2007 CIR* 2007
Acute anterior poliomyelitis 0 0 0 0.00
Acute infectious gastroenteritis 2398 2306 2520 59.44
Anthrax 0 0 0 0.00
Bacillus cereus food-borne infection/intoxication 0 0 0 0.00
Bacterial meningitis (not otherwise specified) 29 46 33 0.78
Botulism 0 1 0 0.00
Brucellosis 53 29 28 0.66
Campylobacter infection 1801 1812 1891 44.60
Cholera 0 0 0 0.00
Clostridium perfringens (type A) food-borne disease 1 0 0 0.00
Creutzfeldt Jakob disease 4 6 3 0.07
Creutzfeldt Jakob disease (new variant) 2 1 0 0.00
Cryptosporidiosis 568 367 609 14.36
Diphtheria 0 0 0 0.00
Echinococcosis 0 0 0 0.00
Enterohaemorrhagic Escherichia coli 134 174 192 4.53
Giardiasis 57 65 62 1.46
Haemophilus influenzae disease (invasive) 34 38 31 0.73
Hepatitis A (acute) 56 39 32 0.75
Hepatitis B (acute and chronic) 874 811 863 20.35
Hepatitis C 1432 1220 1558 36.75
Influenza 316 276 280 6.60
Legionellosis 9 13 16 0.38
Leptospirosis 15 20 22 0.52
Listeriosis 12 7 21 0.50
Malaria 44 96 71 1.67
Measles 93 83 53 1.25
Meningococcal disease 203 209 179 4.22
Mumps 1079 427 142 3.35
Noroviral infection 1045 1635 1317 31.06
Paratyphoid 0 1 4 0.09
Pertussis 83 62 78 1.84
Plague 0 0 0 0.00
Q fever 10 12 17 0.40
Rabies 0 0 0 0.00
Rubella 17 14 19 0.45
Salmonellosis 347 422 456 10.76
Severe Acute Respiratory Syndrome (SARS) 0 0 0 0.00
Shigellosis 36 54 43 1.01
Smallpox 0 0 0 0.00
Staphylococcal food poisoning 6 0 0 0.00
Streptococcus group A infection (invasive) 49 61 57 1.34
Streptococcus pneumoniae infection (invasive) 271 293 361 8.51
Tetanus 0 0 1 0.02
Toxoplasmosis 45 44 49 1.16
Trichinosis 0 0 2 0.05
Tuberculosis 0 0 0 0.00
Tularemia 0 0 0 0.00
Typhoid 5 9 9 0.21
Typhus 0 0 0 0.00
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Viral encephalitis 6 16 8 0.19
Viral haemorrhagic fevers 0 0 0 0.00
Viral meningitis 35 148 46 1.08
Yellow fever 0 0 0 0.00
Yersiniosis 3 1 6 0.14
Total 11172 10818 11079 -
See explanatory note on first page of Appendix 1.
*Crude incidence rate per 100,000 total population. 
Infectious Disease 2005 2006 2007 CIR* 2007
 
Table A1.2  (continued)  Number of notifiable infectious diseases, 2005-2007 and crude incidence rates of diseases, 2007
-114- HPSC Annual Report 2007Appendix 1 - Notifiable Infectious Diseases in Ireland
Table A1.3 Number of notifiable infectious diseases in 2007 by HSE area
Infectious Disease
HSE-
E
HSE-
M
HSE-
MW
HSE-
NE
HSE-
NW
HSE-
SE
HSE-
S
HSE-
W Total
Acute infectious gastroenteritis 718 272 74 106 176 418 279 477 2520
Bacterial meningitis (not otherwise specified) 10 1 3 2 0 10 3 4 33
Brucellosis 1 2 24 1 0 0 0 0 28
Campylobacter infection 646 146 173 141 101 174 250 260 1891
Creutzfeldt Jakob disease * * * * * * * * 3
Cryptosporidiosis 22 34 57 24 25 79 60 308 609
Enterohaemorrhagic Escherichia coli 29 20 17 13 79 9 14 11 192
Giardiasis 28 1 3 6 0 9 9 6 62
Haemophilus influenzae disease (invasive) 12 3 2 0 1 5 2 6 31
Hepatitis A (acute) 16 2 1 2 1 4 4 2 32
Hepatitis B (acute and chronic) 521 37 61 43 18 58 80 45 863
Hepatitis C 1206 42 47 55 20 44 67 77 1558
Influenza 59 7 114 17 16 32 24 11 280
Legionellosis 10 3 1 2 0 0 0 0 16
Leptospirosis 5 2 3 2 1 4 3 2 22
Listeriosis 11 3 1 1 1 1 2 1 21
Malaria 32 8 3 6 0 9 6 7 71
Measles 29 0 3 1 1 7 3 9 53
Meningococcal disease 59 10 18 21 13 18 22 18 179
Mumps 53 3 6 8 34 12 8 18 142
Noroviral infection 582 77 134 88 36 125 195 80 1317
Paratyphoid * * * * * * * * 4
Pertussis 24 3 6 5 3 9 11 17 78
Q fever 1 1 9 0 0 0 4 2 17
Rubella 14 0 0 1 0 2 0 2 19
Salmonellosis 143 23 29 29 21 37 131 43 456
Shigellosis 21 2 2 4 0 2 9 3 43
Streptococcus group A infection (invasive) 28 0 2 3 3 10 4 7 57
Streptococcus pneumoniae infection (invasive) 117 14 29 30 30 84 35 22 361
Tetanus * * * * * * * * 1
Toxoplasmosis 25 3 0 3 4 8 4 2 49
Trichinosis * * * * * * * * 2
Typhoid 6 0 0 2 0 0 1 0 9
Viral encephalitis 2 0 0 1 0 1 1 3 8
Viral meningitis 16 6 1 5 3 6 4 5 46
Yersiniosis 2 1 0 0 1 0 0 2 6
See explanatory note on first page of Appendix 1.
* Data not reported to HSE area level when total number in Ireland <5 cases
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Table A1.4 Number of notifiable infectious diseases in 2007 by age group (years)
Infectious Disease 0-4 5-9 10-14 15-19 20-24 25-34 35-44 45-54 55-64 65+ Unknown Total
Acute infectious gastroenteritis 2357 59 12 2 5 23 10 3 9 22 18 2520
Bacterial meningitis (not otherwise specified) 18 0 2 3 0 5 2 0 1 2 0 33
Brucellosis 0 0 0 0 0 4 0 9 11 4 0 28
Campylobacter infection 483 121 57 89 167 319 191 179 105 170 10 1891
Creutzfeldt Jakob disease 0 0 0 0 0 0 0 0 2 1 0 3
Cryptosporidiosis 306 96 42 14 23 57 20 14 11 24 2 609
Enterohaemorrhagic Escherichia coli 68 17 10 1 7 11 20 10 6 14 28 192
Giardiasis 20 5 2 1 4 11 8 5 3 3 0 62
Haemophilus influenzae disease (invasive) 9 0 1 0 1 2 2 0 3 13 0 31
Hepatitis A (acute) 2 6 4 2 2 5 3 2 2 4 0 32
Hepatitis B (acute and chronic) 3 3 3 36 151 320 225 71 30 17 4 863
Hepatitis C 7 0 5 20 126 752 372 177 57 30 12 1558
Influenza 53 14 9 22 12 42 51 39 22 15 1 280
Legionellosis 0 0 0 1 0 1 4 3 5 2 0 16
Leptospirosis 0 0 0 0 3 5 6 3 4 1 0 22
Listeriosis 3 0 0 0 2 4 1 2 1 8 0 21
Malaria 7 7 3 3 5 19 18 5 3 1 0 71
Measles 32 10 5 2 2 0 0 0 1 0 1 53
Meningococcal disease 106 14 13 20 5 10 2 3 2 4 0 179
Mumps 24 13 10 16 17 18 22 12 7 3 0 142
Noroviral infection 265 19 8 17 24 59 56 54 86 704 25 1317
Paratyphoid 0 0 0 0 2 0 1 0 0 1 0 4
Pertussis 63 3 4 3 2 0 2 1 0 0 0 78
Q fever 1 0 0 1 0 6 3 2 1 3 0 17
Rubella 16 0 0 0 0 3 0 0 0 0 0 19
Salmonellosis 108 27 16 24 38 76 43 38 35 51 0 456
Shigellosis 7 1 1 1 6 16 4 5 2 0 0 43
Streptococcus group A infection (invasive) 13 4 1 0 2 8 5 3 6 15 0 57
Streptococcus pneumoniae infection (invasive) 68 2 4 3 5 19 31 31 46 150 2 361
Tetanus 0 0 0 0 0 0 0 0 0 1 0 1
Toxoplasmosis 3 0 2 2 3 21 10 6 2 0 0 49
Trichinosis 0 0 0 0 0 2 0 0 0 0 0 2
Typhoid 2 0 1 0 2 3 1 0 0 0 0 9
Viral encephalitis 1 1 0 1 0 0 0 1 2 2 0 8
Viral meningitis 21 3 2 3 3 5 6 0 2 0 1 46
Yersiniosis 2 1 0 1 0 0 0 0 0 2 0 6
Total 4068 426 217 288 619 1826 1119 678 467 1267 104 11079
             
See explanatory note on first page of Appendix 1.
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Table A1.5 Number of notifiable infectious diseases in 2007 by gender
Infectious Disease Male Female Unknown Total
Acute infectious gastroenteritis 1281 1213 26 2520
Bacterial meningitis (not otherwise specified) 18 15 0 33
Brucellosis 25 3 0 28
Campylobacter infection 1011 866 14 1891
Creutzfeldt Jakob disease 1 2 0 3
Cryptosporidiosis 327 278 4 609
Enterohaemorrhagic Escherichia coli 96 96 0 192
Giardiasis 36 23 3 62
Haemophilus influenzae disease (invasive) 25 6 0 31
Hepatitis A (acute) 17 15 0 32
Hepatitis B (acute and chronic) 462 361 40 863
Hepatitis C 979 551 28 1558
Influenza 130 147 3 280
Legionellosis 9 7 0 16
Leptospirosis 21 1 0 22
Listeriosis 8 13 0 21
Malaria 43 26 2 71
Measles 29 24 0 53
Meningococcal disease 97 82 0 179
Mumps 84 58 0 142
Noroviral infection 584 730 3 1317
Paratyphoid 1 3 0 4
Pertussis 40 38 0 78
Q fever 6 11 0 17
Rubella 9 10 0 19
Salmonellosis 238 214 4 456
Shigellosis 16 27 0 43
Streptococcus group A infection (invasive) 26 31 0 57
Streptococcus pneumoniae infection (invasive) 189 172 0 361
Tetanus 1 0 0 1
Toxoplasmosis 17 32 0 49
Trichinosis 1 1 0 2
Typhoid 7 2 0 9
Viral encephalitis 6 2 0 8
Viral meningitis 28 18 0 46
Yersiniosis 2 4 0 6
Total 5870 5082 127 11079
See explanatory note on first page of Appendix 1.
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Table A1.6 Number of notifiable infectious diseases in 2007 by case classification
Infectious Disease Confirmed Probable Possible
Not 
Specified
Total
Acute infectious gastroenteritis 2327 193 0 0 2520
Bacterial meningitis (not otherwise specified) 11 8 14 0 33
Brucellosis 7 21 0 0 28
Campylobacter infection 1888 2 0 1 1891
Creutzfeldt Jakob disease 3 0 0 0 3
Cryptosporidiosis 609 0 0 0 609
Enterohaemorrhagic Escherichia coli 140 52 0 0 192
Giardiasis 62 0 0 0 62
Haemophilus influenzae disease (invasive) 31 0 0 0 31
Hepatitis A (acute) 29 1 2 0 32
Hepatitis B (acute and chronic) 863 0 0 0 863
Hepatitis C 1558 0 0 0 1558
Influenza 276 0 4 0 280
Legionellosis 15 1 0 0 16
Leptospirosis 22 0 0 0 22
Listeriosis 21 0 0 0 21
Malaria 71 0 0 0 71
Measles 20 0 33 0 53
Meningococcal disease 161 1 17 0 179
Mumps 68 1 73 0 142
Noroviral infection 1270 47 0 0 1317
Paratyphoid 4 0 0 0 4
Pertussis 47 3 27 1 78
Q fever 4 13 0 0 17
Rubella 3 0 16 0 19
Salmonellosis 440 16 0 0 456
Shigellosis 43 0 0 0 43
Streptococcus group A infection (invasive) 57 0 0 0 57
Streptococcus pneumoniae infection (invasive) 310 51 0 0 361
Tetanus 1 0 0 0 1
Toxoplasmosis 49 0 0 0 49
Trichinosis 2 0 0 0 2
Typhoid 8 1 0 0 9
Viral encephalitis 8 0 0 0 8
Viral meningitis 35 10 1 0 46
Yersiniosis 6 0 0 0 6
Total 10469 421 187 2 11079
See explanatory note on first page of Appendix 1.
 Case classifications are assigned to notifications as per the Case Definitions for Notifiable Diseases booklet, available at http://www.hpsc.ie
*As per the case definitions, meningococcal disease notifications are classified as definite, presumed and possible. For convenience they are 
reported in this table as confirmed, probable and possible, respectively.    
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Notifiable Infectious Diseases
Computerised Infectious Disease Reporting (CIDR) 
system
For the majority of the notifiable infectious diseases (see 
appendix 1), data were collated using the Computerised 
Infectious Disease Reporting (CIDR) system.  Notification 
data were inputted directly by areas using the system.  
For areas not yet on CIDR, data were forwarded weekly 
to HPSC for input to CIDR. Enhanced surveillance was 
undertaken for certain diseases and these data collated 
on CIDR.  Outbreak data were also collated on CIDR 
using the same process outlined above.  Weekly Reports 
on infectious disease notifications and outbreaks were 
produced by HPSC.  
Throughout the year data were cleaned and validated 
on an ongoing basis and final data checks and cleaning 
were undertaken following year end by HPSC and 
the Departments of Public Health.  Data analysis was 
performed using Business Objects Reporting and MS 
Excel.  Figures for the relevant chapters within this 
report were extracted from CIDR during August and 
September 2008.  These figures may differ from those 
previously published due to ongoing updating of data 
on CIDR.
Data on the notifiable infectious diseases not yet on 
CIDR were collated as follows:
National Tuberculosis Surveillance System (NTBSS)
TB notification data (including enhanced information) 
for 2006 were collated in the regional Departments of 
Public Health, where data were entered on the Epi2000 
NTBSS database.  Each HSE Area provided finalised 
2006 data with outcome information to HPSC in early to 
mid 2007.  Data were validated and cleaned with each 
area and the national data were collated.  Provisional 
2007 data were obtained from each area in August 
2008.
European Antimicrobial Resistance Surveillance 
System (EARSS)
Data were collected by participating EARSS laboratories 
in 2007 on the first invasive isolate per patient per 
quarter on Staphylococcus aureus and Enterococcus 
faecalis from blood only and on Streptococcus 
pneumoniae, Escherichia coli, Klebsiella pneumoniae 
and Pseudomonas aeruginosa from blood and 
cerebrospinal fluid (CSF).  Data were reported quarterly 
to HPSC and collated in the WHONET database.  
Quarterly and annual reports were produced.  
Note:  In general, invasive infections due to K. 
pneumoniae and P. aeruginosa are not notifiable but 
these pathogens are now included for surveillance 
under the EARSS project.
Sexually Transmitted Infections (STIs)
Clinicians and laboratories notified their respective 
Departments of Public Health of probable and 
confirmed cases of STIs in 2006.  Notifications were 
anonymised prior to notification.  Data were collated 
and analysed by Departments of Public Health and 
aggregated data were reported quarterly to HPSC.  
National data were collated on an MS Access database, 
analysis preformed and reports produced by HPSC. At 
the time of writing, finalised STI data for 2007 had not 
yet been received by HPSC.
Other Surveillance Systems
Influenza Surveillance
A sentinel surveillance system is used in Ireland for the 
surveillance of influenza activity.  For the 2007/2008 
influenza season (October to May), 52 geographically 
distributed general practices participated (representing 
4.8% of the population) in collaboration with the ICGP, 
NVRL, DoHC and HPSC.  Each week the participating 
GPs reported electronically to the ICGP the number 
of patients who consulted with influenza-like illness 
(ILI).  The NVRL reported to HPSC on a weekly 
basis the number of influenza positive specimens 
tested (from sentinel and non-sentinel sources).  The 
Departments of Public Health notified HPSC weekly 
of all cases of influenza and all influenza/ILI outbreaks.  
Other indicators of influenza activity reported by 
the Departments of Public Health to HPSC included 
a regional influenza activity index, sentinel hospital 
admission levels, sentinel school absenteeism and 
enhanced surveillance data on hospitalised cases of 
influenza in 0-14 year olds.  HPSC was notified of all 
registered deaths on a weekly basis from the General 
Register Office. At HPSC data were collated from the 
various sources and weekly influenza reports were 
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produced. Clinical and virological data were reported 
weekly to EISS. Following the end of the influenza 
season, annual data were analysed and reports 
produced.  During the summer of 2008 the surveillance 
of influenza activity continued involving the ICGP, NVRL 
and HPSC.  Data were reported to EISS biweekly and 
monthly influenza reports were produced by HPSC.
HIV
HIV and AIDS surveillance in Ireland is voluntary 
and anonymised and operates in co-operation with 
laboratories, clinicians and Departments of Public 
Health.  In 2007, clinicians completed surveillance forms 
on newly diagnosed HIV cases, AIDS cases and AIDS 
related deaths and forwarded these to the appropriate 
Department of Public Health who in turn forwarded 
them to HPSC where national data were collated on an 
MS Access database.  Bi annual analysis of these data 
were performed at HPSC and reports produced, which 
are available at www.hpsc.ie 
Immunisation Uptake
Each HSE Area maintains a childhood immunisation 
database.  In 2007, each HSE Area provided HPSC with 
immunisation uptake data for their area and for each 
of the Local Health Offices in their area on a quarterly 
basis.  National data were collated and analysed at 
HPSC using a MS Excel database.  Quarterly reports 
were produced and are available on the HPSC website.  
For further details on methods used, please see the 
immunisation uptake chapter within this report.
Denominator Data
To calculate disease incidence rates, Census of 
Population data were used as the denominator 
(available from the Central Statistics Office, http://www.
cso.ie).  Population figures were applied as follows: 
Census 2006 for analysis of 2004-2007 data, Census 
2002 for 2000-2003 data and Census 1996 for 1999 
data. 
Population size was estimated between 1993 and 2007 
for non-census years using a curve interpolation method 
for the calculation of outpatient antibiotic consumption 
rates.  Bed-days used and other activity data for public 
acute hospitals were provided by the National Hospital’s 
Office of the HSE and used to calculate rates of MRSA 
and hospital antibiotic consumption.
HSE Areas
Although organisational changes have taken place 
in the Health Services, the term HSE Areas are used 
in this report when analysing and presenting data by 
geographical area (equating to the eight former health 
board regions/areas).  This is because operationally 
the surveillance, prevention and control of infectious 
diseases are still managed by eight Departments of 
Public Health, one in each HSE Area.
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Glossary of Terms 
CIDR Computerised Infectious Diseases Reporting
DoHC Department of Health and Children
EARSS European Antimicrobial Surveillance System
EISS European Influenza Surveillance System
EPIET European Programme for Intervention Epidemiology Training
FSAI Food Safety Authority of Ireland
FSPB Food Safety Promotion Board
ICGP Irish College of General Practitioners
IDU Injecting Drug User
IgM  Immunoglobulin M
IMMRL Irish Meningococcal and Meningitis Reference Laboratory
HPSC Health Protection Surveillance Centre
HSE Health Services Executive
HSE-E HSE Eastern Region
HSE-M HSE Midland Area
HSE-MW HSE Mid-Western Area
HSE-NE HSE North Eastern Area
HSE-NW HSE North Western Area
HSE-SE HSE South Eastern Area
HSE-S HSE Southern Area
HSE-W HSE Western Area
MRSA Methicillin Resistant Staphylococcus aureus
MSM Men who have Sex with Men
NVRL National Virus Reference Laboratory
STIs Sexually Transmitted Infections
TB Tuberculosis
WHO  World Health Organization
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